




Solving Challenging Structures using 
Single-Particle Cryogenic Electron Microscopy 
 

















Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
under the Executive Committee 






















































Yong Zi Tan 






Solving Challenging Structures using Single-Particle Cryogenic Electron Microscopy 
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Single-particle cryogenic electron microscopy (cryo-EM) has become a powerful mainstay tool 
in high resolution structural biology thanks to advances in hardware, software and sample 
preparation technology. In my thesis, I utilized this technique to unravel the function of various 
challenging biological macromolecules. 
 
My first focus was bacterial ribosomal biogenesis: understanding how bacteria assemble their 
ribosomes. Ribosomes are the factories of the cell, responsible for manufacturing all proteins. 
Ribosomes themselves are huge, with the bacterial version made of 52 proteins and 4566 RNA 
nucleotides. How these components assemble has long been a mystery. Early groundbreaking 
work sketched out a biogenesis pathway using purified components in vitro – but under non-
physiological conditions. We sought to understand how the bacterial ribosome – specifically the 
large subunit 50S – is built inside the cell. To achieve this, we engineered a conditional knock-
out bacterial strain that lacked one specific ribosomal protein (L17). This caused the cells to 
accumulate incomplete intermediates along the 50S biogenesis pathway. These intermediates 
were purified and examined with mass spectrometry and single-particle cryo-EM. 
 
Two major hurdles arose in this project: firstly, the biogenesis intermediates exhibited a 
preferred orientation when vitrified for cryo-EM analysis. This means that instead of showing 
many different views required for reconstruction of the 3D structure, the intermediates only 
adopted one view on the cryo-EM grid. To overcome this problem, we engineered a method to 
induce additional views on the microscope by tilting the stage. Using another test protein that 
also exhibited preferred orientation (hemagglutinin), we optimized and characterized this new tilt 
methodology and showed it was generally applicable to overcoming preferred orientation, 
regardless of type of specimen. We also created a software tool, called 3DFSC (3dfsc.salk.edu), 
for other microscopists to calculate the degree of directional anisotropy in their structures due to 
preferred orientation. Using this tilt strategy finally enabled the structural elucidation of our 50S 
 
 
intermediates. The second challenge in the project was the large amount of heterogeneity present 
in the sample. Through hierarchical 3D classification schemes using the latest software tools, we 
obtained 14 different 50S intermediate structures, all from imaging a single cryo-EM grid. By 
analyzing the missing components of each intermediate, and corroborating these observations 
with mass spectrometry data, we outlined the first in vivo 50S assembly pathway, and showed 
that ribosome assembly occurs step-wise and in parallel pathways. 
 
My second focus was on pushing the resolution limits of single-particle cryo-EM using adeno-
associated virus (AAV) serotype 2 homogeneous virus-like particles (VLPs) that lack DNA. 
Exploiting several technical advances to improve resolution, including use of gold grids, per-
particle CTF refinement, and correction for Ewald sphere curvature, we managed to obtain a 
1.86 Å resolution reconstruction of the AAV2L336C variant VLP, the highest resolution 
icosahedral virus reconstruction solved by single-particle cryo-EM to date. Using our structure, 
we were able to show improvements using Ewald sphere curvature correction and shed light on 
the mechanistic basis as to why the L336C mutation resulted in defects in genome packaging and 
infectivity compared to the WT viral particles.  
 
My third focus was the understanding of small membrane proteins involved in infectious 
diseases. Membrane proteins are a challenge to work with due to the need for them to be 
extracted from the lipid bilayer for studies as compared to soluble proteins. Infectious diseases 
have a huge burden on society, with the top three infectious agents accounting for 2.7 million 
deaths in 2016. The third most deadly infectious disease is malaria, a mosquito-borne parasite 
which kills 450,000 people annually. One drug used early on for treating malaria was 
chloroquine but its usefulness waned due to development of resistance. Chloroquine resistance is 
mediated by the chloroquine resistance transporter (PfCRT). Although small (49 kDa) for single-
particle cryo-EM, we solved its structure by using fragment antibody technology to add mass and 
help with image alignment and 3D reconstruction. The 3.2 Å structure resembles other drug 
metabolite transporters, and the chloroquine resistance mutations map to a ring around the 




Tuberculosis (TB) is the top killer, above malaria and HIV/AIDS, being responsible for 1.3 
million deaths. In TB, a common antibiotic target is the bacterium’s cell wall synthesis 
machinery. One family of such enzymes is the arabinosyltransferases, which synthesize the 
critical arabinose sugars. Using single-particle cryo-EM, we solved two high resolution 
structures of one such essential enzyme, AftD. Due to the low yield of the protein, a picoliter 
automated sample dispensing robot was crucial to allow for initial cryo-EM analysis. We then 
performed mutagenesis studies in M. smegmatis, a TB model organism, which uncovered the 
critical amino acid residues in the active site and determined that a bound acyl-carrier-protein 
was likely involved in allosteric inhibition of AftD’s active site. Another member of the family, 
EmbB, is the target of a widely used frontline TB drug called ethambutol. We have solved the 
high resolution structures of the apo and putative drug-bound states of EmbB, allowing us to map 
out, for the first time, both the active site and drug-resistance mutations of this crucial enzyme. 
The atomic structures of the functional pockets of Mycobacterial AftD and malarial PfCRT will 
hopefully enable structure-based drug design to improve existing drugs or potentially even 
develop new treatments against these infectious maladies. 
 
In conclusion, the continual and breathtaking improvements in single-particle cryo-EM 
methodology has been instrumental in allowing the elucidation of the aforementioned biological 
macromolecules from ribosome biogenesis intermediates, to AAV2 vehicle, Plasmodium drug 
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“Necessity is the mother of invention” 
 
This English proverb aptly summarizes both how my graduate career has meandered, as well as 
how I have chosen to present it in this thesis. When I joined Dr. Bridget Carragher and Dr. Clint 
Potter as a graduate student as The Scripps Research Institute, I was fascinated not only at the 
opportunity to pursue cutting edge biological research, but also energized by the prospect of 
being able to develop tools that will help me, and others, to dig deep at the challenging scientific 
problems of the day. Being the heads of the National Resource for Automated Molecular 
Microscopy (NRAMM), their lab has been one of the pioneers to bring automation to cryo-EM, 
at the microscope level (Leginon), software processing level (Appion) and more recently the 
sample preparation level (Spotiton), and have continued to do so due to the need for such 
technologies in research. 
 
After my move to Columbia University, I had the immense pleasure and gratitude of also being 
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problems, from ribosomal biogenesis to AAV2 delivery vehicles to malarial transporters and to 
mycobacterial enzymes. In each of these biological projects, the need to obtain meaningful and 
novel understanding of the system was the driving factor in overcoming many of the technical 
challenges that were laid down. In each of the chapters, I have devoted a section specifically to 




I am extremely pleased as well that we were also able to dig deep enough into one of the 
methodological solutions, tilted data collection strategy, to be able to publish a protocol that can 
serve as template for other single-particle cryo-EM practitioners to follow to solve their own 
problems of preferred orientation. One thing that impressed deeply upon me in the field of cryo-
EM is the willingness of many of the experts to share and exchange their best ideas to assist 
others, and I am honored to have had the chance to give my small bit back to this generous 
community. 
 
Finally, I would like to end off with another quote: 
 
“If it was easy, then someone else would have already done it” 
 
I hope the work by me and my colleagues presented here can make a small contribution to the 
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Introduction to Single-Particle Cryo-EM 
 
Single-particle cryo-EM is a biological structure determination technique in which 
macromolecules are frozen in a layer of vitreous ice and imaged using electrons (Cheng, 2015). 
Electrons are then transmitted through this sample, and projection images (De Rosier and Klug, 
1968) of the particles are recorded on a detector. Many of these 2D images from particles in 
similar conformations are then computationally averaged to produce a three-dimensional electron 
potential map (Frank et al., 1978). In the past, single-particle cryo-EM could only attain 
nanometer to subnanometer resolution reconstructions, which pales in comparison to the two 
other main structural biology techniques of X-ray crystallography and biological nuclear 
magnetic resonance (Cheng, 2015). The advent of hardware and software breakthroughs 
heralded a “resolution revolution” (Kühlbrandt, 2014) in the field – many structures that have 
previously eluded other structural techniques have now been solved at sub-4 Å resolution, from 
the TRPV1 ion channel (Liao et al., 2013) to the mitochondrial ribosome (Amunts et al., 2015). 
The highest currently attainable single-particle cryo-EM resolutions are below 2 Å (Merk et al., 
2016, Bartesaghi et al., 2018, Tan et al., 2018), and are only likely to improve. 
 
Here in this introduction, I will go through the basic single-particle cryo-EM workflow, and 




One advantage that single-particle cryo-EM has over X-ray crystallography and 2D electron 
crystallography is the lack of need for crystals. Purified macromolecule samples can be directly 
vitrified on a grid for imaging, and hence the concentrations required are also much lower, being 
in the range of micrograms (Takizawa et al., 2017). 
 
Once the macromolecule is purified, negative stain electron microscopy is usually done first to 
assay for sample quality as it is quick to perform and inexpensive (Takizawa et al., 2017). In 
negative staining, the macromolecules are adsorbed to a continuous carbon support on a grid. 
Excess sample is blotted away, and a heavy metal stain (such as uranyl formate or uranyl acetate) 
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is added. After excess stain is removed by blotting, the residual stain is left to dry and will leave 




Once the sample has been judged to be of sufficient quality through biochemical assays and 
negative staining, the macromolecule can be flash frozen. Vitrification preserves the 
macromolecules in their native state (Taylor and Glaeser, 1974), makes them more resistant to 
the vacuum and radiation damage experience in teh electron microscope. The process starts by 
application of the sample to a grid, which is then blotted to remove excess liquid before being 
plunged into liquid ethane or ethane/propane mix cooled by liquid nitrogen to roughly around -
160°C (Dubochet et al., 1982). This rapid freezing ensures that ice formed is in the vitreous and 
not crystalline state – the latter is avoided because water expands when crystallizing to damage 
cellular structure (Dobro et al., 2010), and because crystalline ice degrade image quality by 
diffracting electrons (Thompson et al., 2016). Sample vitrification is usually done nowadays on a 
semi-automated machine that can control the humidity, temperature and blotting settings (such as 
FEI Vitrobot, Gatan Cryoplunge 3, Leica EM GP). 
 
One major challenge in sample vitrification is poor reproducibility of grids and their ice quality 
(Dobro et al., 2010). The logical solution would be greater automation of the sample vitrification 
pipeline, which is indeed the goal of vitrification robots like Spotiton (Dandey et al., 2018, 
Razinkov et al., 2016, Jain et al., 2012, Wei et al., 2018). An additional benefit of automation is 
the reduction of the amount of sample required from microliters to picoliters (Dandey et al., 




After the samples have been vitrified on the grid, they are usually screened on a lower end 
microscope to ascertain the ice thickness, particle distribution and particle integrity. Grids that 
are optimal are then imaged on a high end microscope, which typically has an electron source 
made of a field emission gun (FEG) operating at 200 or 300 keV. A series of electromagnetic 
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lenses will focus and adjust the beam and pass it through the specimen before reaching a detector. 
Improvements in the microscope itself, such as constant power lenses and better electron sources, 
have helped pushed the resolution limit for single-particle cryo-EM (Cheng, 2015). Data 
collection is also automated with help of software like EPU, Leginon (Suloway et al., 2005, 




One recent area of development in the field is the advent of direct electron detectors. These 
cameras do not require an intermediate substrate to convert the electrons into light for detection, 
and are superior to previous imaging media in a few aspects: 1) they have better detective 
quantum efficiency, a measure of the signal and noise performance of the micrograph across 
various spatial frequencies (McMullan et al., 2009), 2) they output files that are digital in nature, 
compared to film whereby an additional step is required to digitize the raw micrographs, and 3) 
they are fast enough to record movies instead of just still images. 
 
The advantage of recording movies is twofold. Firstly, it was noticed when movies were initially 
recorded that images were blurred if the movie frames were directly summed due to beam-
induced movement (Campbell et al., 2012, Brilot et al., 2012, Li et al., 2013, Bai et al., 2013). 
When this movement was corrected, the image quality improved and higher resolution 
reconstructions were achieved. Secondly, the recording of multiple frames allows for a means to 
deal with radiation damage by low pass filtering frames based on the amount of radiation 
damage they experience (Baker and Rubinstein, 2010, Grant and Grigorieff, 2015b, Bai et al., 
2013). This allows for longer exposures to be used to extract as much low resolution information 
as possible from the particle to aid in alignment, without compromising the high resolution data. 
The future challenge will be for camera manufacturers to continue to improve both the detective 






In biological cryo-EM, as compared to material science applications, the sample is inherently 
less tolerant to radiation damage. In turn, the overall electron dose used is deliberately set low in 
order to preserve high resolution information in the macromolecules of interest. This results in 
poor signal-to-noise ratio for individual images. In order to enhance the signal, computational 
averaging is done – particles exhibiting the same view and conformation are averaged together to 
boost the signal-to-noise ratio (De Rosier and Klug, 1968). 
 
During imaging, micrographs are not perfect representations of the sample. Instead, they are 
modulated in amplitude and phase by a contrast transfer function (CTF) (Penczek, 2010a). CTF 
is a sinc function and is encompassed in an envelope that dampens the high resolution 
amplitudes of the CTF. Proper estimation of the CTF and application of it to correct the imaged 
particle is therefore necessary in order to salvage the high resolution information present (Cheng, 
2015).  
 
When vitrified in ice, the macromolecule particles are orientated randomly. In order to determine 
their exact spatial orientation and position (defined by six parameters, although the Z height is 
often initially assumed to be constant in an image), iterative refining of the projection images 
particles against an initial model is required (Frank, 2006). Once refinement has reached 
convergence, the final parameters (called Euler angles and shifts) will be applied and the final 
reconstruction is made through back projection of the 2D particles (Penczek, 2010a). This 
electron potential map can then be modeled into, to build the atomic model of the biological 
macromolecule. 
 
In an ideal case, all the particles picked from the micrographs will go into a single high 
resolution reconstruction. In reality, biological samples are rarely homogeneous for various 
reasons: due to conformational heterogeneity, compositional heterogeneity or degradation. In 
turn, computational purification will be required to separate out the most consistent high 
resolution classes. Huge improvements in computational algorithms to analyze, sort, classify and 
refine single-particle cryo-EM datasets have contributed greatly to the “resolution revolution”. 
Software packages such as Relion (Scheres, 2012a, Kimanius et al., 2016), cisTEM (Grant et al., 
2018b, Grigorieff, 2007), CryoSPARC (Punjani et al., 2017a), SPHIRE (Moriya et al., 2017) and 
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EMAN (Ludtke et al., 1999, Tang et al., 2007) provide a near complete software environment for 
analysis and processing of single-particle cryo-EM data. Future challenges in the software realm 
will be the development of a full pipeline that stretches from data collection to map, as well as 
development of more refined methods to take advantage of the innate heterogeneity present in 
single-particle cryo-EM datasets, not just between particles, but also within a single structure 
(Nakane et al., 2018). 
 
In this chapter, a review and book chapter are appended that dives deep into automated data 
collection in single-particle cryo-EM. The linking of automated data collection systems at 
Simons Electron Microscopy Center (between Leginon and Appion (Lander et al., 2009a)) not 
only enhances the throughput, but also allows for easy integration of various new imaging 
modalities (such as phase plates and image shift data collection), and have been invaluable in 
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As highlighted from the two articles included above, automated data collection has been 
instrumental in enhancing the throughput in single-particle cryo-EM. Nevertheless, the rate of 
data collection is still more than an order of magnitude slower than X-ray crystallography 
(Bombicz, 2016). A full set of reflections for a crystal can be collected using the PILATUS 6M 
detector in under a minute, and if a homology model is available the electron density map can be 
obtained within half an hour after the diffraction data have been collected (Henrich et al., 2009). 
For single-particle cryo-EM, data collection usually takes two to three days, while total 
processing time can range from months for a tricky dataset to an hour for an ideal test specimen, 
like rabbit muscle aldolase (Kim et al., 2018). 
 
Several aspects of the data collection pipeline can be optimized to trim this timeline down. The 
first aspect is methodological advancement. Recent advances include using image shift, instead 
of stage shift, to move to imaging targets, and this cuts down on the time spent waiting for the 
stage to settle (Cheng et al., 2018b). Other advances include automatic determination of ice 
thickness, using objective scattering and/or the post-column energy filter (Rice et al., 2018a), to 
allow for unsupervised selection of holes that have the optimal ice thickness. A further aspect 
would be improvements in computational infrastructure, such as faster and more affordable 
CPUs and GPUs (Baldwin et al., 2018) as well as the availability of cloud computing 
infrastructure that can be easily scaled up to provide bursts of high performance computing 
(Cianfrocco and Leschziner, 2015). Eventually, an integrated data collection-data processing 
pipeline will become the norm, and will allow for instant feedback to the data collection 
(Baldwin et al., 2018). Developments in deep learning can make use of the large single-particle 
cryo-EM databases and statistics available at large centers to further optimize the workflow 
(Pichkur et al., 2018). 
 
All of this automation in data collection serves not only to allow for more projects and allow 
more users to obtain their structures, but also makes feasible collection of large datasets 
necessary to solve structures of either rare macromolecule conformations or highly 
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The prokaryotic ribosome, made of the small 30S (SSU) and large 50S subunit (LSU), is the 
protein factory of the cell. It is this catalytic core that is responsible for translation of all the 
cellular proteins, using mRNA as a template (Gold et al., 1981). Medically, prokaryotic 
ribosomes are the main target of antibiotics (Wilson, 2014). The process in which these 
complicated biological machines are assembled in vivo has also been extensively studied in the 
last 30 years (Davis and Williamson, 2017). Prokaryotic ribosomal biogenesis is a highly 
coordinated process and occurs in the following steps: 1) rRNA transcription, processing and 
modification, 2) ribosomal protein translation and modification, 3) rRNA and ribosomal protein 
folding, 4) ribosomal protein binding, and finally 5) assembly factors binding and release 
(Shajani et al., 2011). Many of these steps occur in parallel, is tightly regulated by the cell, and 
takes just ~2 minutes to complete for a single ribosome (Lindahl, 1975, Chen et al., 2012). 
 
The first historical milestone in understanding prokaryotic ribosomal biogenesis came in the late 
1960s when Traub and Nomura (Traub and Nomura, 1968) demonstrate that it is possible to 
reconstitute the SSU in vitro using free rRNA and ribosomal proteins alone. This shows that the 
information required for assembly of the SSU is already present in these aforementioned 
components. Using this in vitro system, Nomura and colleagues systematically removed various 
ribosomal proteins from the reconstitution mixture and determined that SSU assembly follows a 
set hierarchy, with certain primary proteins (S4, S7, S8, S15, S17, S20) binding first before the 
other proteins can come on (Mizushima and Nomura, 1970). These results are compiled in the 
classic Nomura map. The similar experiment was also replicated on the LSU by Nierhaus and 
Dohme (Nierhaus and Dohme, 1974), and a corresponding Nierhaus map for the hierarchical 
assembly of the 50S was elucidated. 
 
While these early studies have been instrumental in laying the foundation for understanding of 
prokaryotic ribosomal biogenesis, they have the drawback of being non-physiological in nature: 
high temperatures of 40°C and high magnesium ion concentrations were used to coax the full 
assembly of the SSU and LSU (Sieber and Nierhaus, 1978), and assembly factors are also absent 
in the mix. These non-physiological conditions are reflected in the much slower observed rate of 
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ribosomal assembly in vitro compared to in vivo (Lindahl, 1975). Thus to gain further biological 
insights in ribosomal biogenesis, in vivo studies have to be done. 
 
One powerful biophysical technique that has been used to study prokaryotic ribosomal 
biogenesis in vivo is quantitative mass spectrometry (Chen and Williamson, 2013). Bacterial 
cells in experimental conditions can first be grown in growth media containing 15N isotopes, 
before being pulsed with fresh 14N isotope containing media for a fixed amount of time. Cells 
grown fully in 14N media serve as references – known amounts of their ribosomes will be spiked 
into the experimental sample before LC-MS analysis. After cell lysis, the ribosomal 
intermediates can be separated on a sucrose gradient, and each fraction analyzed by LC-MS, with 
the idea that earlier ribosomal assembly intermediates will be smaller and hence elute earlier. 
Ribosomal proteins that are primary binders will therefore be enriched in the earlier fractions, 
and this was observed by Chen and Williamson (Chen and Williamson, 2013), thereby allowing 
the construction of an in vivo map of ribosomal biogenesis, akin to the Nierhaus and Nomura 
maps mentioned earlier.  
 
With these fractions, structural studies can also be performed. The SSU was subjected to single-
particle cryo-EM analysis allowed for resolution of various immature SSU intermediates 
(Sashital et al., 2014). Based on success of this combined quantitative mass spectrometry-single-
particle cryo-EM approach, we decided to tackle the in vivo biogenesis of the more complicated 
LSU. In order to enrich the potential biogenesis intermediates, a depletion system was set up to 
starve bacterial cells of one of the r-proteins, L17. The results of this study are presented in this 
chapter as a published manuscript.  
 
 
Single-Particle Cryo-EM Challenges 
 
The first single-particle cryo-EM challenge encountered in this project was the issue of preferred 
orientation (Glaeser, 2015, Glaeser and Han, 2017). When the LSU assembly intermediates were 
vitrified, the particles were orientated with a single view – this lack of views in turn precluded 
the proper three dimensional reconstructions of the particles through conventional single-particle 
techniques. Various methods to ameliorate this problem were tried, from using a carbon substrate 
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to addition of detergents like NP40 and chemicals like poly-L-lysine, but they either failed to 
abolish the preferred orientation (carbon substrate, NP40) or drastically reduced the attainable 
resolution due to background interference (poly-L-lysine). Eventually, the sample was vitrified 
onto a gold grid and a novel method was ued to physically induce different views from the 
sample by tilting the stage (Tan et al., 2017). This worked and allowed us to obtain high 
resolution reconstructions of the LSU assembly intermediates. Details of this tilting methodology 
will be elaborated in chapter 3. 
 
The second single-particle cryo-EM challenge we faced in this project was the issue of 
heterogeneity. The LSU assembly intermediates could only be crudely separated on a sucrose 
gradient – hence even though we are only vitrifying a single fraction, it still contains a 
heterogeneous mix of intermediates. We solved this problem through supervised in silico 
purification using the Frealign software package (Lyumkis et al., 2013a), and Relion software 
package (Scheres, 2016), eventually reconstructing 14 different LSU intermediates. 
 
A third challenge is tied to the analysis of the 14 different maps – what is the best way to fairly 
and quantitatively compare these maps? What we came up with was to align all the maps 
together, amplitude scale them to the lowest resolution structure, before finally segmenting the 
map based on positions of r-proteins and RNA helices. The density present in each of the 
segmented regions will range from 0 to 1, and will be a proxy of the relative occupancy of that 
subunit in the particular map. The various occupancies can then serve as a signature for each 
map, and be compared across various maps. Hierarchical clustering of these occupancy data was 








































































Our work here provides a template to investigate the biogenesis of other large molecular 
machines. Indeed, the same single-particle cryo-EM approach has been used independently by 
others to elucidate the assembly pathways of nucleolar pre-60S ribosomes (Kater et al., 2017, 
Sanghai et al., 2018) and mitochondrial ribosome (Brown et al., 2017). Here, we have only 
investigated the effect of L17 depletion on altering the ribosomal biogenesis landscape. 
Sequential and systematic limitation of other r-proteins (in the same manner as Nierhaus and 
Nomura) would be laborious but should eventually be able to elucidate a full in vivo prokaryotic 
ribosomal assembly map, complete with high resolution structures of the relevant intermediates. 
 
Although our intermediates were purified from cells, this is still one step removed from a true in 
vivo picture of ribosomal biogenesis. In order to better determine not just the true in vivo 
structures, but also the localization of these different intermediates in the bacteria, cellular 
electron tomography is the next logical step (Beck and Baumeister, 2016). Cells with r-protein 
limitation can be vitrified on grids and through focused ion beam milling (Villa et al., 2013) 
could be thinned to allow for electron penetrance. Electron tomograms collected on these 
lamellae could then be analyzed for presence of ribosomal intermediates. One big issue with 
tomography is the need to have a target structure to look for – this could potentially be solved by 
utilizing the high resolution structures of the biogenesis intermediates like we have here. These 
structures can be used as templates to search in the tomogram for the in vivo intermediates 
(Rickgauer et al., 2017). The eventual goal would thus be to attain a true in vivo assembly map of 
the prokaryotic ribosome, which is not just of interest biologically, but also medically as 
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Introduction and Challenge 
 
In single-particle cryo-EM, one problem has persisted despite the technological advances that 
have occurred at breathtaking speed in the field – the issue of preferred particle orientation 
(Glaeser, 2016). Ideally, macromolecular objects adopt random orientations within a layer of 
vitreous ice suspended over a substrate supported by an EM grid, which in principle results in 
isotropic distribution of angular projection orientations. This, however, is rarely true in practice, 
presumably due to surface properties that cause specific regions to preferentially bind to the air-
water interface or the substrate support (Taylor and Glaeser, 2008, Noble et al., 2018). 
Adherence to the air-water or substrate interface in one or several “preferred orientations” results 
in non-uniform distribution of angular projection views of the individual particles, a proportional 
under-sampling of Fourier components within the final reconstruction (Glaeser, 2016, Cheng et 
al., 2015), and an overall loss of resolution orthogonal to the preferred orientation axis (a 
“smearing effect” of the map (Barth et al., 1989)). In extreme cases, reconstructions would be 
characterized by large amounts of missing information in Fourier space, or may completely 
misrepresent the true structure of the imaged object. These effects can be collectively described 
by directional resolution anisotropy. 
 
The effects of directional resolution anisotropy have been studied in the context of cryo-electron 
tomography or 2D electron crystallography, techniques wherein physical tilting of the 
goniometer is required for obtaining alternative views of, and reconstructing the imaged object. 
Both techniques are affected by limitations that prevent tilting beyond ~60-70°, leading to 
missing information in Fourier space (Kovacik et al., 2014). In general, physical tilting of an EM 
grid leads to increased beam-induced movement, higher background contrast due to inherently 
thicker ice, and variation of the contrast transfer function (CTF) across individual micrographs 
(Liu et al., 2013). These factors limit the attainable structural resolution and have promoted the 
development of various measures to estimate resolution anisotropy within the reconstructed 
objects (Diebolder et al., 2015, Dudkina et al., 2011). 
 
By contrast, the effects of resolution anisotropy have not been extensively studied in single-
particle experiments, primarily because the specimen is assumed to adopt multiple orientations 
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within the vitreous ice layer, leading to multiple views that can be back-projected into a 
reconstruction. However, if the distribution of projection orientations is not uniform, the 
reconstructed object is still affected by anisotropic angular resolution. Given the plethora of 
samples affected to various extents by preferred particle orientation, efforts have been made to 
solve this problem. Experimentally, collecting the same micrograph at two tilts will physically 
provide additional orientations, as exemplified by the random conical (Radermacher et al., 1987) 
or orthogonal tilt reconstruction (Leschziner and Nogales, 2006) schemes, or at multiple tilts 
through constrained electron tomography (Bartesaghi et al., 2012). The drawback of these 
approaches is that multiple exposures of the same area generates beam-induced movement that 
cannot be explicitly accounted for by the absolute difference in relative tilt (Henderson et al., 
2011). The grids themselves can also be treated to induce additional orientations, for example by 
using a continuous layer of carbon as a substrate (Frank et al., 1991), coating with self-assembled 
monolayers (Meyerson et al., 2014), treating the carbon support in the presence of N-amylamine 
(Nguyen et al., 2015), or mechanically deforming the grid (Liu et al., 2013). Additives like poly-
L-lysine (Chowdhury et al., 2015) or detergents (Lyumkis et al., 2013b) are also known to 
induce proteins to adopt random orientations. None of these techniques are generally applicable, 
and most have drawbacks, such as reduced particle contrast (e.g. poly-L-lysine or support films) 
or the requirement of significantly higher specimen concentrations (e.g. detergents). 
Computationally, 3D reconstruction procedures can partially compensate for and down-weight 
under-represented views (Penczek, 2010b), but they are not able to recover missing information 
if it is absent. A brute force approach is to simply collect more particles to obtain sufficient 
quantities of low abundance views (Urnavicius et al., 2015). 
 
In our published manuscript, we described a sample agnostic, generalizable strategy to counter 
preferred orientation through physical tilting of the grid while in the microscope. We also show 
this strategy is able to reach ~4 Å resolution using a pathologically preferred hemagglutinin 

































































































Since publication of the article, we have strived to make this method as accessible to the 
community as possible. We have posted a protocol on Nature protocol exchange 
(doi:10.1038/protex.2017.055), scripted with the help of Anchi Cheng (Simons Electron 
Microscopy Center, New York Structural Biology Center) a tilted data collection application into 
Leginon (Suloway et al., 2005), as well as implemented a 3D FSC web server (3dfsc.salk.edu) 
with the help of Carl Negro (Simons Electron Microscopy Center, New York Structural Biology 
Center). 
 
The tilted data collection has since been used by others to solve a variety of structures such as the 
insulin receptor-insulin complex to 4.3 Å resolution (Scapin et al., 2018) using 30° tilt angle and 
vitrification with the Spotiton robot (Dandey et al., 2018), hibernating 100S to 7.9 Å using 40° 
tilt angle (Beckert et al., 2018), chaperonin TRiC-actin complex to 5.8 Å using 15° and 30° tilt 
angle (Balchin et al., 2018), catalytic domain of protein kinase A to ~6 Å using 30° tilt angle 
(Herzik et al., 2019), peptide transporter PepTSo2 to 4.1 Å using 30-50° tilt angle (Nagamura et 
al., 2019) and Pan2-Pan3 deadenylase to 4.8 Å using 0-40° tilt angle (Schäfer et al., 2019). I was 
also involved as an author on two papers which made use of tilted data collection, namely 
solving structures of L17-depletion LSU ribosomal assembly intermediates to 4-5 Å (Davis et al., 
2016) using 0-60° tilt angle (as described in chapter 2), and of insulin degrading enzyme to 4-6 
Å using 20-50° tilt angle (Zhang et al., 2018). The tilted data collection strategy has thus now 
been shown to work with membrane proteins like peptide transporter PepTSo2 (Nagamura et al., 
2019) and even small proteins like 43 kDa catalytic domain of protein kinase A (Herzik et al., 
2019). 
 
We are also glad that our publicly deposited 40° tilted dataset of hemagglutinin trimer on 
EMPIAR (Iudin et al., 2016) has helped other groups develop better software tools to better 
estimate CTF of micrographs collected at tilt. From our original 4.2 Å map, goCTF improved the 
resolution to 3.7 Å (Su, 2019), THUNDER improved the resolution to 3.7 Å (Hu et al., 2018), 
WARP improved the resolution to 3.2 Å (Tegunov and Cramer, 2018) and Relion 3.0 improved 
the resolution to 3.1 Å (Zivanov et al., 2018). Unexpectedly, this dataset has also been used 
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extensively by groups developing automated particle picking methods as a test specimen 
(Wagner et al., 2018, Shapiro and Berger, Zhang et al., 2019, Bepler et al., 2018). 
 
While we are glad that the tilted data collection strategy has become a valuable tool for single-
particle cryo-EM practitioners to ameliorate the preferred orientation problem, there is still a lot 
left to understand about the problem of directional anisotropy and its effect on single-particle 
cryo-EM reconstructions. Rigorous theoretical work from Baldwin and Lyumkis (Baldwin and 
Lyumkis, 2019) show that any sampling due to preferred orientation will directly attenuate 
resolution, and that going forward a better metric to approximate the effect of non-uniform 
sampling on resolution is the sampling compensation factor (SCF). 
 
Another unknown is the exact amount of degradation of envelope function due to the various 
artifacts introduced during tilting (drift, thicker ice, poorer ability to estimate CTF). In order to 
study this, we have been collecting tilted datasets using specimens with almost no preferred 
orientation – i.e. proteins with high degrees of symmetry such as icosahedral viruses and 
octahedral apoferritin. By determining the empirical determined degradation of the envelope 
function at various tilts for particles at various molecular weights, we hope to eventually be able 
to accurately predict the attainable global and directional resolution of a preferentially orientated 
sample after tilting. This would allow for the prescription of the exact tilt angle required to 
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Introduction and Challenge 
 
Resolution is a measure of the resolvability of the electron density map. For X-ray 
crystallography maps, this is usually defined as the smallest possible distance between crystal 
lattice points that can be resolved in the diffraction pattern – i.e. how far out the furthest 
diffractions spot go to – with good statistics (Karplus and Diederichs, 2015). In single-particle 
cryo-EM, resolution is defined using the Fourier Shell Correlation (FSC) between two half maps 
reconstructed from random halves of the dataset. The nominal resolution is then defined by the 
spatial frequency where the curves drop below a specific threshold, usually 0.143 (Rosenthal and 
Henderson, 2003b). 
 
Resolution is important because the better resolved the map features are, the more accurate the 
model that is built into it can be. This includes being certain about the right rotamer to use and 
where ions and water molecules are, which is critical for more mechanistic understanding of 





Figure 1 | EMDB deposition trends for single-particle cryo-EM maps. 
The highest resolution non-icosahedral virus (A) and icosahedral maps (B) as a function of time. The total number 
of new EMDB single-particle cryo-EM depositions per year (C) and as a cumulative number (D). Data obtained 
from EMDB database (Patwardhan, 2017) 
 
Hand-in-hand with the “resolution revolution” (Kühlbrandt, 2014) is the improvement in 
resolution of single-particle cryo-EM maps. As seen in figure 1, 4 Å resolution was first broken 
in 2008 by a 3.8 Å map of the VP6 protein from the bovine rotavirus (Zhang et al., 2008). 3 Å 
resolution was subsequently broken in 2015 by VP6 protein from the bovine rotavirus again 
(Grant and Grigorieff, 2015b), as well as the T20S proteasome (Campbell et al., 2015). Currently 
in single-particle cryo-EM, there are only a handful of maps below 2 Å (Bartesaghi et al., 2018, 
Merk et al., 2016, Tan et al., 2018, Zivanov et al., 2018, Hamaguchi et al., 2019) – in comparison, 
the median resolution of X-ray crystallography maps in the PDB database as of May 19, 2019 is 
2.05 Å (Sussman et al., 1998). Better understanding of the determinants to get to high resolution 





Our foray into the resolution rat race was one of serendipity however – we were investigating the 
use of adeno-associated virus serotype 2 (AAV2) as an icosahedral symmetric particle for 
understanding issues with tilting. When imaging the first sample, we realized the resolution went 
straight down to Nyquist at close to 2 Å. We then decided to do a second collection on the virus, 
this time with more days and better imaging conditions optimized for high resolution. This sub-2 
























































From our results, it is clear that we are indeed seeing the appearance of hydrogen atoms, even at 
this moderate resolution of 1.86 Å compared to the resolution of close to 1 Å that is required for 
hydrogen atoms to be seen in X-ray crystallography maps (Lyumkis, 2019), but similar to that of 
neutron diffraction at 2 Å (Shu et al., 2000). Could this discrepancy be due to innate differences 
in the type of radiation used for imaging? Further work is required to investigate the physics 
behind this, but the immediate upside if this were true for all single-particle cryo-EM maps is 
that hydrogen bonding networks can be resolved at a much worse resolution than X-ray maps, 
hence getting to 1 Å might be unnecessary if that were the goal of solving the structure. 
 
Additionally, we have also shown for the first time at sub-3 Å resolution gains that can be made 
for a single-particle cryo-EM sample by doing Ewald sphere curvature correction. This 
correction has been implemented in the latest generation of refinement software like Relion and 
cisTEM, and would and should (in my opinion) eventually be automatically done, without 
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Malaria is a major global health burden, with an estimated 200 million infected patients in the 
world and 600,000 deaths yearly (Organization, 2016). This places it at the third most deadly 
single infectious agent in the world, behind tuberculosis and HIV/AIDS. Malaria itself is caused 
by five species of Plasmodium parasites, which are in turn transmitted by mosquito vectors of the 
Anopheles species. Out of the five species, Plasmodium falciparum causes the largest number of 
deaths, and it thus typically at the center of attention (Cowman et al., 2016). 
 
Biology of Malaria Parasite 
 
When the pathogen carrying Anopheles mosquito bites a human host, the Plasmodium parasites 
are injected into the bloodstream along with anticoagulants (Phillips et al., 2017). These parasites 
exist as sporozoites, the infective, motile stage of the life cycle. These sporozoites will then 
follow the blood stream and lympathics into the liver, where they invade the human hepatocytes. 
Inside the hepatocytes, the sporozoites divide asexually to form tens of thousands of merozoites. 
These merozoites are then released from lysed hepatocytes into the bloodstream, where they can 
now invade red blood cells. It is at this stage that symptoms of the infection surface. Inside the 
red blood cell, the merozoites go through an asexual reproductive stage last 4 to 8 days, going 
through the ring stage, then trophozoite stage and finally the schizont before being released by 
hemolysis to begin a new infection of fresh red blood cells. During this stage, a small portion of 
the merozoites become sexually committed and differentiate into gametocytes that can be taken 
up by another Anopheles mosquito vector. In the mosquito host, the gametocytes fuse in the gut 
of the mosquito to eventually form an oocyst, which turns into sporozoites that reside in the 
salivary gland of the mosquito, ready for another round of infection (Phillips et al., 2017). 
 
Current Drug Treatments 
 
Historically, quinine is the first drug used against malaria. It is an ancient drug that is derived 
from the bark of the cinchona tree (Harrison, 2015), and has been in use as an antimalarial for 
almost 400 years (Achan et al., 2011). It was then mainly replaced by chloroquine, a drug 
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developed during the Second World War that had less side effects, and proved to be very 
successful in controlling the disease (Wellems and Plowe, 2001). Widespread of the drug 
however brought about the inevitable rise of resistant mutants – first discovered along the 
Thailand-Cambodia border and in Colombia in the late 1950s (Payne, 1987), the strains spread 
across the world and by the late 1970s it has swept across most of the world and rendered sole 
chloroquine therapies ineffective (Bray et al., 2005b). Around this time, Chinese scientists had 
isolated artemisinin and showed its clinically effectiveness against malaria (Klayman, 1985), 
fortuitously taking up the mantle of treating the disease from chloroquine. Resistance for this 
drug has also emerged in recent years from the same Thailand-Cambodia border that festered 
resistance for chloroquine (Dondorp et al., 2009). 
 
Due to development of these resistances, no single drug is effective against all the different 
Plasmodium species (Daily, 2017). Hence the drug regime used is often predicated on the drug 
resistance profiles of parasites found in the patient’s region. The conventional treatment for 
typical P. falciparum malaria is artemisinin combination therapies (ACTs), which consist of an 
artemisinin derivative coupled with another quinoline-containing drug. This combination is done 
because while artemisinin is typically fast acting, it has a very short in vivo half-life of 1 hour in 
patients (White, 2008). In contrast, quinoline-containing drugs have longer half-life that help 
prevent recrudescence and suppress development of parasite resistance (Enserink, 2010). 
 
Artemisinin is a sesquiterpene lactone extracted from the Chinese medicinal herb Artemisia 
annua (Tilley et al., 2016). The drug is activated to become cytotoxic in the parasite through 
iron-catalyzed reductive scission of its endoperoxide bond, and iron is found abundantly in the 
parasitophorous vacuole due to degradation of host cell hemoglobin during infection (Meshnick 
et al., 1991). The activated drug now reacts against any nucleophile in the cell, ultimately 
causing cell death. Resistance against the drug has developed in parasites through mutations in 
the K13 protein, which seem to mediate an enhanced cell stress response that counters the 
nonspecific damage that artemisinin causes in the cell (Tilley et al., 2016).  
 
In terms of the quinoline-containing dugs, quinine has a low therapeutic index and large number 
of adverse side effects, which makes it a less popular as a combination drug with artemisinin. 4-
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aminoquinolines (like chloroquine, amodiaquine, piperaquine and pyronaridin) and amino-
alcohols (like mefloquine or lumefantrine) are the partners of choice instead. The mechanism of 
action for quinoline-containing is likely the inhibition of formation of hemozoin crystals (Foley 
and Tilley, 1998). The resultant accumulation of toxic heme kills the parasite. Mutations in three 
genes, pfcrt, pfmdr1 and pfnhe, seem to be involved in mediating resistance to these drugs. 
 
In this chapter, we used single-particle cryo-EM to determine the high resolution structure of the 
PfCRT protein and show that it has a conserved drug metabolite transporter family fold. We are 
also able to map the various known clinical mutations onto this structure and through 
scintillation proximity assay of PfCRT in liposomes that the likely mechanism for drug 
resistance is transport of the chloroquinine/piperaquine through PfCRT. 
 
Single-Particle Cryo-EM Challenges 
 
The main challenge with structure determination of PfCRT was its size – it is a 48 kDa 
membrane protein. Complicating this is the fact that most of the protein is predicted to be 
embedded in the lipid bilayer, reducing the amount of features that can be used for particle 
alignment. 
 
Our first solution to this problem was to raise an antibody against PfCRT to use as a fiducial 
marker (Wu et al., 2012). Working with the Kossiakoff lab, synthetic antibody (sAB) phage 
display was used to raise such antibodies (Paduch et al., 2013, Dominik and Kossiakoff, 2015a). 
Their library design is to introduce limited amino acid diversity into the three heavy chain 
complementary determining regions (CDRs) and the third light chain CDR. The amino acids are 
biased towards those that are found in protein-protein binding interfaces, such as tyrosine and 
tryptophan. Phages displaying these varied sAB were selected across multiple rounds to identify 
PfCRT specific sAB. The best sABs were checked for binding affinity using ELISA before being 
tested for binding against purified PfCRT on a size exclusion column. 
 
Despite the presence of the sAB (~50 kDa), the molecular weight of PfCRT with the Fab 
complex will only be ~100 kDa. Thus imaging conditions were also optimized – we used a 
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smaller pixel size of 0.5175 Å/pixel. This was also used by Lander and colleagues (Herzik Jr et 
al., 2017, Herzik et al., 2019) to achieve sub-3 Å for their smaller than 200 kDa proteins, as the 
DQE of the camera will be shifted to benefit higher resolution ranges. The trade-off is a smaller 
field of view – by around a quarter – meaning less particles can be collected in a single session. 
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Summary: The emergence and spread of drug-resistant Plasmodium falciparum has been a 
major setback in efforts to control and eliminate malaria. For decades, treatment relied on 
chloroquine (CQ), a safe and affordable 4-aminoquinoline that was highly effective against 
pathogenic intra-erythrocytic asexual blood-stage (ABS) parasites until resistance arose and 
spread, with devastating consequences in Africa(Miller et al., 2013). Resistance to the 
chemically related current first-line combination drug piperaquine (PPQ) has also recently 
emerged, thwarting its treatment efficacy in Southeast Asia. Resistance to both CQ and PPQ has 
been associated with distinct sets of point mutations in the 49 kDa P. falciparum chloroquine 
resistance transporter PfCRT(Fidock et al., 2000), a member of the drug/metabolite transporter 
(DMT) superfamily(Martin and Kirk, 2004), which resides within the digestive vacuole (DV) 
membrane of the parasite. Here we present the structure of the PfCRT CQ-resistant, PPQ-
sensitive 7G8 isoform to 3.2 Å resolution, determined using fragment antigen-binding 
technology and single-particle cryo-electron microscopy. Mutations contributing to resistance to 
CQ and PPQ map to a central cavity, implicating this as the major site of drug interaction. 
Binding and transport studies reveal that the 7G8 isoform binds both drugs, and mediates 
transport of CQ and of the positively charged amino acid arginine in a membrane potential- and 
pH-dependent manner. These data provide the first atomic-level insights into the molecular 






Recent reductions in the global malaria burden have stalled in the past 2-3 years, with the 
situation in Southeast Asia exacerbated by emerging resistance to artemisinin-based combination 
therapies including the bis-4-aminoquinoline partner drug PPQ(Organization, 2018, Fairhurst et 
al., 2012, Blasco et al., 2017). A major determinant of drug resistance in Plasmodium falciparum 
malaria parasites is the 49 kDa putative transporter PfCRT. Amino acid substitutions in this 
protein group as haplotypes that originated independently decades ago in several regions 
subjected to intense drug pressure with the former gold-standard antimalarial, CQ. These include 
the 5-amino acid 7G8 variant that dominates in South America and the Western Pacific, and the 
8-amino acid Dd2 variant that is prevalent in Southeast Asia and that is thought to have seeded 
the introduction of mutant PfCRT and CQ resistance into Africa (Extended Data Fig. 1). 
Extensive use of PPQ in Cambodia is suspected to have recently driven the rapid emergence of 
novel PfCRT mutations, arising in the Dd2 isoform(Ross et al., 2018). For CQ, resistance has 
been attributed to mutant PfCRT-mediated efflux of drug out of the DV (Fig. 1a). It remains 
unclear whether this mechanism would apply to PPQ(Naude et al., 2005, Lakshmanan et al., 
2005, Sanchez et al., 2007, Paguio et al., 2009, Martin et al., 2009). CQ and PPQ are thought to 
act by accumulating in the ABS parasite’s acidic DV as protonated species that bind toxic Fe3+ 
heme (ferri-protoporphyrin IX; FPIX) and inhibit heme incorporation into chemically inert 
hemozoin crystals(Olafson et al., 2015, Dhingra et al., 2017). FPIX is released following 
parasite-mediated proteolysis of host hemoglobin (Hb) that is endocytosed into the DV. 
 
To explore the structural basis of PfCRT-mediated drug resistance, we used single-particle cryo-
electron microscopy (cryo-EM) to determine the structure of the 49 kDa 7G8 PfCRT. To 
overcome current cryo-EM size limitations(Renaud et al., 2018), we screened a synthetic phage 
display library(Dominik et al., 2016) to select for recombinant PfCRT-specific antigen-binding 
fragments (Fabs, ~50 kDa) to form a stable PfCRT-Fab complex (Extended Data Fig. 2 and 3). 
The cryo-EM reconstruction of the nanodisc-incorporated 7G8 PfCRT-Fab complex was 
determined to a nominal resolution of 3.3 Å, with the PfCRT portion resolved to 3.2 Å 
(Extended Data Table 1 and Extended Data Fig. 4). Using this map, a de novo model of 
PfCRT was built comprising residues 47-113 and 123-405 of the 424-amino acid protein (Fig. 
1b, c and Extended Data Fig. 4, 5). PfCRT is monomeric and consists of 10 transmembrane 
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(TM) helices with both termini located on the cytosolic side (Fig. 1b). Two juxtamembrane 
helices (JM1 and JM2), parallel to the DV membrane on opposite sides, are located at the N-
terminus and between TM helices 7 and 8, respectively (Fig. 1b). The 10 TMs are arranged as 
five helical pairs that form two-helix hairpins with an inverted topology, whereby the N-termini 
of helices 1-5 pair on the same side of the DV membrane as the C-termini of helices 6-10 (Fig. 
1b, c and Extended Data Fig. 6). The structure of PfCRT is similar to Vrg4 (PDB ID: 
5OGE/5OGK;(Parker and Newstead, 2017)), YddG (PDB ID: 5I20;(Tsuchiya et al., 2016)) and 
TPT (PDB ID: 5Y78/5Y79;(Lee et al., 2017)), which are also DMTs (Extended Data Fig. 7A).  
 
TM helices 1–4 and 6–9 form a central cavity of ~ 3,300 Å3 that is wider on the DV side of the 
protein and closes approximately halfway into the membrane, suggesting that the structure is in 
an open-to-DV/inward-open state conformation (Fig. 2a). The corresponding cavity in Vrg4, 
TPT and YddG constitutes the known ligand-binding site (Extended Data Fig. 7b), predicting 
that this cavity is also the ligand-binding site for PfCRT. The net charge in the PfCRT cavity is 
negative, determined mainly by the aspartate residues D137, D326 and D329 (Fig. 2a). In 
contrast, both Vrg4 and TPT have a positively charged cavity, whereas that of YddG is neutral 
(Extended Data Fig. 7b). These electrostatic profiles suggest that putative substrates for PfCRT 
are likely positively charged, in contrast to those of the other three DMTs cited. Consistent with 
this proposal, the positively charged residue arginine R111 in the variable loop region of our 
selected Fab occupies the predicted binding site in the cavity of PfCRT (Fig. 2b). Interactions 
between the Fab R111 and PfCRT D326 and D329 presumably help stabilize the PfCRT-Fab 
complex (Fig. 2b).  
 
Alignment of the PfCRT sequence with Plasmodia and other Apicomplexan orthologs reveals 
extensive sequence conservation within the helices that line the cavity, as well as the adjacent 
TM5 / TM10 inverted helices that are separate from the cavity (Fig. 2c and Extended Data Fig. 
8). None of the PfCRT mutations associated with CQ or PPQ resistance mapped to residues that 
were fully conserved across our set of Apicomplexan CRT orthologs (Extended Data Fig. 8), 
suggesting structural and/or functional constraints. We also identified density in a separate cleft 
region, delineated by JM1, TM1, TM9 and TM10, near the cytosolic side of the DV membrane. 
We tentatively assigned this density to cholesterol hemisuccinate, present during the purification 
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(Extended Data Fig. 9). This hydrophobic cleft is absent in the other DMT superfamily 
members cited above, which also lack JM1.  
 
Extensive conservation was also observed in JM2 and the ensuing long loop connecting TM 
helices 7 and 8. This loop, extending into the DV, consists of four highly conserved cysteines 
that likely form two disulfide bridges (Fig. 2c, d and Extended Data Fig. 8), suggesting that 
this particular region might be involved in redox sensing through formation of reversible 
disulfide bonds(Cremers and Jakob, 2013). A role for PfCRT in redox sensing is plausible given 
the release in the acidic DV (pH 5.2-5.5) of Hb-derived Fe2+-protoporphyrin IX, whose 
oxidation to the Fe3+ state produces reactive oxygen species(Gorka et al., 2013).  
 
The structure of PfCRT provides key insights into how mutations can confer resistance to CQ 
and PPQ (Fig. 3a). All CQ-R isoforms, irrespective of geographic origin, share a common and 
requisite K76T mutation, substituting a positive lysine that is believed to repel CQ2+ for an 
uncharged threonine(Lakshmanan et al., 2005, Callaghan et al., 2015). Our structure places 
residue 76 directly in the lining of the central cavity (Fig. 3b). The CQ-R 7G8 isoform has four 
additional mutations (C72S, A220S, N326D, I356L; compared with the canonical wild-type CQS 
3D7 isoform), which also line the cavity (Fig. 3b), supporting this region as the primary site of 
CQ interactions. Indeed, this cavity, with a ~25Å maximum diameter, is in principle able to 
accommodate CQ or PPQ (~14 and ~21Å maximum lengths, respectively). The C350R mutation, 
which reverses CQ resistance when added to 7G8(Pelleau et al., 2015), also resides in this cavity 
where presumably the introduction of the positive Arg residue minimizes interactions with CQ2+. 
Similarly, the CQ-R Dd2 isoform has six (M74I, N75E, K76T, A220S, N326S, I356T) of its 
eight mutations located within the cavity, with two additional mutations (Q271E and R371I) 
located at its entrance (Fig 3b and Extended Data Fig. 1b).  
 
Our structural data support a primary role for PfCRT in PPQ resistance, with the associated 
amino acid substitutions lining the cavity (including C350R that arose on the 7G8 isoform; as 
well as H97Y, F145I, and G353V that emerged on the Dd2 isoform; Fig. 3b). The high-grade 
resistance mutation F145I resides close to the cavity entrance, and both H97Y and G353V are in 
line with the plane of CQ-R mutations. M343L, which confers low-grade PPQ resistance in the 
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Dd2 isoform, lies above the cavity, close to the cytosol. Almost all mutations that promote PPQ 
resistance in Dd2 parasites result in at least some loss of CQ resistance, suggesting differences in 
CQ and PPQ binding and transport (Fig. 3b and Extended Data Fig. 1a;(Ross et al., 2018)).  
 
Using scintillation proximity-based assays(Quick and Javitch, 2007) on structurally-validated 
purified protein reconstituted in nanodiscs, we found that PfCRT 7G8 binds both CQ and PPQ 
(Fig. 4a). Isotopic dilution assays yielded mean half-maximal binding constants of ~300 nM for 
CQ, similar to earlier studies with Dd2 PfCRT(Zhang et al., 2004, Lekostaj et al., 2008), and 
~190 nM for PPQ (Fig. 4b). Each drug competitively inhibited the binding of the other with 
virtually identical mean half-maximal inhibition constants (IC50 values) of ~170 nM (Fig. 4c).  
 
Binding of these two drugs was partially inhibited by verapamil (Fig. 4d), a known CQ 
resistance reversal agent that has been reported to inhibit CQ transport by resistant 
parasites(Bellanca et al., 2014). Near-complete inhibition was observed with amodiaquine, a 
related 4-aminoquinoline first-line partner drug against which PfCRT 7G8 mediates cross 
resistance(Sa et al., 2009), implying similar drug occupancies in the PfCRT cavity. Control 
assays found no inhibition for [3H]-CQ or [3H]-PPQ binding with the structurally unrelated 
antimalarial drugs lumefantrine and atovaquone that have separate modes of action. No [3H]-CQ 
or [3H]-PPQ binding was observed with the unrelated transporter LeuT .  (Shi et al., 2008)
 
We also examined drug uptake using protein reconstituted in proteoliposomes, which allowed us 
to investigate energetic requirements for transport. Our data showed that active [3H]-CQ uptake 
required an inwardly directed pH gradient (pH 5.5-7.5, corresponding to the gradient observed in 
the DV of the parasites(Kuhn et al., 2007)), and a membrane potential Ψ (Extended Data Fig. 
10a). Here, Ψ was created by an outward-directed K+ diffusion gradient from the 
proteoliposomes in the presence of the K+-specific ionophore valinomycin. Using these 
conditions, we observed [3H]-CQ uptake, peaking within one minute (Fig. 4e). These results 
support proton motive force-dependent CQ efflux as the mechanism underlying mutant PfCRT 
7G8-mediated CQ resistance, and are consistent with earlier reports(Zhang et al., 2004, Bray et 
al., 2005a, Sanchez et al., 2007, Martin et al., 2009, Paguio et al., 2009, Bellanca et al., 2014). 
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Under our experimental conditions, no detectable uptake was observed with [3H]-PPQ, as 
expected for this PPQ-S isoform (Fig. 4e).  
 
Based on the observed interaction between the Fab R111 and the cavity of PfCRT (Fig. 2b), 
earlier evidence that mutant PfCRT isoforms can result in excess accumulation of Hb-derived 
peptides in the DV(Lewis et al., 2014, Lee et al., 2018), the cationic nature of putative PfCRT 
substrates, and prior transport studies(Juge et al., 2015), we also tested the inhibition of Arg on 
[3H]-CQ binding. Indeed, this positively charged amino acid inhibited [3H]-CQ binding, whereas 
control experiments using Leu revealed no interaction of this amino acid with PfCRT 7G8 (Fig. 
4d). We also assayed for Arg as a potential transported substrate for PfCRT. Like CQ, [3H]-Arg 
uptake in proteoliposomes required a pH gradient and a Ψ (Extended Data Fig. 10b), and its 
accumulation peaked within one minute (Fig 4e). Scintillation proximity-based binding revealed 
that [3H]-Arg binds to PfCRT 7G8 (Extended Data Fig. 10c), with a half-maximal binding 
constant of ~400 µM (Extended Data Fig. 10d). Binding of [3H]-Arg was effectively competed 
by both CQ and PPQ, as well as by amodiaquine and non-radiolabeled Arg or Lys. In contrast, 
the aliphatic amino acid Leu failed to inhibit [3H]-Arg binding (Extended Data Fig. 10e). 
Binding of [3H]-Arg, [3H]-CQ and [3H]-PPQ was competed by the Fab in a concentration-
dependent manner (Fig. 4f), indicating overlapping binding of Arg, CQ, PPQ and the Fab to the 
PfCRT cavity. In our proteoliposome uptake assays, we also observed partial to strong inhibition 
of [3H]-CQ and [3H]-Arg uptake by verapamil and 4-aminoquinolines, at levels similar to those 
observed in the binding assays (Fig. 4g and Extended Data Fig. 10e). These data further 
implicate a crucial role for the central cavity in dictating PfCRT 7G8-mediated binding and 
transport.  
 
In summary, our 3.2 Å resolution cryo-EM structure reveals that mutations previously identified 
to be involved in antimalarial drug resistance surround a central cavity, implicating this as the 
likely site of parasite protein interaction leading to resistance to these drugs. Moreover, we show 
that PfCRT mediates binding and transport of the 4-aminoquinoline CQ and positively charged 
amino acids in the presence of both membrane potential and pH gradients as driving forces. Our 
binding data and mutational analysis also support emerging PfCRT mutations as drivers of high-
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grade PPQ resistance. These results create new tools and perspectives to further elucidate PfCRT 
function and its relation to drug binding and transport, and to assess whether inhibition of PfCRT 
itself can be leveraged as a strategy to overcome its ability to mutate and mediate parasite 





Figure 1 | Single-particle cryo-EM structure of PfCRT 7G8. a, PfCRT (PlasmoDB ID 
PF3D7_0709000) is localized within the membrane of the P. falciparum intra-erythrocytic 
parasite’s digestive vacuole (DV), wherein imported host hemoglobin (Hb) is catabolized and 
toxic free heme is released. The related 4-aminoquinoline antimalarial drugs chloroquine (CQ) 
and piperaquine (PPQ) are believed to bind heme and prevent its incorporation into inert 
hemozoin(Lakshmanan et al., 2005, Dhingra et al., 2017). PfCRT is thought to efflux CQ out of 
the DV into the cytosol away from its heme target. b, Topology of PfCRT with disordered 
regions shown as dotted lines. Transmembrane helices are numbered 1 to 10, while the 
juxtamembrane helices (JM) are labeled JM1 and JM2. c, 3.2 Å cryo-EM structure of PfCRT 
7G8, with the 10 transmembrane helices colored in rainbow. The N- and C- termini are labeled. 









Figure 2 | Structural features of PfCRT. a, Surface representation of the electrostatic potential 
of the central cavity with red and blue being negatively and positively charged, respectively. On 
the right, a central slice through the structure (dotted lines) as an insert shows the arrangement of 
transmembrane helices, which are labeled from N- to C-terminus. b, Interaction between the 
CTC Fab and PfCRT 7G8. PfCRT is rendered in cartoon and colored based on conservation. 
Residues in PfCRT 7G8 that are proximal to R111 in the Fab variable region (pink and red 
arrowed) are colored on the basis of their conservation in our selected panel of Apicomplexan 
parasites (Extended Data Fig. 9 and 10). c, PfCRT and Fab are rendered in cartoon and colored 
in conservation and pink, respectively. d, Cysteine residues that likely form disulfide bonds at 





Figure 3 | Mapping of mutations onto the PfCRT structure. a, Chemical structures of CQ and 
PPQ. b, Residues known to contribute to resistance to CQ and PPQ have their side chains 
rendered as sticks and are colored based on their resistance profiles. The remaining structure is 
rendered in cartoon and colored in grey. Highlighted residues are topologically represented in 
Extended Data Fig. 1. Mutations in the 7G8 and Dd2 regional haplotypes of PfCRT (Extended 
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Figure 4 | Functional characterization of PfCRT 7G8. a, Binding of 370 nM [3H]-CQ (red) or 
3H]-PPQ (blue)  75 nM [ to PfCRT 7G8 ± imidazole (Imid.; data are means±SEM; N,n=3,3). b, 
Isotopic dilution of [3H]-CQ ( 3H]-PPQ () revealed LogEC50 of -6.53 ± -) or [   0.04 M and 
6.70 ± 0.05 M (corresponding to means of 296.5 nM CQ and 189.6 nM PPQ), respectively. c, 
Competition of [3H]-CQ ( 3H]-PPQ () binding with non-radiolabeled PPQ or CQ, ) or [
respectively, revealed LogIC50 values of -6.77 ±  -6.78 ± 0.06 M (corresponding to  0.03 M and 
means of 170.9 nM and 167.3 nM), respectively. d, Specific binding of [3 3H]-PPQ H]-CQ or [
performed in the absence (-) or presence of 10 µM verapamil (VP), 1 µM amodiaquine (ADQ), 
10 µM lumefantrine (LMF) or atovaquone (ATQ), or 1 mM Arg or Leu. Nanodiscs containing 
LeuT(Shi et al., 2008) served as control. e, Time course of 93 nM [3H]-CQ, 75 nM [3H]-PPQ, or  
125 nM [3H]-Arg, uptake measured with 7G8 PfCRT-containing proteoliposomes (PLs). Data 
are mean±SEM; N,n=2,3.  f, Fab binding to the PfCRT 7G8 isoform reduces binding of 250 nM  
[3H]-Arg, 370 nM [3H]-CQ, or 75 nM [3H]-PPQ in a concentration-dependent manner, yielding 
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IC50 values of 0.18 ± 0.02 µM, 0.15 ± 0.02 µM, and 0.20 ± 0.02 µM, respectively. g, One-minute 
uptake of 370 nM [3H]-CQ or 250 nM [3H]-Arg was determined in the presence or absence of 1 
µM Fab, 10 µM VP, CQ, PPQ, ADQ, or 1 mM Leu. Data are shown as mean±SEM (N,n=2,3) 
and values are normalized to the signal in the absence of non-radiolabeled compound. Data in 
panel a, c, d, and f are shown as mean±SEM (N,n=3,3) and are normalized to the specific signal 
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Small-scale expression screen of CRT variants. Initial expression studies were performed with 
twelve CRT variants, including the Plasmodium falciparum pfcrt sequences 7G8 (AF233064), 
HB3 (Q9N623), HB3 that was codon optimized for Xenopus laevis, Dd2 (D5L5S2), Dd2 codon 
optimized for Xenopus laevis, Plasmodium berghei CRT (PbCRT, Q9GSD8), Plasmodium 
knowlesi CRT (PkCRT, Q9GSD7), Plasmodium vivax CRT (PvCRT, Q9GSD3), PvCRT codon 
optimized for Spodoptera frugiperda, Theileria parva CRT (TpCRT, Q4N5R6), Theileria 
annulata CRT (TaCRT, Q4UDS9), and Cryptosporidium parvum CRT (CpCRT, Q7YZ23). To 
express these in mammalian cells, the sequences were cloned into pFM1.2(Assur et al., 2012) as 
a GFP fusion with a decahistidine affinity tag at either the 5’ or 3’ end of the gene. One g of 
each construct was diluted into 100 l opti-MEM (ThermoFisher Scientific) and mixed with 100 
l opti-MEM containing 4 g of polyethylenimine (PEI) Max MW 40,000 (Polysciences). This 
mixture was added to 1.0×106 HEK293T cells (Invitrogen) cells in a total volume of 2 mL, in a 
6-well plate (Corning). The cell transfection mixture was incubated at 37°C for 72 hr in 5% CO2. 
Transfected cells were then harvested, centrifuged at 800×g for 10 minutes at 4°C, and washed 
once on ice in 1×PBS. Each pellet was resuspended and solubilized in 20 mM HEPES pH 7.5, 
200 mM NaCl, 20 mM MgSO4, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), cOmplete, 
EDTA-free Protease Inhibitor Cocktail (Roche), 10 µg/mL DNaseI (Roche) and 8 µg/mL RNase 
(Sigma-Aldrich) supplemented with 1% n-dodecyl-β-D-maltopyranoside (DDM) and 0.1% 
cholesteryl hemisuccinate (CHS) at 4°C for 2 hr. Insoluble material was removed by 
ultracentrifugation in a single angle rotor at 4°C for 45 min. The supernatant of each sample was 
subjected to western blot analysis using a rabbit anti-GFP antibody (diluted 1:5,000; Invitrogen) 
and a secondary goat anti-rabbit IgG conjugated to horseradish peroxidase (diluted 1:7,000; 
Invitrogen). Labeling was detected using a western blot Luminol reagent (Santa Cruz).  
 
Expression and stability were further evaluated by fluorescence-coupled size exclusion 
chromatography (FSEC)(Kawate and Gouaux, 2006). In these assays, each GFP-tagged construct 
was transfected into HEK293 Freestyle cells (Invitrogen) in the presence of PEI. Transfected 
cells were incubated at 37°C for 72 hr with 8% CO2 and 70% humidity. Cell supernatants for the 
FSEC analysis were prepared as described above. DDM-solubilized supernatants were loaded 
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onto a TSKgel G4000SWxl column (Tosoh Bioscience LLC) attached to a Prominence UFLC 
(Shimadzu) coupled to a RF-10AXL fluorescence detector (Shimadzu). These studies identified 
the PfCRT 7G8 construct as having the best yield and mono-dispersity.  
 
PfCRT 7G8 protein expression, purification and nanodisc reconstitution. The pfcrt 7G8 full-
length open reading frame was cloned into the pEG BacMam vector(Goehring et al., 2014) using 
the Gibson Assembly method(Gibson et al., 2009). pfcrt was fused at its 3’ end with a Tobacco 
Etch Virus (TEV) protease cleave site (ENLYFQSYV) and a decahistidine affinity tag followed 
by a streptavidin affinity tag (WSHPQFEK). The resulting plasmid was transformed into 
DH10Bac E. coli competent cells to generate the bacmid using bac-to-bac (Invitrogen) protocol. 
Recombinant P1 baculovirus was transfected into Sf9 cells (Expression System) in the presence 
of PEI and cultured in ESF 921 Protein-free insect cell culture medium (Expression Systems). 
For protein expression, 100 mL P4 virus was used to infect 1L cultures of HEK293S GnTi- cells 
(Invitrogen) at 3×106 cells/mL in Freestyle 293 media (GIBCO) supplemented with 2% FBS 
(GIBCO). After infection, the cells were incubated at 37°C for 8 to 10 hr in the presence of 8% 
CO2 and 70% humidity. We then added 10 mM sodium butyrate (Sigma-Aldrich) to enhance 
BacMam protein expression. Cells were incubated at 37°C for another 48 hr prior to their harvest. 
Cell pellets were homogenized in low salt buffer 10 mM HEPES pH 7.5, 10 mM KCl, 10 mM 
MgCl2, 0.5 mM PMSF, cOmplete, EDTA-free Protease Inhibitor Cocktail, 10 µg/mL DNaseI 
and 8 µg/mL RNase in a glass homogenizer. Membrane fractions were isolated by 
ultracentrifugation at 40,000×g in Type 45 Ti Rotor (Beckman Coulter). Membrane fractions 
were further homogenized and washed twice with high salt buffer containing 10 mM HEPES pH 
7.5, 10 mM KCl, 10 mM MgCl2, 1 M NaCl, 0.5 mM PMSF, cOmplete, EDTA-free Protease 
Inhibitor Cocktail, 10 µg/mL DNaseI and 8 µg/mL RNase in a glass homogenizer followed by 
ultracentrifugation. The washed membrane fractions were resuspended again by homogenizing 
in buffer containing 20 mM HEPES pH 7.5, 200 mM NaCl and 0.5 mM PMSF, and cOmplete, 
EDTA-free Protease Inhibitor Cocktail, and then stored at -80°C until use. 
 
The thawed membrane fraction was solubilized by adding DDM with CHS in a 10:1 (w/w) ratio 
to a final concentration of 1% (w/v) detergent and incubating at 4°C for 2 hours with gentle 
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agitation. Insoluble material was removed by ultracentrifugation at 40,000×g in a type 45 Ti 
rotor (Beckman Coulter) at 4°C for 30 min. The supernatant was filtered (Millipore) into a 
Falcon tube containing pre-equilibrated Ni2+-NTA resin (Qiagen) in the presence of 20 mM 
imidazole and incubated 4°C overnight with gentle rotation. The resin was washed with 10 
column volumes of buffer containing 20mM HEPES pH 7.5, 200 mM NaCl, 60mM imidazole, 
0.1% DDM and 0.01% CHS and eluted with buffer consist of 20 mM HEPES pH 7.5, 200 mM 
NaCl, 200 mM imidazole, 0.05% DDM and 0.005% CHS. The eluted protein was incorporated 
into lipid nanodiscs with a molar ratio 1:600:10 of protein:1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (POPG): membrane scaffold protein 1D1 (MSP1D1) and incubated at 
4°C for 2.5 hr with gentle agitation. Reconstitution was initiated by removing detergent with the 
addition of Bio-beads (Bio-Rad) at 4°C overnight with constant rotation. Bio-beads were 
removed and the nanodisc reconstitution mixture was bound again to Ni2+-NTA resin for at 4°C 
for 2 hr to remove free nanodiscs. The resin was washed with 10 column volumes of wash buffer 
(20 mM HEPES pH 7.5, 200 mM NaCl and 20 mM Imidazole) followed by 4 column volumes 
of elution buffer (20 mM HEPES pH 7.5, 200 mM NaCl and 200 mM Imidazole). The eluted 
protein was further purified by loading on a Superdex 200 Increase 10/300 GL size-exclusion 
column (GE Healthcare Life Sciences) in gel filtration buffer (20 mM HEPES pH 7.0 and 150 
mM NaCl).  
 
Identification of PfCRT-specific Fab fragments using phage display. For the purposes of Fab 
screening, PfCRT 7G8 was reconstituted into nanodiscs using biotinylated MSP1D1. Prior to 
nanodisc assembly, MSP1D1 was chemically biotinylated as previously described(Paduch et al., 
2013, Dominik et al., 2016, Dominik and Kossiakoff, 2015b). Efficient biotinylation was 
confirmed using a pull-down assay with streptavidin-coated paramagnetic particles (Promega). 
Biopanning was performed using Fab Library E(Fellouse et al., 2004, Fellouse et al., 2007) in 
Selection Buffer (25 mM HEPES pH 7.4, 150 mM NaCl, and 1% Bovine Serum Albumin). In 
the first round, biopanning was performed manually using 200 nM of PfCRT 7G8-MSP1D1 
nanodiscs immobilized onto magnetic beads. Following three washes with Selection Buffer, the 
resuspended beads enriched for PfCRT-specific Fab fragments were used to infect log-phase E. 
coli XL-1 Blue cells. Phages were amplified overnight in 2xYT media supplemented with 
ampicillin (100 µg/mL) and M13-KO7 helper phage (109 pfu/mL). To increase the stringency of 
182 
 
selection, four additional rounds of sorting were performed with decreasing target concentration, 
from 150 nM to 75 nM to 40 nM to 20 nM. For each round, the amplified phage pool from each 
preceding round was used as the input. For rounds 2-5, biopanning was performed semi-
automatically using a Kingfisher magnetic beads handler (Thermo Fisher Scientific). To reduce 
the presence of non-specific binders, the phage pool for rounds 2-5 was pre-cleared with 100 µL 
of streptavidin particles. Moreover, for all rounds empty, non-biotinylated 1D1 nanodiscs were 
used as soluble competitors in excess at a constant concentration of 1.5 µM. Finally, in rounds 2-
5, bound phage particles were removed by elution from magnetic beads following a 15 min 
incubation step with 1% Fos-choline-12 prepared in Selection Buffer.  
  
Single-point phage ELISA. The initial validation for selection was performed by single-point 
phage ELISA using individual clones from rounds 4 and 5. All ELISA experiments were 
performed in 96-well plates (Nunc) coated with 2 µg/mL Neutravidin and blocked with Selection 
Buffer. Colonies of E. coli XL-1 blue harboring phagemids were used to inoculated 400 µL 
2xYT media supplemented with 100 µg/mL ampicillin and 109 pfu/mL M13-KO7 helper phage. 
Phages were amplified overnight in 96-well deep-well blocks at 37°C with shaking at 280 rpm. 
Amplified phages were diluted 10-fold into Selection Buffer and assayed against either PfCRT-
loaded or empty biotinylated nanodiscs. Target proteins were immobilized at room temperature 
for 30 min followed by incubation with phage dilutions for 30 min. Bound phage particles were 
detected with TMB substrate (Thermo Fisher Scientific) following a 30 min incubation with 
HRP-conjugated anti-M13 monoclonal antibody (GE Healthcare). The reaction was quenched 
with 1.0 M HCl and the absorbance at 450 nm was measured. Wells containing empty nanodiscs 
were used to determine non-specific binding.  
 
Fab expression and purification. Specific binders from phage ELISA were selected based on 
their signal/background ratio(Dominik et al., 2016) and were sequenced at the University of 
Chicago Comprehensive Cancer Center DNA Sequencing facility. Unique clones were then sub-
cloned in pRH2.2 using the In-Fusion Cloning kit (TaKaRa Bio). Sequence-verified Fab 
expression vectors were then transformed into E. coli BL21-Gold competent cells (Agilent) and 
used to inoculate overnight cultures. Inocula were used the following morning to seed 1L 2xYT 
broth supplemented with 100 µg/mL ampicillin, which were subsequently grown to an OD600 of 
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0.8 and then induced for 4 hours. Cells were harvested by centrifugation and stored at -80°C 
until use. Cell pellets were resuspended in buffer (20 mM HEPES pH 7.4, 150 mM NaCl and 0.5 
mM MgCl2) supplemented with 1 mM PMSF and 1 µg/mL DNase I (Gold Biosciences). These 
preparations were sonicated (Branson Sonifier) until complete lysis was achieved. Lysates were 
then incubated at 60°C for 30 min to eliminate potential Fab proteolyzed fragments, 
subsequently cooled on ice, and cleared by centrifugation. Supernatants were filtered and then 
loaded onto a 5-mL HiTrap MabSelect SuRe column (GE Healthcare) equilibrated with Wash 
Buffer (20 mM HEPES pH 7.4 and 500 mM NaCl). The column was washed 10 times with 
Wash Buffer and Fabs were eluted with 0.1 M acetic acid. Fractions containing Fab fragments 
were loaded onto a 1 mL Resource S column (GE Healthcare) equilibrated with buffer A (50 
mM sodium acetate, pH 5.0). Following washing with 10 column volumes of buffer A, Fab 
fragments were eluted by a linear 0-50% gradient with buffer B (buffer A with 2 M NaCl). 
Fractions containing Fab fragments were evaluated for purity by SDS-PAGE and subsequently 
pooled and dialyzed overnight in 20 mM HEPES pH 7.4 and 150 mM NaCl.  
 
Multi-point protein ELISA. To estimate apparent binding affinity, we performed multi-point 
ELISA with purified Fab fragments(Dominik et al., 2016). Purified Fab fragments were diluted 
serially 3-fold starting from 3 µM maximum concentration. ELISA plates were coated and 
blocked as described above for the phage ELISA studies. 50 nM of biotinylated PfCRT 7G8-
MSP1D1 nanodiscs were immobilized on the plates by 30 min incubation, followed by washing. 
Fab dilutions were added to wells containing immobilized PfCRT and allowed to bind for 30 min. 
Bound Fab was detected with TMB substrate following a 30 min incubation with HRP-
conjugated mouse anti-human IgG F(ab’)2 monoclonal antibody (Jackson). Reactions were 
quenched with 1.0 M HCl and the absorbance at 450 nm was measured. A450 values were plotted 
against the log10 of the Fab concentration. EC50 values were then calculated in Prism (GraphPad 
Software) using a variable slope model and assuming a sigmoidal dose response. 
 
PfCRT 7G8 in nanodisc complexed with Fab CTC. Size-exclusion chromatography fractions 
of purified PfCRT in nanodisc were incubated with the CTC Fab on ice for 2 hr in a 1:3 molar 
ratio of protein to Fab. The PfCRT-Fab complex was then concentrated and filtered, and then 
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loaded on a Superdex 200 Increase 10/300 GL size-exclusion column in gel filtration buffer 
(20mM HEPES pH 7.0 and 150mM NaCl). 
 
Negative stain electron microscopy. In order to determine the quality of the sample and success 
of the Fab binding, purified protein was diluted to 0.01 mg/ml (for PfCRT without Fab) or 0.005 
mg/ml (for PfCRT with Fab) and applied onto copper grids (Ted Pella). These grids were 
overlaid by a thin (∼1.5 nm) layer of continuous carbon that had been plasma-cleaned (Gatan 
Solarus) for 30s using a mixture of H2 and O2. Thereafter, filter paper (Whatman 4) was used to 
remove the protein solution. 3 µl of 2% uranyl formate was then added and immediately 
removed by absorbing with filter paper – this repeated seven times. The grid was imaged on 
either a Tecnai T12 microscope (FEI) (for PfCRT without Fab) or a Tecnai TF20 microscope 
(FEI) (for PfCRT with Fab). Both microscopes were equipped with a Tietz F416 CCD camera 
(Tietz) at 1.23 Å or 1.10 Å per pixel respectively, using the Leginon software package(Suloway 
et al., 2005). 166 and 87 images were collected respectively and were processed using the 
Appion software package(Lander et al., 2009b) to obtain 2D classes with Relion 2.1(Scheres, 
2012b, Kimanius et al., 2016). The micrographs showed good particle dispersion (Extended 
Data Fig. 3). 2D class averages showed that the Fab addition resulted in a clear fiducial for 
particle alignment. 
 
Single-particle cryo-EM vitrification and data collection. Purified PfCRT-Fab complex was 
concentrated to 1.56 mg/ml using a 30-kDa concentrator (Amicon). 2.5 μL of sample was added 
to a plasma-cleaned (Gatan Solarus) 1.2/1.3 µm holey gold grid (Quantifoil UltrAuFoil) and 
blotted using filter paper on one side for 2s using the Leica GP plunger system before plunging 
immediately into liquid ethane for vitrification. The plunger was operating at 6°C with >80% 
humidity to minimize evaporation and sample degradation. 
 
Data acquisition. Images were recorded on a Titan Krios electron microscope (FEI) equipped 
with a Cs corrector and K2 summit direct detector (Gatan) operating at 0.5175 Å per pixel 
(calibrated using an AAV2 dataset) in counting mode using the Leginon software 
package(Suloway et al., 2005). Energy filter slit width of 15 eV was used during the collection 
and was aligned automatically every hour using Leginon. Data collection was performed using a 
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dose of ~91.56 e-/Å2 across 80 frames (75 msec per frame) at a dose rate of ~4.0 e–/pix/sec, 
using a set defocus range of -1.2 μm to -1.8 μm. A 100 µm objective aperture was used. In total, 
3,377 micrographs were recorded over a single 2.5-day collection using an image beam shift data 
collection strategy(Cheng et al., 2018a). Ice thickness was monitored after every 4th exposure 
using the Leginon zero-loss peak (ZLP) algorithm(Rice et al., 2018b) and was determined to be 
23.1 ± 9.1 nm (SD) 
 
Data processing. Movie frames were aligned using MotionCor2(Zheng et al., 2017b) with 3 by 
3 patches, a grouping of 3, and a B-factor of 100, using the Appion software package(Lander et 
al., 2009b). Micrograph CTF estimations were performed using both CTFFind4(Rohou and 
Grigorieff, 2015) and GCTF(Zhang, 2016), and the best estimates based on confidence were 
selected using the Appion software package. Micrographs that had estimated resolution at 0.5 
confidence level of worse than 10 Å were removed, resulting in 3,297 micrographs. DoG 
picker(Voss et al., 2009) was used to pick 682,520 particles (extracted binned by 2), which were 
transferred into Relion 2.1(Scheres, 2012b, Kimanius et al., 2016) for 2D classification. 2D class 
averages that showed clear structural details of PfCRT were used as templates for template-based 
picking using Gautomatch (https://www.mrc-lmb.cam.ac.uk/kzhang/Gautomatch; Kai Zhang, 
unpublished). To not miss any particles, we chose a lenient threshold that resulted in 1,095,304 
initial picks. These were pared down to 183,241 particles after Relion 2D classification. Two 
rounds of CryoSPARC 2 (Punjani et al., 2017b) ab initio (using 2 models) were then performed 
to further refine the particle stack to 35,682 particles, which yielded an 8.27 Å resolution upon 
3D homogeneous refinement. Particles were then re-centred and re-extracted using Relion and 
per-particle CTF estimation using GCTF was then performed. The particle stack was brought 
back into CryoSPARC for one round of ab initio refinement (using 2 models). The best set of 
particles and model was then used for non-uniform refinement. This resulted in a 3.7 Å map 
from 17,034 particles. 
 
The mag_distortion_correct software(Grant and Grigorieff, 2015a) was then used on the 
micrographs to correct for magnification anisotropy of 1.3%, which was determined previously 
using gold-replica grating using the mag_distortion_estimate software(Grant and Grigorieff, 
2015a). The resulting particles were then subjected to three rounds of CryoSPARC non-uniform 
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refinement, re-centering and re-extracting in Relion, with removal of overlapped particles 
centered no more than 20 pixels from each other, and CTF refinement using cisTEM(Grant et al., 
2018a). This resulted in 3.6 Å from 17,030 particles. 
 
In an effort to optimize the alignment of frames, movie frames were re-aligned using 
MotionCor2 with 2 by 2 patches, a grouping of 3, correction for in-frame motion, and a B-factor 
of 150 for global frame alignment and 50 for local frame alignment. Visual inspection of the 
resulting micrographs showed that certain micrographs fared better using the new frame 
alignment parameters (these were less blurry), while some fared worse than with the 3 by 3 
patches described above. To determine the best frame alignment parameter on a per-particle 
basis, particles were extracted from micrographs using both conditions. These particles were then 
subjected to a CryoSPARC 2 non-uniform refinement and one round of cisTEM refinement. 
Thereafter, for each particle, we chose the alignment parameter that produced the highest score. 
This resulted in 7,191 particles coming from micrographs aligned with 2 by 2 patches, and 9,714 
particles coming from micrographs aligned with 3 by 3 patches. Particle polishing algorithms 
that require neighboring particles to aid in alignment were tested but gave consistently worse 
results, likely because of the low average number of particles per micrograph (~5.3) caused by 
the high magnification used and sizeable number of free Fab contaminants. 
 
Thereafter, signal subtraction using Relion was performed. Subtraction of just the nanodisc did 
not improve the overall resolution. However, subtraction of both the nanodisc and constant 
domain of the Fab improved the resolution of the reconstruction, after CryoSPARC non-uniform 
refinement, to 3.3 Å overall, and 3.2 Å for PfCRT alone. 
 
This final map was sharpened using phenix.auto_sharpen(Adams et al., 2010), which 
automatically selected b_iso sharpening to high_resolution cutoff as the algorithm to use. Overall 
b_sharpen applied was 28.3 Å2, final b_iso obtained was 47.3 Å2 and the high-resolution cut-off 
was 3.2 Å. 
 
All conversions between Relion, CryoSPARC, and cisTEM were performed using Daniel 




Model building and refinement. To build the PfCRT model, we first used the 
Chimera(Pettersen et al., 2004) program to approximately segment out the PfCRT part of the 
map from the nanodisc and Fab density. De novo model building for the PfCRT cryo-EM map its 
primary sequence was initiated using Rosetta(Wang et al., 2016). After two rounds of Rosetta 
model building, the partial model was brought into Coot(Emsley and Cowtan, 2004) program for 
manual model building. For model building of the Fab, the Fab portion of the deposited yeast 
nucleoprotein complex (PDB-ID:4XMM(Stuwe et al., 2015)) was used as a starting template as 
it had the same scaffold backbone. An extra electron density between PfCRT helices 1, 9 and 10 
was not modelled by protein density and was likely of lipid origin. Out of the lipids potentially 
present in the nanodisc, CHS produced the best density fit and was therefore incorporated into 
the model. 
 
Thereafter, model adjustment and refinement were performed iteratively in Coot and Phenix, 
with the statistics being examined using Molprobity(Chen et al., 2010) until no further 
improvements were observed. The final map and model were then validated using 1) 
EMRinger(Barad et al., 2015) to compare map to model, 2) ResMap(Kucukelbir et al., 2013) to 
calculate map local resolution, and 3) a program suite with 3D Fourier shell correlations (FSC; 
(Tan et al., 2017)). To calculate the FSC values, we used a cut-off criterion of 0.143(Rosenthal 
and Henderson, 2003a). The 3D FSC program suite(Tan et al., 2017) was used to calculate the 
degree of directional resolution anisotropy. Map-to-model FSCs were also calculated by first 
converting the model to a map using Chimera molmap function at Nyquist resolution (2.07 Å). A 
mask was made from this map using Relion (after low-pass filtering to 8 Å, extending by 1 pixel 
and applying a cosine-edge of 3 pixels), and was then applied to the density map. Map-to-model 
FSC was calculated using EMAN(Ludtke et al., 1999). 
 
Model analysis. A cavity search using the Solvent Extractor from Voss Volume Voxelator 
server(Voss and Gerstein, 2010) was performed using an outer probe radius of 10 Å and inner 
probe radius of 3 Å. We then used a Dali server(Holm and Laakso, 2016) to search for other 
PDB structures with a similar fold. This search produced top results for Vrg4 (PDB ID: 
5OGE/5OGK;(Parker and Newstead, 2017)), YddG (PDB ID: 5I20;(Tsuchiya et al., 2016)) and 
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TPT (PDB ID: 5Y78/5Y79;(Lee et al., 2017)), with Z scores from 26.7 to 16.0. Thereafter, there 
was a large drop in Z score for the next best hit at 8.5 (the chloride pumping rhodopsin, PDB ID: 
5B2N) that visually did not superimpose well with PfCRT (Root mean square deviation of 
superimposition was 8.1 Å). 
 
Amino acid sequence alignments. For conservation analysis in Apicomplexan parasites, we 
obtained nine orthologs of CRT from OrthoMCL-DB(Chen et al., 2006). Their amino acid 
sequences were then aligned using MUSCLE(Edgar, 2004).  
 
For the pairwise alignments shown in Extended Data Fig. 6, the PfCRT 7G8 sequence was 
trimmed of residues 1-50 (N-terminus and JM1), 181-202 (TM5), 262-303 (JM2) and 368-424 
(TM10 and C-terminus) and put through the AlignMe(Stamm et al., 2014, Stamm et al., 2013, 
Khafizov et al., 2010) server. 
 
For the sequences used for Extended Data Fig. S8, the sequences used are Pf3D7_0709000, 
PVX_087980, PKNH_0107600, PY05061, PBANKA_1219500, PCHAS_1220200, Chro.60564, 
cgd6_4890, and TA12005. Multiple sequence alignments were displayed using ESPript(Robert 
and Gouet, 2014). 
 
Scintillation proximity assay (SPA)-based binding. All radiolabeled compounds were 
purchased from American Radiolabeled Chemicals. Unless other concentrations are indicated, 
binding of 125 nM [3H]-Arg (40 Ci/mmol), 370 nM [3H]-CQ (5.45 Ci/mmol), or 75 nM [3H]-
PPQ (15 Ci/mmol) (unless was performed with the SPA, as described previously(Quick and 
Javitch, 2007). 100 ng of PfCRT 7G8 reconstituted into nanodiscs were assayed in buffer 
composed of 50 mM Tris/Mes, pH 7.5, 5 % glycerol, 0.1 mM TCEP, 0.1 % PEI in the presence 
of 125 µg of YSi-His Tag SPA beads (Perkin Elmer), and in the presence or absence of indicated 
reagents or Fab. 800 mM imidazole, which competes with the His tag (fused to PfCRT) for 
binding to the copper-coated YSi SPA beads, was used to determine the non-proximity 
background signal. Concentrations of radiolabeled compounds were chosen in pilot experiments 
to obtain a signal-to-noise ratio ≥ 5, and specific binding was determined by subtracting the cpm 
in the presence of imidazole from the cpm measured in its absence. Control binding experiments 
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[3H]-CQ of employed nanodiscs containing 100 ng of the unrelated Aquifex aeolicus bacterial 
amino acid transporter LeuT. Non-linear regression analysis of the data was performed with 
means GraphPad Prism 7. Kinetic constants represent the ± SEM of the fit.  
 
Transport measurements. Purified PfCRT 7G8 was reconstituted in preformed liposomes made 
E. coli total lipids:CHS 94:6 (w/w) at a protein-to-lipid ratio of 1:150 (w/w). The lumen of the of 
proteoliposomes was composed of 100 mM KPi, pH 7.5 and 2 mM β-mercaptoethanol. Uptake of 
[3H]-Arg (40 Ci/mmol), [3H]-CQ (5.45 Ci/mmol), or [3H]-PPQ (15 Ci/mmol) was performed by 
diluting PfCRT-containing proteoliposomes (40 ng PfCRT per assay) in 50 µL of 100 mM 
Tris/Mes, pH 5.5. When indicated, 1 µM valinomycin (Val) was added to the reaction to 
generate a K+ diffusion potential-driven membrane potential. The reactions were stopped after 
the indicated time periods by the addition of ice-cold 100 mM KPi, pH 6.0/100 mM LiCl and 
filtered through 0.45 µm nitrocellulose filters (Millipore). Filters were dried and incubated in 
scintillation cocktail, and the radioactivity captured on the filters was counted in a Hidex SL300 
scintillation counter. Specific radioactivity of all compounds was confirmed by counting known 
amounts of each radiolabel by determination of the decays-per-minutes (dpm) to transform the 
dpm of the samples into pmol. Unspecific binding of all compounds with the nitrocellulose 
filters was determined by measuring mock uptakes in the absence of liposomes or 
proteoliposomes, and these values (determined for each experiment) were used to calculate the 
uptake activity in liposomes or proteoliposomes. For data shown in Extended Data Fig. 13, the 
specific uptake was determined by subtracting the time-dependent accumulation of the tested 






Extended Data Figure 1 | Major PfCRT haplotypes and location of residues involved in 
chloroquine (CQ) or piperaquine (PPQ) drug resistance phenotypes. a, Listing of the PfCRT 
canonical CQ-sensitive 3D7 haplotype, the 7G8 (South America and Western Pacific) and Dd2 
(Southeast Asia) variant haplotypes, and mutations that have emerged in P. falciparum parasites 
in malaria-endemic areas that contribute to PPQ resistance. b, Localization of PfCRT mutations 
associated with CQ or PPQ resistance, based on the solved PfCRT structure. Most mutations 
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localize within or near the boundary of one of the 10 transmembrane helices. JM, 
juxtamembrane. Extended Data Table 2 shows an expanded list of mutations observed in the 




Extended Data Figure 2 | Identification of PfCRT-specific antigen-binding fragments (Fab) 
and preparation of purified PfCRT±Fab protein in nanodiscs. a, Complementarity-
determining region (CDR) sequences of unique antigen-binding fragments (Fabs) panned for 
binding to recombinant PfCRT incorporated into MSP1D1 nanodiscs. Fabs were selected 
following multiple rounds of enrichment from the phage display library E(Fellouse et al., 2004, 
Fellouse et al., 2007, Miller et al., 2012). Enriched SYGW residues are highlighted by color code 
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(red, yellow, green and blue, respectively) and are numbered according to the Kabat system(Wu 
and Kabat, 1970). b, Single-point ELISA quantifying the binding of phage-displayed Fab to 
PfCRT-incorporated nanodiscs, empty nanodiscs, or buffer (empty wells), as measured at 450 
nm absorbance. c, EC50 evaluation for purified Fab binding to PfCRT incorporated into 
biotinylated nanodiscs, showing high affinity binding for the CTC Fab (3.7 nM). d, High-
performance liquid chromatography profile of PfCRT ± bound CTC Fab. e, SDS-PAGE gel of 
pooled and concentrated size-exclusion chromatography fractions from PfCRT±CTC Fab. The 
contaminant glutamate dehydrogenase, GDH (present as a left shoulder in d), was excluded from 
single-particle analyses. MSP1D1 is a membrane scaffold protein used to assemble the 





Extended Data Figure 3 | Negative-stain electron microscopy of PfCRT with and without 
Fab. a, Representative micrograph and 2D class averages from Relion(Scheres, 2012b) 2D 
classification of nanodisc-incorporated PfCRT without Fab. b, Representative micrograph and 






Extended Data Figure 4 | Cryo-EM analysis of the PfCRT-Fab complex. a, Representative 
micrograph (0.5175 Å per pixel, 1.65 μm defocus). Picked particles contributing to the final 
reconstruction are circled in green. b, Representative 2D class averages from Relion 2D 
classification. c, Euler angle distribution plot of the final 3D reconstruction from CryoSPARC 
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2(Punjani et al., 2017b). d, Fourier shell correlation (FSC) curves for PfCRT complexed with the 
Fab variable domain as well as for PfCRT alone. Data show the half-map (blue) and map-to-
model (purple) resolutions (at 0.143 and 0.5 cut-offs respectively), with embedded histograms of 
directional resolutions sampled evenly over the 3D-FSC(Tan et al., 2017) (yellow). The 
corresponding sphericity values are indicated. e, Local resolution(Hohn et al., 2007) display of 
unsharpened reconstructions of PfCRT complexed with the Fab variable domain, in orthogonal 





Extended Data Figure 5 | Fit of cryo-EM density with model. Cryo-EM densities (mesh) are 
superimposed with TM and JM helices of the PfCRT model. The model is rendered as a cartoon, 





Extended Data Figure 6 | Symmetrical arrangement in inverted topology repeats of PfCRT. 
a, View of PfCRT from opposite directions of the DV and cytoplasm, with labeling of the four 
helices that are closest to the center (thus contributing to the cavity). b, AlignMe(Stamm et al., 
2014, Stamm et al., 2013, Khafizov et al., 2010) sequence alignment between the two structural 
repeats within this pseudo-symmetric transporter reveals a high degree of sequence conservation, 
with each helix lining up with its corresponding helix from the pseudo-repeat. Residues 1-50 (N-
terminus and JM1), 181-202 (TM5), 262-303 (JM2) and 368-424 (TM10 and C-terminus) were 







Extended Data Figure 7 | Structural comparison of PfCRT with other DMT superfamily 
members. a, Structural conservation of PfCRT compared with its DMT family members Vrg4 
(PDB ID: 5OGE;(Parker and Newstead, 2017)), YddG (PDB ID: 5I20;(Tsuchiya et al., 2016)) 
and TPT (PDB ID: 5Y78;(Lee et al., 2017)), generated using the Dali server(Holm and Laakso, 
2016). b, Electrostatic representation of slices revealing the cavities of these four proteins in their 
solved structural states. Note the highly negatively charged (red) residues in the PfCRT cavity, 
contrasting with the positively charged (blue) or neutral residues in the other DMT transporters. 





Extended Data Figure 8 | Sequence alignment and secondary structure of PfCRT. 
Sequences of different PfCRT isolates and other CRT homologs aligned using MUSCLE(Edgar, 
2004) and displayed using ESPript(Robert and Gouet, 2014). Sequences of nine orthologs of 
CRT in other Plasmodium or other Apicomplexan parasites were obtained from OrthoMCL-
DB(Chen et al., 2006). The sequences used are Plasmodium falciparum PfCRT strain 3D7 (the 
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canonical wild-type sequence; UNIPROT Q9N623), P. chabaudi CRT strain chabaudi (PcCRT, 
Q7Z0V9), P. yoelii CRT strain 17XNL (PyCRT; Q7REK3) P. berghei CRT strain ANKA 
(PbCRT, Q9GSD8), P. vivax CRT strain Sal-1 (PvCRT, Q9GSD3), P. knowlesi CRT strain H 
(PkCRT; Q9GSD7); Theileria annulata CRT strain Ankara (TaCRT, Q4UDS9); 
Cryptosporidium hominis CRT strain TU502 (ChCRT; RefSeq XP_666698); Cryptosporidium 
parvum strain Iowa II (CpCRT; XP_627815). The secondary structure of PfCRT is shown as a 
cartoon above the alignments, along with the positioning of the variant residues indicated in 
Extended Data Fig. 1 (with same color scheme). The cysteine residues that likely form disulfide 
bonds are shown as green colored numbers below the alignment. Residues conserved (i.e. 
identical or similar) in at least 6 of 9 species are indicated in bold red text. Residues conserved in 
all species are in white text with red highlighting. None of the mutations associated with CQ or 





Extended Data Figure 9 | Binding cleft of cholesterol hemisuccinate (CHS) in PfCRT. a, A 
cleft formed by JM1, TM1, TM 9 and TM10 in the PfCRT demonstrates the binding of CHS 
(colored in olive green) in the PfCRT. PfCRT is colored based on conservation. b, PfCRT is 
rendered as surface colored by hydrophobicity, from orange (hydrophobic) to blue (hydrophilic). 






Extended Data Figure 10 | Binding and Transport Assays for PfCRT 7G8. a and b, one 
minute uptake for (a) 370 nM [3H]-CQ or (b) 250 nM [3H]-Arg were determined with PfCRT  
7G8-containing proteoliposomes preloaded with 100 mM KPi, pH 7.5 diluted in buffer 
composed of 50 mM Tris/MES, pH 5.5 or 7.5 ± the K+ ionophore valinomycin (5 µM). The 
valinomycin (Vlm)-mediated K+ efflux proceeding down its concentration gradient generated an 
inside-negative membrane potential. Empty liposomes lacking PfCRT 7G8 served as controls. 
c, Total bData are mean±SEM (N,n=2,3). inding of 125 nM [3H]-Arg to 100 ng of nanodisc-
in the absence (-) or presence (+) of 800 mM imidazole incorporated PfCRT 7G8 was measured 
(which competes with the His-tagged PfCRT 7G8 isoform for binding to the copper-coated YSi 
SPA beads).  Data are mean±SEM (N,n=3,3). d, Isotopic dilution of 125 nM [3  with non-H]-Arg
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radiolabeled Arg revealed a LogEC50 value of -3.401 ± (corresponding to 397.2 µM).   0.03254 M 
We note that the primary source of Arg in parasitized red blood cells (RBCs) is from the 
proteolysis of Hb, which in its native state as a tetramer is present at 5 mM in RBCs(Francis et 
al., 1997). e, Binding of 125 nM [3H]-Arg in the presence or absence of 10 µM verapamil (VP), 
1 µM CQ or PPQ, 0.1 µM amodiaquine (ADQ), or 1 mM Arg, Lys or Leu. Data in panels d and 
e are shown as mean±SEM (N,n=3,3) values and are normalized to the signal in the absence of 
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The first structure of the PfCRT paves the way for a multitude of follow-up experiments. On the 
structural side, obtaining a drug bound structure is the obvious next step. It will inform us on the 
binding mechanism and reveal any potential conformational changes upon drug binding. 
Chloroquine and piperaquine can be first investigated because they have already been shown 
here to bind to PfCRT. Mutations in PfCRT have also been associated with resistance to other 
drugs like amodiaquine, desethylamodiaquine and lumefantrine (Hietala et al., 2007, Eyase et al., 
2013) – these drugs can be also be tested for their binding and transport. 
 
In terms of drug resistant isoforms, the structure of PfCRT determined here is of the 7G8 isoform 
which is resistant to chloroquine but sensitive to piperaquine. Structure-wise, a few amino acid 
mutations that convert this isoform into other resistance profiles might not result in a gross 
structural change. However, they are likely to affect its biochemical properties, which can be 
probed using our liposome based assays. Purifying other isoforms for this purpose will thus be 
extremely useful to map out the exact mechanism of drug resistance. 3D7, the wild-type isoform, 
for instance has sensitivity to both chloroquine and piperaquine. DD2 has resistance to 
chloroquine, but still maintains sensitivity to piperaquine. 
 
The PfCRT transporter solved here is in the inward-open state. To obtain other functional states, 
two feasible plans of action are possible: 1) raise Fabs that will be able to lock the transporter in 
other states, or 2) do mutagenesis to obtain mutants that lock in a certain state, and then raise 
Fabs against these. For the mutagenesis, an exhaustive alanine-scanning mutagenesis strategy 
can be done (Unkles et al., 2012), coupled with a functional read-out to isolate mutants with 
different properties. Specific differences that would be interesting are the ability to transport 
drugs at different pH, or a much greater rate of transport compared to wild-type. 
 
Eventually, it is hoped that all these structural understanding of PfCRT will help in the structure-
based drug design of future 4-aminoquinolines, helping them evade resistance and keeping them 
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Tuberculosis is the leading cause of death from a single infectious agent, out-ranking even 
HIV/AIDS, causing over a million deaths annually (WHO, 2018). It is caused by Mycobacterium 
tuberculosis and is spread through the air. The mycobacterium generally targets the lungs, but 
can also opportunistically infect other organs. Most infections are asymptomatic and are called 
latent tuberculosis. Only 10% of infections become active tuberculosis, which has a mortality 
rate of 50%. Common symptoms include chronic cough with blood in the sputum, loss of weight, 




Upon infection of the lungs, the bacteria actually target the immune cells present in the alveolar 
air sacs – the macrophages. When macrophages try to neutralize the intruders through 
phagocytosis, the bacteria survives within the phagolysosome in the macrophages due to its 
unique, thick cell wall made of mycolic acids (Jankute et al., 2015, Barry III, 2001). As M. 
tuberculosis bacteria are obligate aerobes, they start their infection from the upper part of the 
lung first, where oxygen is more readily available. This primary site of infection is known as the 
Ghon focus (Kumar et al., 2017). As the disease progresses, the infection will eventually spread 
first to the lower lung, and then into the bloodstream. When the bacteria enters the bloodstream, 
it inevitably can readily spread and infect all parts of the body – patients at this stage of the 
disease have a high mortality rate even with treatment (Habermann and Ghosh, 2007). 
 
Biology of Mycobacterium 
 
M. tuberculosis belongs to a genus of about 60 or so gram-positive rod-shape bacterium. Most 
species are soil dwelling in nature and are non-pathogenic; only a minority causes human 
diseases such as tuberculosis (M. tuberulcosis) and leprosy (M. leprae) (Ducati et al., 2006). The 
mycobacterial cell envelope is extremely unique. Firstly, the peptidoglycan has N-gly-
colylmuramic acid instead of N-acetylmuramic acid like other bacteria. Secondly, the outer 
membrane is made of long chain fatty acids (70 to 90 carbon atoms long) called mycolic acids. 
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Together with arabinogalactans and the peptidoglycan, it forms the mycolyl-arabinogalactan-
peptidoglycan (mAGP) complex of the cell envelope (Alderwick et al., 2015, Grzegorzewicz et 
al., 2016). This mAGP is in turn decorated by glycolipids phosphatidyl-myo-inositol mannoside 
(PIM), lipomannan (LM) and lipoarabinomannan (LAM). On the outer membrane, porins are 
also present that modulate the diffusion of small hydrophilic molecules (Jarlier and Nikaido, 
1994). In M. tuberculosis, the species-specific porins it has make it one of the more permeable 
hydrophilic molecules compared to other mycobacteria, hence fortunately for us make it less 
resistant as well to soluble drugs like ethambutol (Brennan and Nikaido, 1995). This unique and 
resistant cell envelope protects mycobacterium from harsh chemical and physical treatment, 
bestowing upon it the ability to be resistant to many conventional antibiotics, and also for the 
case of M. tuberculosis the ability to survive within the phagolysosome of macrophages. 
 
Treatment of Tuberculosis 














Bedaquiline ATP synthase Inner cell membrane Clofazimine NADH dehydrogenase 










RNA polymerase Rifampin 
Rifapentine 
Levofloxacin DNA gyrase Moxifloxacin 
Aminosalicylic acid Folate metabolism 
Table 1 | Antibiotics against tuberculosis (Horsburgh Jr et al., 2015) 
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Despite the tough cell envelope, a plethora of drugs have been developed that can harm this 
pathogen (Table 1). The use of these drugs for clinical treatment differs based on the disease 
progression. Latent tuberculosis usually involves isoniazid by itself or with rifampicin or 
rifapentine (Borisov et al., 2018) for three months. Active tuberculosis that has occurred for the 
first time will require a cocktail of antibiotics (rifampicin, isoniazid, pyrazinamide and 
ethambutol) for two months and the former two drugs for the next four months (Lawn and Zumla, 
2011). If the tuberculosis relapses, this indicates that the M. tuberculosis has developed drug 
resistance. Laboratory testing is therefore required to determine which antibiotics are still 
effective, and a cocktail of four of them has to be taken for up to two years for effective 
clearance of the pathogen (Lawn and Zumla, 2011). 
 
A combination of a lengthy treatment regime and irresponsible authorities in high risk 
developing nations downplaying the disease has resulted in development of multidrug resistant 
(MDR) and extensively resistant (XDR) tuberculosis. MDR is resistant to at least isoniazid and 
rifampicin, while XDR tuberculosis is also resistant to one drug that targets the ribosome and one 
that targets the DNA gyrase (Table 1) (Lawn and Zumla, 2011). 
 
In our study, we focus on a class of membrane bound enzymes called 
arabinofuranosyltransferases specifically aimed at building the lipoarabinomannan and 
arabinogalactan component of the cell envelope. This is also the target of the first line drug 
ethambutol (Islam et al., 2017). The enzyme we investigated was AftD, for which we elucidated 
the structure, function and regulation of through a combination of genetics knock-out and single-
particle cryo-EM analysis. 
 
Single-Particle Cryo-EM Challenges 
 
The first challenge of obtaining structures of these membrane bound enzymes is the 
reconstitution into a membrane mimic. Initially, the membrane protein was studied structurally 
after solubilization in detergents (Helenius and Simons, 1975). The protein however was not 
very stable in this condition and fell apart when vitrified; the same thing occurred using 
amphipols (Tribet et al., 1996) which had worked for the TRPV1 channel structure (Liao et al., 
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2013) and in the lab for STRA6 (Chen et al., 2016). It was only through reconstitution into 
nanodiscs (Bayburt and Sligar, 2010, Ritchie et al., 2009) that the protein was able to be vitrified 
on a grid stably. 
 
The second challenge with AftD was the yield miniscule of around 20 μg per purification run 
from 9.6 L cultures of E. coli, which was only enough to freeze one or two grids using a 
conventional vitrification setup. Luckily, the Spotiton vitrification robot was available in the lab, 
and my colleagues were able to use the small amount of specimen to make multiple grids for 
screening and optimization. Thanks to these optimizations, I was able to obtain good grids for 
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Mycobacterium tuberculosis causes tuberculosis, a disease that kills over one million people each 
year. Its cell envelope is a common antibiotic target and has a unique structure due, in part, to two 
lipidated polysaccharides – arabinogalactan and lipoarabinomannan. Arabinofuranosyltransferase D 
(AftD) is an essential enzyme involved in assembling these glycolipids. We present the 2.9 Å 
resolution structure of M. abscessus AftD determined by single particle cryo-electron microscopy. 
AftD has a conserved GT-C glycosyltransferase fold and three carbohydrate binding modules. 
Glycan array analysis shows that AftD binds complex arabinose glycans. Additionally, AftD is non-
covalently complexed with an acyl carrier protein (ACP). 3.4 and 3.5 Å structures of a mutant with 
impaired ACP binding reveal a conformational change that suggests the ACP may regulate AftD 
function. Using a conditional knock-out constructed in M. smegmatis, mutagenesis experiments 






Globally, tuberculosis (TB) is the leading cause of death from a single infectious agent, out-ranking 
even HIV/AIDS (WHO, 2018). The causative agent of TB is Mycobacterium tuberculosis, which 
belongs to a genus with a unique cell envelope made of lipids and carbohydrates (Figure 1A). The 
major component of the mycobacterial cell envelope is a large macromolecule consisting of 
covalently linked peptidoglycan (PG), branched heteropolysaccharide arabinogalactan (AG) and 
long chain (70 to 90 carbon atoms long) mycolic acids, termed the mycolyl-arabinogalactan-
peptidoglycan (mAGP) complex (Alderwick et al., 2015, Grzegorzewicz et al., 2016). This mAGP 
complex is in turn decorated by a variety of glycolipids called phosphatidyl-myo-inositol mannoside 
(PIM), lipomannan (LM) and lipoarabinomannan (LAM) (Figure 1A). M. tuberculosis produces 
between 2,000 to 10,000 distinct lipids (Layre et al., 2014), most of which form an outer membrane 
of very low permeability (Hoffmann et al., 2008, Nikaido and Jarlier, 1991). This cell envelope is 
crucial for growth and virulence of M. tuberculosis (Jankute et al., 2015, Barry III, 2001) and is a 
major contributor to the resistance of M. tuberculosis to common antibiotics. The importance of this 
unique structure in mycobacteria makes its biosynthetic enzymes attractive drug targets (Barry et al., 
2007, Abrahams and Besra, 2016). For example, isoniazid and ethambutol, two of the four TB 
front-line drugs, target mycobacterial cell wall synthesis (Islam et al., 2017). 
 
Of the enzymes involved in mAGP biosynthesis, arabinofuranosyltransferases are responsible for 
the addition of D-arabinofuranose sugar moieties to AG and LAM (Abrahams and Besra, 2016). All 
mycobacterial arabinofuranosyltransferases are predicted to be multi-pass transmembrane (TM) 
proteins that use decaprenylphosphoryl-D-arabinofuranose (DPA) to donate an arabinofuranose 
residue to the mAGP (Wolucka et al., 1994). Arabinofuranosyltransferases add 90 arabinofuranose 
residues to the galactan core of AG and 55–72 arabinofuranose residues to the mannan core of 
LAM. The best characterized arabinofuranosyltransferases are EmbA, EmbB and EmbC (Telenti et 
al., 1997, Belanger et al., 1996), which are named Emb because they are putative targets of 
ethambutol (Takayama and Kilburn, 1989, Goude et al., 2009). Other family members include AftA 
(Alderwick et al., 2006), AftB (Seidel et al., 2007), AftC (Birch et al., 2008), AftD (Škovierová et 
al., 2009), and possibly other yet to be identified enzymes (Angala et al., 2016). AG synthesis starts 
when AftA adds a single D-arabinofuranose to the C5 of the D-galactofuranose at positions 8, 10 
and 12 of the existing galactan. Thereafter, EmbA and EmbB extend the arabinan chain through α-
(15) linkages; α-(13) branching is then introduced by AftC and possibly AftD. AftB is the final 
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enzyme to cap off the AG with addition of a terminal β-(12)-linked D-arabinofuranose. For LAM, 
an unknown enzyme (Angala et al., 2016) primes the mannan chain with an α-(16) glycosidic 
bond before being extended through α-(15) linkages by EmbC. AftC and possibly AftD then 
catalyzes α-(13) branching and capping in a β-(12) manner by AftB, as in the synthesis of AG. 
These pathways are by no means fully characterized (Alderwick et al., 2006). 
 
Arabinofuranosyltransferase D (AftD) is essential for growth (Škovierová et al., 2009) and, with a 
theoretical molecular mass of 150 kDa, it is the largest predicted glycosyltransferase encoded in the 
mycobacterial genome. It is described as being involved in either α-(13) (Škovierová et al., 2009) 
and/or α-(15) (Alderwick et al., 2018) branching activity, and is thought to add the final few α-
linked arabinofuranose residues to AG and LAM (Alderwick et al., 2018) (Figure 1B). Little is 
known about both the function and structure of AftD, although its large size in comparison to the 
other arabinofuranosyltransferases (which range from 49 to 118 kDa) has raised the question of 
whether it has additional functions beyond catalyzing glycosidic bond formation (Škovierová et al., 
2009).  
 
To better understand the function of this enzyme, we determined the 2.9 Å structure of recombinant 
AftD from M. abscessus produced in E. coli using single-particle cryogenic electron microscopy 
(cryo-EM). We analyzed its in vitro carbohydrate binding capability via glycan array analysis and 
we constructed a conditional aftD deletion mutant in M. smegmatis to interrogate the functionality 
of AftD mutants in vivo. Unexpectedly, analysis of the structure revealed that AftD is tightly bound 
to an acyl carrier protein (ACP). The physiological relevance of this interaction was confirmed in M. 
smegmatis through mass spectrometry. Finally, we purified and determined structures of an AftD 
mutant designed to abrogate ACP binding to 3.4 and 3.5 Å resolution. These structures revealed 
ordering of a loop at the putative active site, suggesting that the ACP may regulate AftD function.  
 
RESULTS 
Phylogenetic Analysis Reveal Existence of AftD Homologs Across Actinobacteria 
Iterative rounds of PSI-BLAST (Altschul and Koonin, 1998) were used to identify homologs of 
AftD using the amino acid sequence of the protein from M. tuberculosis as a template. This analysis 
revealed that AftD is found not just in the Corynebacteriales order, but also in 11 other orders of the 
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Actinobacteria class (Ludwig et al., 2015) including Streptomycetales, Propionibacteriales and 
Frankiales (Figure S1). The homologs all have a similar predicted topology, computed using the 
TMHMM server (Krogh et al., 2001), with an N-terminal TM region, followed by a long 
periplasmic region, and a shorter C-terminal TM region. The average length of all AftD proteins is 
1381 amino acids. Most sequences (including the mycobacterial ones) cluster around this length, 
while AftD homologs in corynebacteria are significantly shorter with an average length of 1070 
residues (Figure S2A). Excluding corynebacteria, the average length of AftD from the remaining 
genera is 1422 residues. 
 
Conditional Deletion of the M. smegmatis aftD Gene Results in Altered Cell Phenotype 
As AftD has been reported to be an essential enzyme in M. tuberculosis (DeJesus et al., 2017) and 
in M. smegmatis (Škovierová et al., 2009), a conditional knock-out was designed to interrogate the 
function of AftD in M. smegmatis and provide a system for structure-based mutagenesis studies. 
First, we constructed the M. smegmatis ML2217 strain (WT), which constitutively produces the 
reverse Tet repressor TetR38. Then, the chromosomal aftD gene in M. smegmatis ML2217 was 
placed under the control of the tetO-4C5G operator (Kim et al., 2013), which is constitutively 
transcribed in the absence of tetracycline (Figure S2B). In the presence of tetracycline, the TetR38 
binds to tetO-4C5G, repressing transcription of the aftD gene. To our knowledge this is the first 
conditional AftD knock-out in mycobacteria that can be readily controlled in a temperature-
independent fashion. 
 
Phenotypic analyses of wild-type M. smegmatis (WT, ML2217) and the conditional aftD knock-out 
mutant (cKO, ML2218) were performed in medium with and without tetracycline (Figure 1). When 
grown in 7H9 medium without tetracycline, both WT and cKO strains had similar growth curves, 
reaching an OD600nm of 2.5 after about 32 hours (Figure 1C). When 20 ng/mL of tetracycline was 
added to the growth media, OD600nm failed to reach 0.5 after 48 hours (Figure 1C), confirming that 
aftD is indeed essential for growth of M. smegmatis under those conditions. In the presence of 
tetracycline to silence aftD expression, cKO cells readily aggregated under low shaking speed, 
suggesting the properties of the cell surface have changed (Figure 1E). The colony morphology of 
the conditional aftD mutant was also altered, appearing less rough than the controls (Figure 1F). 
When imaged by scanning electron microscopy, cells from the cKO strain appeared shorter in the 
presence of tetracycline (Figure 1G). Indeed, this observation was corroborated by measurements of 
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the cell length and width, showing a statistically significant reduction in cell length of the cKO 
strain in the presence (1.9 ± 0.6 μm) versus the absence (2.5 ± 0.8 μm) of tetracycline, while the 
widths remained the same (Figure 1H). 
 
Genomic Expansion and Complementation of the M. abscessus aftD Gene 
To study the AftD function in vitro and determine its structure, we adopted a structural genomics 
approach (Love et al., 2010, Bruni and Kloss, 2013, Mancia and Love, 2010) to identify homologs 
that yielded high expression levels in E. coli and were stable in detergents compatible with structure 
determination (see Methods). High-throughput small-scale expression and purification screens of 
AftD from 14 mycobacterial species revealed that under our experimental conditions only the M. 
abscessus homolog was expressed and purified from E. coli in quantities detectable in Coomassie-
stained protein gels. This homolog has a high sequence identity of 62% and 70% with the M. 
tuberculosis and M. smegmatis AftDs, respectively. 
 
To confirm the in vivo functionality of M. abscessus AftD, we complemented the cKO with the M. 
abscessus aftD gene. Initial experiments using tetracycline or acetamidase promoters to express the 
aftD gene resulted in cell aggregation, suggesting altered cell surface properties of M. smegmatis, 
probably resulting from aftD overexpression. However, an expression plasmid containing the M. 
abscessus aftD gene transcribed from its endogenous promoter (located in a 200 base pair upstream 
fragment) fully restored wild-type growth of the cKO strain in the presence of tetracycline (Figure 
1D). From these results we could conclude that M. abscessus AftD is functional in M. smegmatis, 
and that the phenotype observed in the conditional M. smegmatis mutant is indeed due to the 
depletion of the M. smegmatis AftD protein.  
 
Structure Determination Using Cryo-EM 
We determined the structure of the full-length M. abscessus apo-state AftD using single-particle 
cryo-EM. Despite substantial efforts to optimize the over-expression and purification of AftD in E. 
coli, final yields after purification were low: less than 100 μg of protein could be isolated from 9.6 L 
of cell culture. AftD was successfully incorporated into lipid-filled nanodiscs after a two-step 
purification in detergent (Figures S3A and S3B). To generate multiple cryo-EM grids of the sample 
at various conditions for screening and data collection despite the low yield, a picoliter dispensing 
robot (Spotiton) was used to vitrify the sample (Razinkov et al., 2016, Jain et al., 2012, Dandey et 
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al., 2018). Data were collected on a Titan Krios microscope equipped with a Gatan K2 Summit 
camera fitted with an energy filter. 7,274 micrographs were collected and 889,985 particles were 
initially processed (Figure S3C and Table S1). After data processing, the final map was produced 
from 490,616 particles, resulting in a reconstruction with an overall resolution of 2.9 Å (Figure S3). 
An atomic model for the entire protein was built, with the exception of both termini (residues 1 and 
1392-1410) and some disordered loop regions (253-259, 270-286, 330-356, 390-401, 1281-1285, 
1358-1367) (Figure 2). The region represented by residues 950-1090 was flexible; signal 
subtraction followed by focused classification of this part (Bai et al., 2015) (see Methods) improved 
the map quality to allow for better model building. The final refined model exhibits good 
stereochemistry and correlates well with the density map (Figure S4 and Table S1). 
 
Architecture of AftD 
AftD consists of a membrane embedded portion with 16 TM helices and a soluble portion that 
resides on the periplasmic side (Hoffmann et al., 2008) of the inner membrane (Figure 2A). Both 
termini of AftD project into the cytoplasm. Starting from the N-terminus, the first 11 TM helices 
form a typical GT-C glycosyltransferase fold (Figures 2A and 2B) (Liu and Mushegian, 2003). 
Thereafter, the polypeptide chain enters the periplasm. The soluble, periplasmic portion of AftD is 
large, accounting for ~60% of the mass of the protein, and is made up of five distinct domains: a 
domain of mixed α/β folds that is homologous to other solved GT-C structures (discussed below), 
three carbohydrate binding modules (CBMs) and one structural β-sandwich domain (Figure 2C). 
Though these domains are discrete, they have extensive inter-domain interactions that maintain 
them tightly associated, including some secondary structural elements: β4 from the soluble GT-C 
domain forms a beta-sheet with β29 and β30 of CBM3, β7 of CBM1 forms a beta-sheet with β16 of 
CBM2 (Figure 2C). After the soluble domains, the polypeptide chain enters back into the membrane 
via a single TM helix (TM12) that connects via a long loop to TMs 13-16 and the C-terminus as a 
separate membrane-bound domain from the N-terminal TM helices (Figure 2C). 
 
AftD Has a Conserved Glycosyltransferase GT-C Fold 
Using the Dali server (Holm and Laakso, 2016), atomic structures with structural similarity to AftD 
were retrieved and top hits corresponded to all full-length GT-C structures deposited in the database: 
yeast oligosaccharyltransferase STT3 (PDB ID: 6EZN, 6C26) (Wild et al., 2018, Bai et al., 2018), 
Archaeoglobus fulgidus oligosaccharyltransferase AglB (PDB ID: 3WAJ, 5GMY, 3WAK) 
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(Matsumoto et al., 2013, Matsumoto et al., 2017), Campylobacter lari oligosaccharyltransferase 
PglB (PDB ID: 3RCE, 5OGL, 6GXC) (Lizak et al., 2011, Napiórkowska et al., 2017, 
Napiórkowska et al., 2018) and Cupriavidus metallidurans aminoarabinose-transferase ArnT (PDB 
ID: 5EZM, 5F15) (Petrou et al., 2016). The first ~600 residues of AftD correspond to this 
homologous GT-C fold, and will subsequently be referred to as the GT-C super-domain of AftD 
(Figures 2C and S5C). This GT-C super-domain comprises a total of 11 TM helices (colored blue in 
Figure 2B) – two less than all the other solved GT-Cs (STT3, AglB, PglB and ArnT). The two 
missing TM helices are also not conserved amongst GT-Cs (Petrou et al., 2016) and correspond to 
TM helix 8 for STT3 (Figure S5D), helix 8 and 9 for PglB (Figure S5E), and helix 12 and 13 for 
ArnT (Figure S5F). The remaining 11 TM helices are structurally homologous to the other solved 
GT-Cs in several aspects: 1) They are in the same arrangement in AftD as seen in the other four 
solved GT-C structures; 2) There are two periplasmic juxtamembrane (JM) helices (JM1 and JM2) 
between TM1 and TM2; 3) TM3 is kinked by a proline and broken into two smaller helices; 4) TM7 
extends beyond the membrane into the periplasm and is joined by a longer loop to TM8. A short 
alpha helical JM helix (JM3) is present in the loop; 5) A soluble periplasmic domain is always 
present, composed of an α/β/α arrangement (Figure 2C).   
 
Putative Active Site and Substrate Binding Pocket 
The postulated substrates for AftD are the donor DPA (Alderwick et al., 2007) and a poly-arabinose 
acceptor that is part of the growing AG or LAM (Škovierová et al., 2009) (Figure 1B). Although the 
structure of AftD was solved in the apo state, the high degree of homology as described above 
between AftD’s GT-C super-domain and the other solved GT-C glycosyltransferases allows for 
inference of mechanistic insights. In the GT-C super-domain, a large cavity is present between the 
periplasmic domain and the periplasm-facing ends of TM4, 6, 7, 9 and 10, with a volume of ~1240 
Å3 (Figure 3A). Using the unique AftD sequences of Actinobacteria class, sequence conservation 
was mapped onto the structure of AftD to reveal that this cavity contains a number of highly 
conserved residues, including E251, D474 and E475, which are the most plausible catalytic residue 
candidates. When representative eukaryotic (STT3) and bacterial (PglB) structures were aligned 
with the GT-C super-domain, the active sites of both structures are in the same area as that of AftD 
(Figure 3B). Other GT-C glycosyltransferases like PglB require the use of divalent metal cations to 
function (Sharma et al., 1981), and AftD seems to have a putative cation binding pocket (Figures 
3A and 3B, red dotted line circle). Interestingly, the charge around the putative active site for AftD 
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is slightly positive, compared to slightly negative for STT3 and PglB. This is consistent with the 
different acceptor substrates of these proteins: STT3 has preference for peptides with aromatic 
residues at the -2 position (Wild et al., 2018), PglB has preference for negatively charged side chain 
at the -2 position (Napiórkowska et al., 2017), while AftD binds to a poly-arabinofuranose glycan 
moiety (which can form ion-dipole interactions with positively charged residues). 
 
A shallow groove along TMs 6, 9 and 13 of AftD starts at the cytoplasmic side of the membrane 
and ends at the putative active site, and is likely to accommodate the putative DPA donor (Figure 
S5B). A diacyl-phospholipid (modeled as phosphatidylethanolamine) can be resolved in the density 
map near the cytoplasmic region. There is moderate conservation in this region, and it is also 
homologous to the polyprenol binding pockets of STT3 (Figure S5D), PglB (Figure S5E) and ArnT 
(Figure S5F), making this site the likely binding pocket for the lipidic section of DPA. In 
comparison with the locations of lipidic donor substrates in the other homologs, it seems that 
although the general binding area is conserved, the exact identities of the helices that form the 
binding site are likely to differ.  
 
There are three long loops (N-EL4 between TM 7-JM 3, C-EL4 between JM 3-TM 8 and EL5 
between TM 9-10) that do not have clear density present, and consist of 7, 17 and 27 residues, 
respectively (Figures 2C and 3A). Given that the structure of AftD was solved in the apo-state, 
these unresolved loops could be analogous to those of other glycosyltransferases that span across 
the active site and become ordered only upon ligand binding. Indeed, superimposition against the 
structures of STT3 (Figure S5D), PglB (Figure S5E) and ArnT (Figure S5F) suggests that the STT3 
EL5, PglB EL5 and ArnT PL4 loops are analogous to the AftD EL4 loop, as they all extend from 
analogous TM helices. In contrast, AftD EL5 seems to be unique to this enzyme (Figures S5D, S5E 
and S5F). A number of conserved residues are present on both the loops, suggesting these segments 
are likely to be important for AftD’s enzymatic function. In particular, W272 is 100% conserved 
and D351 is moderately conserved (Figure 3A). 
 
We designed a series of mutants based on the apo structure of AftD to examine structure-based 
functional hypotheses. Mutations around the putative active site were designed to target highly 
conserved residues that could be involved in substrate binding or catalysis (Figure 3C). These 
residues (K39, D41, E251, K361, D474) were mutated to alanine. All mutated AftD proteins were 
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expressed in E. coli and purified using non-ionic detergents to yields comparable to WT, suggesting 
that the proteins produced were properly folded (Figure S6). All of these aftD mutations were also 
cloned in the mycobacterial expression vector to examine whether these mutated aftD genes 
restored WT growth of the conditional M. smegmatis aftD mutant with tetracycline. None of these 
AftD mutants were capable to complement the growth defect of the conditional M. smegmatis aftD 
mutant under non-permissive conditions. These results suggest that these residues play essential 
roles for proper functioning of AftD (Figures 3D and 3E). 
 
Carbohydrate Binding Modules of the AftD Soluble Domain Help Bind Complex 
Arabinofuranose Chains 
In addition to the GT-C super-domain, AftD has a large soluble domain consisting of three 
carbohydrate binding modules (CBMs) that exhibit beta-sandwich folds (Figure 4A). There is an 
unusual structural motif of four consecutive prolines (residues 863-866) on CBM2, which appears 
to serve a structural role by making hydrophobic interactions with six other neighboring prolines 
from within CBM2 and also from a region between CBM1 and the GT-C soluble domain (Figure 
S5A). The structure shows that two CBMs (CBM1 and CBM3) bind an ion that is likely calcium, 
based on comparison with other structural homologs (PDB ID: 1UYY and 4A45). Notably, CBM3 
is more flexible than the other two CBMs, as evidenced by the smearing of the cryo-EM density at 
CBM3 before focused classification. 
 
Structural homologs for each of the CBMs were identified using the Dali server and the highest 
scoring structural homolog with a ligand is shown in Figure 4A to illustrate putative glycan binding 
sites. The putative glycan binding sites of CBM1 and 3 have an extensive network of polar (S, T, N, 
Q) and charged (D, E, R, K) residues that can form ion-dipole or hydrogen bonds with the 
carbohydrate ligand (Figure 4B). In addition, CBM1 and CBM3 have aromatic side chains (W757, 
W818 for CBM1 and F1066 for CBM3) that can facilitate hydrophobic stacking interactions with 
the face of carbohydrate rings, an important mechanism of binding in CBMs (Boraston et al., 2004). 
These findings suggest that CBM1 and CBM3 are likely carbohydrate binding modules. CBM2, on 
the other hand, has only four polar/charged and no aromatic residues at the putative binding site 




The relative locations of these three CBMs are quite far from each other, between 26 to 42 Å apart 
(Figure 4C). All three CBMs are in turn 30-36 Å away from the edge of the putative active site, and 
they fan out in different directions from it. The length of one arabinofuranose residue in an extended 
conformation is about 3.6 Å. This arrangement of the CBMs suggests that AftD may have evolved 
to bind long (>10 units) and possibly non-linear arabinan chains. 
 
To test the above hypothesis, we probed the carbohydrate-binding ability of the protein in vitro by 
screening purified AftD against an array of mycobacterial glycan fragments (Zheng et al., 2017a). 
AftD appears to have specific binding to long and branched arabinofuranose chains (Figure 4D). 
Notably, the arabinofuranose glycans to which AftD binds have 10 or more arabinofuranose 
residues. Conversely, AftD appears not to bind to other mycobacterial glycans on the array: 
glycopeptidolipid, phosphatidyl-myo-inositol mannoside (PIM), phenolic glycolipids (PGL), 
trehalose mycolates and lipooligosaccharides (LOS), and capsular α glucans, with the exception of 
tetra-mannose which, surprisingly, appears to bind weakly (Figure 4D). These results corroborate 
both our structural hypothesis and the previously predicted function of AftD acting as a late 
arabinosyltransferase in the biosynthesis of LAM/AG (Alderwick et al., 2018, Škovierová et al., 
2009). 
 
AftD is Complexed with Acyl Carrier Protein 
At the C-terminus of the soluble domains of AftD, the protein chain re-enters into the membrane via 
TM 12, followed by an 18 residue loop that arches over TMs 5, 6, 7, 9 and 10 to reach TM 13 
(Figures 2C and 5A). TMs 13-16 then form a four-helical bundle that interfaces with TM 8 and 9, 
which is unique to AftD in comparison to other Aft/Emb enzymes. This four-helical bundle shows a 
contiguous density adjoining the cytoplasmic side, consistent with the presence of an associated 
protein (Figure 5A). Using mass spectrometry, this additional component was identified as the acyl 
carrier protein (ACP) from E. coli, and the ACP crystal structure (PDB ID: 1T8K) was readily 
accommodated in the density (Figure 5A). The density map for ACP was of lower resolution (~4-5 
Å, Figure S3F) than for AftD, likely due to conformational flexibility. Indeed, focused classification 
of the ACP portion revealed multiple low-resolution conformational states. Notably, there were no 
classes without density for ACP, consistent with the tight association of the two proteins during 




The negatively charged surface of E. coli ACP, which has an isoelectric point around 4, interacts 
with a positive patch of AftD comprising the arginine residues R310, R315 and R1389 (Figures 5B, 
5C and 5D). ACP is found in its holo-form with 4’-phosphopantetheine covalently linked via a 
phosphodiester bond to S36 (Majerus et al., 1965). This prosthetic group can either be buried within 
the ACP hydrophobic tunnel-like cavity in the core of the four helices or extended towards its 
cognate protein (Cronan, 2014). The coulombic potential map shows that the 16 Å long 4’-
phosphopantetheine fills the hydrophobic pocket of the four-helical bundle (TMs 13-16) of AftD 
(Figures 5C and 5D). Its C-terminal thiol group points towards the interspace between TM15 and 
TM16. Moreover, 4’-phosphopantetheine not only forms extensive hydrophobic interactions with 
AftD residues L1332, V1335 and F1324, but also establishes hydrogen bonds between its O33 and 
the backbone carbonyl of A1386, and its phosphate group with the side-chain of R315, a highly 
conserved residue among AftDs (Figure 5D). 
 
To determine the physiological relevance of the ACP-AftD interaction, we purified M. abscessus 
AftD from a M. smegmatis mycobacterial expression system. Mass spectrometry analysis of the 
purified protein revealed the presence of M. smegmatis meromycolate extension acyl carrier protein 
AcpM (UniProtKB accession: ACPM_MYCS2, Table S2), a 99 residue protein that has 39% 
sequence identity with E. coli ACP. AcpM also has a negatively charged surface (PDB ID: 1KLP, 
Figure 5B insert) like the E. coli ACP (Wong et al., 2002). M. smegmatis has another ACP 
(UniProtKB accession: A0QUA2_MYCS2) which shares around 40% sequence identity with AcpM, 
and it was not detected via mass spectrometry. These results indicate that the presence of ACP in 
the AftD structure was not an artefact due to the overexpression system in E. coli. 
 
Five mutants in the region of AftD that interacts with ACP were also generated with the aim of 
disrupting ACP binding. These were successfully purified in E. coli (Figure S6) and cloned into the 
mycobacterial expression vector. To investigate the functional relevance of the ACP-AftD 
interaction, we examined whether these mutant genes restored WT growth of the conditional M. 
smegmatis aftD mutant with tetracycline. The insertion of a stop codon at T1285 produced a C-
terminal truncation that eliminated the four-helical ACP-binding bundle all together (Figure 5F). 
This truncated protein resulted in a growth defect akin to the empty plasmid, suggesting that either 
the four-helical bundle of the enzyme per se, or its interaction with ACP is important for AftD 
function (Figures 5G and 5H). Mutations were also made to three arginine residues (R310A, R315A, 
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R1389S) to abolish (by mutations to alanine) or reduce (by mutations to serine) the charge 
interactions between the protein part of ACP and AftD (Figure 5E). R310A and R315A mutants 
fully restored growth of the conditional M. smegmatis aftD mutant in the presence of tetracycline, 
indicating these residues were not important for proper AftD function (Figures 5G and 5H). By 
contrast, R1389S showed a severe growth defect, consistent with a functional role of this residue 
(Figures 5G and 5H). Another mutation was introduced at G1339 to add a bulky tryptophan to 
prevent the binding of 4’-phosphopantetheine to AftD’s four-helical bundle (Figure 5E). This 
mutant only partially rescued growth of the M. smegmatis aftD cKO in the presence of tetracycline, 
suggesting that G1339 is also important for the function of AftD (Figures 5G and 5H). 
 
To further characterize the two classes of AftD mutants that were made (targeting putative active 
site versus ACP binding), we performed microplate appearance (Figure 6A) and colony morphology 
assays (Figure 6B) on a representative mutant from each class: D474A (putative active site) and 
R1389S (ACP binding). Both mutants showed similar phenotypes to the cKO (Figures 1E and 1F) 
and to each other, suggesting that disruption of ACP binding may be linked to loss of enzymatic 
function. 
 
The Structure of AftD-R1389S Mutant Shows Ordering of EL5 Loop with Disordering of 
ACP 
To investigate how ACP binding might be correlated to enzyme activity, we determined the 
structure of AftD-R1389S mutant using single-particle cryo-EM (Figures 6 and S7). The structure 
determination pipeline was similar to that described for wild-type AftD, with two notable 
exceptions: 1) TEV cleavage was not performed as the mutation resulted in TEV cleavage being 
very inefficient (Figures S7A and S7B); and 2) AftD-R1389S was vitrified on gold grids using the 
Leica GP, using conditions optimized earlier with Spotiton (Figure S7C). 4,886 micrographs were 
collected and 226,478 particles were initially processed following data collection on a Titan Krios 
equipped with a Gatan K2 Summit camera fitted with an energy filter (Table S1, Figures S7C and 
S7D). After data processing, the consensus reconstruction with an overall resolution of 3.4 Å was 
obtained from 150,978 final particles (Figure S7E). 2D class averages of the dataset revealed a 
fuzzy but identifiable density for the ACP – in comparison, the WT 2D class average showed a very 
distinct density with sharp features for the ACP (Figure 6C). This suggests that the mutation did not 
fully abrogate ACP binding, but caused it to be weakly associated with AftD-R1389S and hence 
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highly flexible. This was corroborated by mass spectrometry analysis of the AftD bands from the 
SDS-PAGE gel (Figure S7B). 
 
When inspecting the consensus reconstruction of AftD-R1389S, a distinct density near the active 
site that was not seen in the wild-type structure was observed (Figure S7E). Signal subtraction 
followed by focused classification was performed to resolve the heterogeneity, which produced two 
high resolution maps of AftD: class 1 at 3.5 Å and class 2 at 3.4 Å (Figures 6D, S7E, S7F and S7G). 
For both these classes, 2D class averages (Figure 6C) had fuzzy density for the ACP, and both of 
them also showed worse resolution for the last four TMs at ~5 Å (Figure S7F). When the maps were 
low pass filtered to 4 Å and compared at similar display thresholds, TM14 was the most disordered 
helix and its density was hardly seen compared to the other helices (Figure 6D). The linker between 
TM14 and TM15 was also poorly ordered. No density was observed where the ACP bound to the 
WT structure, and no density for the 4’-phosphopantetheine was apparent in both AftD-R1389S 
classes (Figure 6D). 
 
Between the two classes, the most notable difference was in the putative active site region (Figure 
6F). Here, the class 2 structure highly resembles the WT structure. However, in class 1, there 
appears to be a significant conformational change. Firstly, the previously disordered EL5 loop 
between TM 9 and 10 is now resolved, and physically occludes the putative active site. Secondly, 
the previously disordered N- and C-EL4 loop between TM 7 and 8 still remain poorly ordered, but 
the JM3 now appears to be disordered with poor map density (Figure 6E). In comparison, JM3 is 
still present in class 2 (Figure 6E). 
 
An atomic model was built into the resolved EL5 loop density, resulting in a U-shaped structure 
connecting TMs 9 and 10 (Figure 6F). Out of the residues present in the loop, R357 is absolutely 
conserved. Two prolines, P340 and P355, are responsible for the sharp turns in the loop structure, 





The Conditional aftD Mutant in M. smegmatis Provides a System to Examine Structure-
Function Relationships of AftD 
In this study, we constructed a tetracycline-inducible conditional aftD mutant in M. smegmatis and 
showed that AftD is essential in M. smegmatis as reported previously (Škovierová et al., 2009) in 
contrast to closely related corynebacteria which produce a much shorter AftD protein (Figure S2A) 
(Alderwick et al., 2018). We observed that AftD depletion increased cell clumping and altered the 
colony morphology of M. smegmatis (Figure 1). Both phenotypes are consistent with a change of 
the cell surface properties and the function of AftD in adding to long, branched arabinan as shown 
in this study (Figure 4D). The branched arabinan chain forms an integral part of the arabinogalactan 
polymer and of the attached outer membrane (Hoffmann et al., 2008), which is essential in 
mycobacteria, but not in corynebacteria (Portevin et al., 2004). Presumably, interfering with the 
arabinogalactan synthesis disturbs the proper assembly of the outer membrane and its properties, 
thus explaining the observed phenotypes. AftD depletion resulted in shorter M. smegmatis cells in 
contrast to the phenotype of a previous report which utilized a temperature-sensitive rescue plasmid 
to deplete AftD from M. smegmatis at 42 °C (Škovierová et al., 2009). This discrepancy might 
result from the non-physiological temperature in the latter experiment which is known to trigger a 
heat shock response in mycobacteria altering expression of many genes (Stewart et al., 2002) and 
protein properties. By contrast, our conditional mutant enables for the first time to examine the 
function of AftD in mycobacteria under physiological conditions. 
 
First Full-Length Structure of a Mycobacterial Membrane Glycosyltransferase 
The GT-C membrane glycosyltransferase family (Liu and Mushegian, 2003) is underrepresented in 
the protein databank (PDB), with currently 10 structures of just four different GT-C members (Bai 
et al., 2018, Matsumoto et al., 2013, Matsumoto et al., 2017, Napiórkowska et al., 2018, 
Napiórkowska et al., 2017, Petrou et al., 2016, Wild et al., 2018). None of these previous structures 
are of mycobacterial GT-C glycosyltransferases. The AftD structure presented herein is the first 
full-length structure of this family, and the first determined by cryo-EM (Figure 2). The high degree 
of structural conservation of AftD with other GT-C structures across all three domains of life 
indicates a remarkable retention of the fold across evolutionary time and also points to the likely 
existence of a common ancestral GT-C fold (Figure 4C). However, the structural conservation is not 
uniform – the TM regions are marginally better conserved than the soluble GT-C domain, an 
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observation also predicted previously (Lairson et al., 2008). The variability of the soluble domain is 
likely due to variations in substrates of each GT-C: for the four GT-C members where atomic 
structures are available, their substrates are either lipid-linked glycans and peptides (STT3, PglB 
and AglB), or lipid-linked glycans and lipid A (ArnT). AftD differs from these as its acceptor is 
thought to be a complex glycan (Figure 4D), providing an explanation for the fact that it has three 
additional CBM domains attached to its soluble GT-C domain. 
 
Arabinosyltransferase Function of AftD 
Structure-based alignment with the other GT-C glycosyltransferases of known structure, allowed us 
to locate the putative active site of AftD in a cavity between the membrane-bound TM and soluble 
GT-C domain (Figure 2). We confirmed, by mutagenesis studies, that five of the conserved residues 
(K39, D41, E251, K361, D474) around the putative active site are essential for function and we thus 
postulate that these are involved in either catalysis or substrate binding. For substrate binding, these 
residues need to interact either with the phospho-arabinofuranose moiety of DPA, terminal 
arabinofuranose(s) of arabinogalactan/lipoarabinomannan, or the divalent cation likely required for 
catalysis (Sharma et al., 1981). The map shows poorly resolved densities for the flexible EL4 loop 
around this site for apo-AftD, and we expect this region to become ordered to assist in substrate 
binding, as shown to occur in PglB and ArnT (Napiórkowska et al., 2017, Petrou et al., 2016). N-
EL4 should become ordered to trap DPA (State 2’ in Figure 7), being closest to the putative DPA 
binding site (Figures S5B, S5D, S5E and S5F). On the other hand, C-EL4 is well-positioned to 
become ordered when the growing end of the arabinan acceptor enters the active site (State 2 in 
Figure 7). In our structure, no divalent cation density around the putative active site was observed. 
In analogy with PglB, we predict that substrate binding and ordering of the EL4 loop might be 
required to trap a catalytic cation (Napiórkowska et al., 2017). 
 
We identified three putative CBMs in the periplasmic domain, and showed the possible glycan 
binding interfaces and residues by comparison to other structurally homologous CBMs for which 
ligand-bound structures are available (Figure 4). The sizeable distances between the AftD CBMs 
(26 to 42 Å, Figure 4C) suggests the binding of a large, complex glycan substrate, which 
corroborates previous work placing AftD as a late stage glycosyltransferase that acts near the end of 
the synthesis pathway for the arabinans in both LAM and AG, (Alderwick et al., 2018, Škovierová 
et al., 2009). As observed previously in nature, an example being cellulase Cel5A (Boraston et al., 
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2003), which has two CBMs, CBM multivalency carries two advantages: 1) modules work together 
cooperatively to result in stronger binding than individual CBMs, and 2) each module recognizes 
different regions of the substrate, thus improving binding specificity. In AftD, these domains, which 
rise 70 Å up from the membrane (Figure 2A), are likely to bind specifically to different portions of 
AG/LAM. The glycan array result supports this hypothesis: branched arabinofuranose glycans >10 
residues in length, which are too large to be bound by a single CBM, appear to show the most 
convincing binding profiles (Figure 4D). The fact that both elongating AG and LAM are restrained 
in one dimension, being anchored via a polyprenol-pyrophosphate in the periplasmic membrane 
(Alderwick et al., 2015), and to either the periplasmic membrane through phosphoinositol 
mannoside (Kordulakova et al., 2002, Morita et al., 2006, Lea-Smith et al., 2008) or possibly also to 
the outer mycolate membrane (Alsteens et al., 2008), respectively, will likely significantly impact 
binding affinities.  
 
Combining our results with the knowledge derived from other GT-C membrane 
glycosyltransferases (Petrou et al., 2016, Napiórkowska et al., 2017) studied both structurally and 
functionally, we propose the following putative enzymatic cycle (Figure 7). The solved AftD 
structure represents the apo-state, bearing disordered N-EL4 and C-EL4 regions (State 1 in Figure 
7). Binding of the substrates will result in ordering of N-EL4 and C-EL4, respectively, stabilization 
of the substrate-enzyme complex (State 2 or 2’ in Figure 7), and priming of the system for catalysis 
to occur (State 3 in Figure 7). Thereafter the product is released and the active site is re-primed.  
This would reset AftD back to the apo-state, readying it for another catalytic cycle.  
 
Further understanding of the order of substrate binding and of the precise structural rearrangements 
that occur in the active site will require structures of substrate bound of AftD. Attempts to obtain 
such structures have been made – we have tried adding various glycan moieties as indicated from 
our glycan array results, decaprenyl-phosphate and an analog of DPA (Joe and Lowary, 2006) to 
obtain a substrate bound conformation of AftD. No ligand density was observed in these 
preliminary structures, possibly due to the transient nature of binding of such natural ligands, 
technical difficulties in substrate incorporation, or presence of the E. coli (non-native) ACP that 
might be inhibitory. An alternative strategy might involve the chemical synthesis of substrate 
analogues or inhibitors of AftD that have higher binding affinity than the endogenous counterparts. 
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Such an approach has previously yielded positive results for PglB (Napiórkowska et al., 2017) and 
STT3 (Bai et al., 2018, Wild et al., 2018). 
 
Role of the Acyl Carrier Protein in AftD 
In the structure of AftD, an E. coli ACP was so tightly bound to the cytoplasmic face of the enzyme 
at a C-terminal four-helical bundle, that it remained associated during purification (Figure 5A). The 
tight binding of the ACP is quite remarkable because complexes of ACP with partner proteins have 
typically been difficult to observe due to the transient and weak nature of their interactions (Cronan, 
2014). Indeed, some of these complexes could only be obtained via crosslinking experiments 
(Tallorin et al., 2016). Neither the ACP nor the four-helical bundle it associates with is present in 
other GT-C glycosyltransferases, for which structural information is available. This interaction was 
found to be: 1) physiological, as AftD purified from M. smegmatis also remained associated with 
the M. smegmatis ACP homolog AcpM (Table S2), and 2) likely essential for function, as AftD 
variants genetically engineered to disrupt AcpM binding did not rescue the growth defect of AftD-
depleted M. smegmatis (Figure 5H).  
 
Structurally, mycobacterial ACP is very similar to its E. coli counterpart, with helix II (the 
recognition helix) being the most conserved (Wong et al., 2002). The only notable difference is the 
presence of a ~35 residue extension at the C-terminus, which is highly flexible and is thought to 
interact with long chain intermediates of mycolic biosynthesis or mediate specific protein-protein 
interactions (Figure 5B) (Schaeffer et al., 2001). The highly conserved helix II contains the serine 
36 residue, which is located within a signature motif of DSL/X-hydrophobic residue and is modified 
by a 4’-phosphopantetheine that interacts with AftD in our structure. The high degree of 
conservation of ACP across species is the likely reason why we were able to isolate an ACP-AftD 
complex from a heterologous expression system. In contrast to E. coli, the genome of M. smegmatis 
encodes two different ACPs. The AcpM variant is involved in both fatty acid (Kremer et al., 2001) 
and mycolic acid synthesis (Zimhony et al., 2015).  
 
As no further electron density was observed beyond the terminal thiol group of the 4’-
phosphopantetheine, it is not clear whether the ACP has no cargo bound, a disordered cargo, or a 
variety of different cargos in different conformations that average out during cryo-EM analysis. In 
AftD, the ACP could be serving as a shuttle for starting materials and intermediates throughout the 
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fatty acid biosynthetic pathway. In E. coli, ACP interacts with at least twelve enzymes involved in 
fatty acid biosynthesis, as well as with seven other enzymes from disparate biosynthetic pathways 
(Nguyen et al., 2014). In mycobacteria, the ACP also functions as a shuttle for mycolic acid 
biosynthesis (Takayama et al., 2005). Intriguingly, ACP has been reported to be essential for an E. 
coli enzyme catalyzing the synthesis of β-(12)-linked glucan in membrane-derived 
oligosaccharides from UDP-glucose, although the 4’-phosphopantetheine moiety was not needed 
(Therisod and Kennedy, 1987).  
 
The elucidation of the structures of mutant AftD-R1389S (Figures 6 and S7) pointed to another 
hypothesis for the presence of the ACP – as a possible regulator of AftD enzyme activity (Figure 7). 
ACP regulation of catalytic activity has indeed been observed in other proteins like WaaP (Kreamer 
et al., 2018) and possibly SpoT-like proteins (Battesti and Bouveret, 2009). When the 4’-
phosphopantetheine is removed from the four-helical bundle, the helices become more disordered, 
as evidenced by the lower resolution, especially for TM14 (Figure 6D and State I1 in Figure 7). 
This, in turn, results in JM3 moving away and the EL5 loop becoming ordered (Figure 6E and State 
I2 in Figure 7). The ordered EL5 now appears to block the putative active site, possibly preventing 
substrates from entering, and thus effectively halting enzymatic function (Figure 6F and State I3 in 
Figure 7). Out of the two solved dominant structures of AftD-R1389S, class 2 may represent an 
intermediate state in this conformational change as the four-helical bundle is disordered but JM3 is 
still present. Class 1, on the other hand, likely represents the final state of this postulated 
conformational change, with EL5 ordered and JM3 displaced. The fact that a mutation of the 
enzyme active site (AftD-D474A) results in M. smegmatis that looks phenotypically similar to that 
of AftD-R1389S is consistent with the observation that both these mutations could abrogate the 
same function of AftD – presumably its glycosyltransferase activity (Figures 6A and 6B). As the 
ACP binds the cytoplasmic face of AftD, this could enable the transmission of intracellular signals 
across the membrane. Given that AftD is the crucial arabinofuranosyltransferase that adds the final 
α-linked arabinofuranose sugars on AG (Alderwick et al., 2018), inactivating this enzyme could 
effectively prevent the attachment of mycolic acids and block the proper assembly of the entire 
outer membrane. 
 
AftD as a Potential Drug Target 
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AftD is an essential gene in mycobacteria and is found on the inner membrane (Figure 1A), making 
it an attractive target for the development of novel anti-tubercular antibiotics (Favrot and Ronning, 
2012). There are no current drugs in the market that are known to target AftD, although there have 
been reports of mutations on the aftD gene that are associated with drug resistance and 
susceptibility. The T797A mutation in M. tuberculosis AftD results in resistance to isoniazid (Jena 
et al., 2016, Shekar et al., 2014), whereas S1080G in M. tuberculosis AftD results in multiple drug 
resistant forms of the pathogen (MDR and XDR) to become susceptible to amoxicillin and 
clavulanic acid (Cohen et al., 2016). Both T797 and S1080 are on poorly conserved regions on the 
surface of the soluble region of AftD, making their functional or structural relevance difficult to 
interpret.  
 
Two additional factors make AftD an attractive potential drug target. Firstly, AftD is well conserved 
across many other bacteria of the Actinobacteria class, which includes other pathogens that cause 
diseases like diphtheria (Corynebacterium diphtheria), leprosy (M. leprae or M. lepromatosis) and 
nocardiosis (various Nocardia species). Secondly, the fact that AftD has two potential sites at which 
to target drugs (the active site and the ACP binding site) that both appear to be essential for function, 
further contributes to the potential of this protein for structure-based drug design efforts. 
 
Conclusions 
Here, we present the first full-length mycobacterial GT-C structure, determined by single-particle 
cryo-EM to 2.9 Å resolution. The structure of wild-type AftD reveals a conserved GT-C fold and 
also pinpoints the location of the putative active site. The residues that are likely involved in 
substrate binding and catalysis were probed through mutagenesis studies using an engineered AftD 
cKO strain in M. smegmatis. Furthermore, the structure and glycan array analysis show that AftD 
binds specifically to large, highly branched arabinofuranose residues that are found in AG/LAM. 
Finally, to the best of our knowledge this is the first report of a glycosyltransferase structure with a 
tightly associated ACP. This interaction, when disrupted using a specific single mutant (AftD-
R1389S), resulted in a series of conformational changes in AftD, as observed in the structures of 
this mutant. These changes lead to ordering of a loop that blocks the putative active site and could 
be a mechanism for transmitting the signal from the cytoplasmic face of AftD to the periplasmic 
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Figure 1. Functional analysis of the role of the arabinofuranosyltransferase AftD in the 
biosynthesis of the mycobacterial cell envelope 
(A) Model of the cell envelope of M. tuberculosis.  Red boxes highlight the arabinogalactan (AG) 
and lipoarabinomannan (LAM) components which are synthesized by AftD (yellow). (B) Reaction 
catalyzed by AftD enzyme. (C) Growth of wild-type M smegmatis (WT) and the conditional aftD 
mutant ML2218 (cKO) without and with 20 ng/mL tetracycline. (D) Complementation of the cKO 
with empty plasmid and plasmid carrying the M. abscessus aftD gene. The strains were grown with 
and without tetracycline. Both growth curves were recorded in biological triplicates. Standard 
deviations are plotted. (E) Clumping of the cKO cells in the presence of 20 ng/mL tetracycline in 
liquid culture in microplates. (F) Colony morphology of WT and cKO M smegmatis without and 
with 20 ng/mL tetracycline grown at 37 °C for 4 and 6 days. (G) Scanning electron microscopy 
micrographs and quantification of the cell length and width (H) from these images. For the cell 
lengths and widths (H), one-way ANOVA Kruskal-Wallis parametric test was done as the 






Figure 2. Architecture of AftD Complex 
(A) Single-particle cryo-EM structure of AftD complex, rendered in cartoon and colored in rainbow 
from N terminus (blue) to C terminus (red). The complexed E. coli acyl carrier protein and ligands 
are colored in brown. Both proteins are rendered as cartoon. Ca2+ ions are rendered as green spheres. 
Two orthogonal views that are perpendicular to the plane of the membrane are shown. The 
approximate dimensions of the monomer are 85, 145, and 75 Å (width, height, and depth). 
Membrane boundaries were derived from the interface between the nanodisc lipids and solvent. (B) 
Transmembrane helices arrangement of AftD, viewed as a slice and magnified. (C) Two-
dimensional topological diagram of AftD. The individual soluble domains are enclosed in separate 
grey boxes. The topology diagram is colored in rainbow from N terminus (blue) to C terminus (red). 
Unbuilt parts of the model due to poor map density are indicated by dotted lines. The two bound 
Ca2+ atoms are shown as green circles, and side chains coordinating them are shown as sticks. The 







Figure 3. Sequence conservation and putative active site of AftD 
(A) Structure of AftD, rendered in cartoon and colored based on sequence conservation. Unique 
sequences recovered from PSI-BLAST search were first pruned to those that are 95% the length of 
M. abscessus AftD (see Figure S3B). Thereafter, closely related sequences were removed by CD-
HIT, giving a list of 289 sequences across the Actinobacteria class. The putative active site cavity, 
generated by Voss Volume Voxelator server (Voss and Gerstein, 2010) using  probes of 2 and 5 Å 
radii, is colored in semi-transparent green. Residues with 100% conservation are colored in magenta 
and have their side chains displayed. The insert shows putative active site cavity with strictly 
conserved residues around it labeled. The primary sequences of the un-modeled flexible loops 
around the active site are shown below the insert, colored by conservation. (B) Columbic potential 
maps of the putative active site region of AftD, aligned PglB and yeast OST (STT3). The putative 
divalent cation binding pocket is circled with a red dotted line, and is mirrored in (A). The ligands 
and Mn2+ ion in the structure of PglB are shown as sticks and ball respectively. (C) Residues that 
have been mutated in the M. abscessus aftD gene have side chains displayed as stick, and the model 
colored by conservation. These mutant plasmids were then transformed into the cKO to assess the 









Figure 4. The Carbohydrate Binding Modules (CBMs) of AftD 
(A) The three soluble CBMs and a β-sandwich fold domain are colored in the AftD structure. The 
model is rendered as cartoon. In the first insert on top, the CBMs are zoomed in and the putative 
active site cavity is colored in semi-transparent green as in Figure 3. In the bottom insert, similar 
protein structures (PDB IDs indicated) aligned to and replacing each AftD CBM to show putative 
glycan binding scheme. (B) Putative sugar binding interfaces of the CBMs, with residues that could 
be involved in binding labelled and the putative location of the sugars circled in red dotted lines. All 
residues are colored by conservation. (C) Distances among the CBMs (top panel) and to the putative 
ligand binding cavity displayed in light green (bottom panel). (D) Glycan array analysis of AftD, 
with top glycan motif hits indicated, where green star represents arabinofuranose and blue sphere 
glucopyranose. The classes of glycans used are: lipoarabinomannan (LAM), trehalose mycolates 
and lipooligosaccharides (LOS), capsular α glucans, phenolic glycolipids (PGL), phosphatidyl-myo-
inositol mannoside (PIM), glycopeptidolipid and bovine serum albumin (BSA) control. For 






Figure 5. Acyl carrier protein (ACP) in complex with AftD 
(A) TM 13, 14, 15 and 16 form a hydrophobic groove where the 4’-phosphopantetheine of ACP 
binds. AftD is rendered as cartoon with TMs 12-16 being colored in the same colors as in Figure 2.  
ACP is colored magenta. The insert shows a zoomed view of ACP and 4’-phosphopantetheine, with 
the corresponding density map shown as mesh. (B) Surface electrostatic potential maps of AftD 
(top), E. coli ACP (below) and M. smegmatis AcpM (below, insert), with red being negatively 
charge and blue positively charged. (C) LigPlot (Wallace et al., 1995b) on 4’-phosphopantetheine 
showing its atomic interactions with AftD. (D) Zoom in on the binding interface between AftD and 
ACP, with side chains of relevant residues displayed as sticks. Residues have been colored by 
conservation using the same scheme as Figure 3 and 4. The primary sequence of the un-model 
flexible loop between TM15 and TM16 is shown below the insert, colored by conservation. (E) 
Residues that have been mutated in the M. abscessus AftD protein have side chains displayed as 
stick, and the model colored by conservation. If the residue is not resolved in the structure, its 
putative position is indicated by a dotted lined box (F).These mutations are also listed in a table (G). 
These mutant plasmids were then transformed into the cKO to assess their effect on the growth rate 








Figure 6. Phenotype and Structure of AftD-R1389S of M. abscessus AftD 
(A) Microplate appearance assay and (B) colony forming assay across 4, 6 and 8 days of AftD 
mutants D474A and R1389S. (C) 2D class averages comparison between the AftD WT particles and 
mutant R1389S class 1 and 2 particles, with the red arrow pointing at the position of ACP. (D) 
Superposition of maps from class 1 and 2 from AftD mutant R1389S with the WT map. The maps 
have been low-pass filtered to 4 Å and displayed at similar thresholds for comparison. (E) 
Superposition of class 1 and 2 models from AftD-R1389S against class 1 map (on top) and class 2 
map (on the bottom) at the JM3 region. Colored scheme follows (D). (F) The model of class 1 from 
AftD-R1389S with the ordered loop (EL5) colored in yellow. The rest of the structure is rendered as 









Figure 7. Postulated Mechanism of Action for AftD 
AftD is rendered as cartoon in blue, orange (JM3), red (TM 13-16) and yellow (ordered EL5). ACP 
is rendered as cartoon in grey. The catalytic cycle for AftD is indicated by the black arrows from 
state 1 through 3. The inhibitory cycle is indicated by red arrows from state I1 to I3. The solved WT 
AftD structure corresponds to state 1, the AftD-R1389S class 2 structure to state I2 and the AftD-





Figure S1. Multiple sequence alignment of AftD across the Actinobacteria class, Related to 
Figure 1 
The sequence alignment was generated using MUSCLE and comprises of the following species 
(order in brackets): Mycobacterium abscessus (Corynebacteriales), Mycobacterium tuberculosis 
(Corynebacteriales), Mycobacterium smegmatis (Corynebacteriales), Actinospica acidiphila 
(Catenulisporales), Streptomyces mirabilis (Streptomycetales), Actinomadura atramentaria 
(Streptosporangiales), Glycomyces fuscus (Glycomycetales), Actinoplanes missouriensis 
(Micromonosporales), Alloactinosynnema album (Pseudonocardiales), Jiangella gansuensis 
(Jiangellales), Intrasporangium calvum (Micrococcales), Kribbella flavida (Propionibacteriales), 
Ilumatobacter nonamiensis (Acidimicrobiales), Frankia inefficax (Frankiales) and 
Corynebacterium glutamicum (Corynebacteriales). The residues are colored by their 
physiochemical properties using the Zappo scheme: Aliphatic/hydrophobic residues are in salmon 
(ILVAM), aromatic residues in orange (FWY), positively charged residues in blue (KRH), 
negatively charged residues in red (DE), hydrophilic residues in green (STNQ), conformationally 
special residues in pink (PG) and cysteines in yellow (C). The intensity of the coloring is 
proportional to the degree of conservation. Secondary structure elements derived from the M. 
abscessus structure are labelled and aligned below. Gaps and unaligned parts of the sequence have 







Figure S2. Lengths of AftD Homologs and Conditional Knock-out Scheme, Related to Figure 
1 
Total number of residues of each AftD homolog against the genus. Corynebacterium genus (pink 
dots) has unusually short AftD sequence compared to the rest of the genus in the Actinobacteria 
class (blue dots), including the Mycobacterium genus (green dots). (B) Conditional knock-out 





Figure S3. Purification and single-particle cryo-EM structural determination of wild-type M. 
abscessus AftD, Related to Figure 2 
(A) Representative size-exclusion chromatography (SEC) trace of AftD incorporated into MSP-
1E3D1 nanodiscs. Fractions corresponding to the peak were used for cryo-EM analysis. (B) SDS-
PAGE gel of the concentrated sample from the peak fractions stained with Coomassie blue. The 
predicted molecular weight of AftD is 150 kDa, while that for MSP-1E3D1 is 32 kDa. (C) 
Representative square, hole and exposure magnification views of the Spotiton nanowire carbon 
patterned grids that were imaged. The exposure image had a defocus of -1.7 μm (estimated by 
CTFFind4 and pixel size of 1.0605 Å/pixel. (D) Representative 2D class averages. (E) Euler angle 
distribution plot of the final 3D reconstruction from CryoSPARC 2. (F) ResMap display of 
unsharpen AftD reconstructions in orthogonal views, showing the nanodisc belt as well as variation 
in local resolution. (G) Fourier shell correlation (FSC) curves for the full AftD map and AftD-
CBM3 focused classified map describing the half-map (blue) resolutions (at 0.143 cut-offs), as well 
as histogram of directional resolutions sampled evenly over the 3DFSC (yellow). The 
corresponding sphericity value is also indicated. (H) Fourier shell correlation (FSC) curves for the 
atomic models of AftD, ACP, CBM3 of AftD and AftD with ACP against the whole composite map 
generated by combining the full AftD map with the AftD-CBM3 focused classified map using 








Figure S4. EM Density of AftD, Related to Figure 2 
The atomic model for the structure of wild-type M. abscessus AftD is colored in rainbow and 
rendered as cartoon, with the side chains rendered as sticks. The map density is displayed as a mesh. 
The residues for each segment of the atomic model are indicated below the name of the segment. 
For all the segments except the acyl carrier protein, the sigma value for display was 8.33, while for 






Figure S5. Structural Features of AftD, Related to Figures 2,3,4,5 
(A) Stretch of consecutive prolines in CBM2 and neighboring prolines shown as green sticks. The 
rest of the structure is rendered as cartoon. (B) Location of the potential binding site (dotted red line) 
for the lipidic tail of the donor DPA. AftD is rendered as cartoon, with residues colored by 
conservation. The density map is shown as transparent grey. (C) Structural conservation of the GT-
C fold of AftD (residues 1 to 600) against other GT-C glycosyltransferases obtained from a Dali 
search. Thereafter, (D) eukaryotic STT3 (PDB ID: 6EZN), (E) bacterial PglB (PDB ID: 5OGL) and 
(F) ArnT (PDB ID: 5EZM) were then superimposed onto full-length AftD and a slice through the 
transmembrane helices are shown as cartoon. The other glycosyltransferase structures were colored 
in green, yellow and purple respectively, while full-length AftD was colored in rainbow. Helices of 
the other glycosyltransferases were labelled, and those that did not have a corresponding 
homologous helix in AftD were indicated with a dotted circle. Locations of the flexible loop that 
becomes ordered upon substrate binding (EL5, PL4) are indicated by the dotted lines. The locations 







Figure S6. Expression of AftD mutants in E. coli, Related to Figures 3,5 
SDS-PAGE gel of samples from small scale purifications of WT AftD and AftD mutants, stained 
with Coomassie blue. The AftD WT and mutants were heterologously expressed in E. coli and 








Figure S7. Purification and single-particle cryo-EM structural determination of AftD-R1389S, 
Related to Figure 6 
(A) Representative size-exclusion chromatography (SEC) trace of AftD-R1389S incorporated into 
MSP-1E3D1 nanodiscs. The insert shows a zoom in of the fractions collected for SDS-PAGE 
analysis. (B) SDS-PAGE gel of the concentrated sample from the peak fractions stained with 
Coomassie blue. The predicted molecular weight of AftD-R1389S is 150 kDa, while that for MSP-
1E3D1 is 32 kDa. Mass spectrometry was used to determine that the higher band at around 150 kDa 
corresponds to AftD-R1389S with ACP still associated. (C) Representative square, hole and 
exposure magnification views of the gold grids that were imaged. The exposure image had a 
defocus of -1.6 μm (estimated by CTFFind4) and pixel size of 1.0605 Å/pixel. (D) Representative 
2D class averages. (E) Signal subtraction and 3D focused classification scheme. (F) ResMap  
display of two classes from focused classification of unsharpen AftD R1389S. (G) Fourier shell 
correlation (FSC) curves for the two classes describing the half-map (blue) resolutions (at 0.143 cut-
offs), map-to-model (purple) resolutions (at 0.5 cut-offs), as well as histogram of directional 
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Table S1. Cryo-EM data collection and modeling statistics WT-AftD, Related to Figure 2 
  AftD-WT AftD-WT-CBM3 
Focus Classification  
EM data collection / processing    
Microscope FEI Titan Krios 
Voltage (kV) 300 
Camera Gatan K2 Summit with Energy Filter 
Energy Filter Slit Width (eV) 15 
Set defocus range (μm) 1.0-2.0 
Defocus mean ± std (μm) 1.6 ± 0.39 
Exposure time (s) 13.05 
Number of frames 90 
Dose rate (e-/pixel/s) 8.2 
Total dose (e-/Å2) 95.72 
Pixel size (Å) 1.0605 
Number of micrographs 7,274 
Number of particles (after initial cleanup) 889,985 
Number of particles (in final map) 490,616 - 
Number of particles (after classification) - 50,410 
Symmetry C1 C1 
Resolution (global) (Å) 2.9 3.0 
Local Resolution Range 2.3 – 4.1 2.3 – 4.1 
Directional Resolution Range 2.7 – 2.9 2.9 – 3.1 
Sphericity of 3DFSC 0.99 0.99 
Map sharpening b-factor (Å2) -56.04 -29.62 
 
Model statistics AftD-WT 
Residue range 2-1391 
Map CC 0.828 
RMSD [bonds] (Å) 0.010 
RMSD [angles] (Å) 1.224 
All-atom clashscore 2.27 
Ramachandran plot  
       Favored (%) 95.45 
       Allowed (%) 4.47 
       Outliers (%) 0.08 
Rotamer outliers 0.00 
C-β deviations 0 
MolProbity Score 1.32 




Table S2. Proteins identified by Liquid MS/MS from M. smegmatis purified AftD-WT M. 
abscessus, Related to Figure 5 














59_MYCS2  38,08 38,08 25 M. smegmatis 21 
ATP synthase subunit alpha  sp|A0R202|ATPA_MYCS2  37,14 37,19 50,4 M. smegmatis 19 
AftD Mycobacterium 
abscessus 1948 F5/8 type C 
domain protein 
  32,81 32,81 11,4 M. abscessus 18 
60 kDa chaperonin 1  sp|A0QQU5|CH601_MYCS2  28,05 28,05 39,2 M. smegmatis 14 
Adenosylhomocysteinase  sp|A4ZHR8|SAHH_MYCS2  24,52 24,52 34,2 M. smegmatis 14 




O_MYCS2  18,94 18,94 24,7 M. smegmatis 10 
Cell wall synthesis protein 
Wag31  
sp|A0R006|WA
G31_MYCS2  16,6 16,6 34,9 M. smegmatis 8 




C_MYCS2  11,91 11,95 22,9 M. smegmatis 6 




T2_MYCS2  8,02 8,02 9,4 M. smegmatis 4 





92_MYCS2  8 8 44 M. smegmatis 4 
ATP synthase epsilon chain  sp|A0R1Z9|ATPE_MYCS2  8 8 41,3 M. smegmatis 4 
30S ribosomal protein S5  sp|A0QSG6|RS5_MYCS2  6 6 25,7 M. smegmatis 3 




 6 6 53,5 M. smegmatis 3 
Pyruvate dehydrogenase E1 
component  
sp|A0R0B0|ODP





E2_MYCS2  5,07 5,13 12,6 M. smegmatis 3 
Acetamidase  sp|Q07838|AMDA_MYCSM  4,01 4,02 5,4 M. smegmatis 2 
50S ribosomal protein L5  sp|A0QSG1|RL5_MYCS2  4 4 14,4 M. smegmatis 2 
ATP synthase subunit b  sp|A0R204|ATPF_MYCS2  2,29 2,29 7,6 M. smegmatis 1 
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Table S3. Cryo-EM data collection and model statistics AftD R1389S, Related to Figure 6 




EM data collection / processing    
Microscope FEI Titan Krios 
Voltage (kV) 300 
Camera Gatan K2 Summit with Energy Filter 
Energy Filter Slit Width (eV) 15 
Set defocus range (μm) 0.8-1.6 
Defocus mean ± std (μm) 1.42 ± 0.35 
Exposure time (s) 13.05 
Number of frames 90 
Dose rate (e-/pixel/s) 8.34 
Total dose (e-/Å2) 96.78 
Pixel size (Å) 1.0605 
Number of micrographs 4,886 
Number of particles (after initial cleanup) 226,478 
Number of particles (in consensus map) 150,978 
Number of particles (after classification) 37,814 68,231 
Symmetry C1 C1 
Resolution (global) (Å) 3.5 3.4 
Local Resolution Range 3.0 – 8.7 3.0 – 7.2 
Directional Resolution Range 3.3 – 3.6 3.2 – 3.6 
Sphericity of 3DFSC 0.98 0.98 




Residue range 5-1388 5-1388 
Map CC 0.8403 0.8045 
RMSD [bonds] (Å) 0.012 0.010 
RMSD [angles] (Å) 1.364 1.310 
All-atom clashscore 4.12 3.23 
Ramachandran plot   
       Favored (%) 92.12 93.62 
       Allowed (%) 7.80 6.30 
       Outliers (%) 0.08 0.08 
Rotamer outliers 0.11 0.32 
C-β deviations 0 0 
MolProbity Score 1.68 1.54 





METHODS AND RESOURCES 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Chemicals, Peptides, and Recombinant Proteins 
Luria Broth medium Fisher Scientific BP1426-2 
Terrific Broth medium Fisher Scientific DF043817 
Ampicillin Sigma Aldrich A0166-25G 
Chloramphenicol Sigma Aldrich C0378-25G 
Isopropyl β-D-1-
thiogalactopyranoside 
Fisher Scientific BP1755-10 
DNAse I Roche 10104159001 
RNase A Roche 10109169001 
EDTA-free cOmplete protease 
inhibitor cocktail 
Roche 11873580001 
n-Dodecyl-β-D-Maltopyranoside Anatrace D310 25 GM 
E. coli polar lipid extract  Avanti 100600P 










Hygromycin Fisher Scientific 10687010 
Tetracycline Alfa Aesar AAB2140822 
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Kanamycin Fisher Scientific BP906-5 
Tyloxapol Sigma Aldrich T8761-50G 
Critical Commercial Assays 
Ni-NTA Agarose Qiagen 30230 
Bio-Beads SM-2 Adsorbents BioRad 152-3920 
Superdex 200 Increase 10/300 
GL size-exclusion column 
GE Healthcare Life 
Sciences 
28990944 
ANTI-FLAG® M2 Affinity Gel  Sigma A2220 
Deposited Data 
AftD-WT composite density 
map 
This paper EMD-XXXX 
AftD-WT global refined density 
map 
This paper EMD-XXXX 
AftD-WT-CBM3 focus 
classified density map 
This paper EMD-XXXX 
AftD-WT Cryo-EM movie 
frames, aligned micrographs and 
particle stack 
This paper EMPIAR-XXXX 
AftD-WT atomic model This paper PDB-XXXX 
AftD-R1389S Class 1 density 
map 
This paper EMD-XXXX 
AftD-R1389S Class 2 density 
map 
This paper EMD-XXXX 
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AftD-R1389S Cryo-EM movie 
frames, aligned micrographs and 
particle stack 
This paper EMPIAR-XXXX 
AftD-R1389S Class 1 atomic 
model 
This paper PDB-XXXX 
AftD-R1389S Class 2 atomic 
model 
This paper PDB-XXXX 
Experimental Models: Organisms/Strains 
BL21 (DE3) pLysS E. coli Promega PR-L1191A 
M. smegmatis mc2155 (Wild-
type) 
N/A (Snapper et al., 1990) 
M. smegmatis ML2253 (M. 
smegmatis mc2155; L5 
attB::pML3621(hygr, loxP-
Psmyc::tetR38-loxP) 
This paper N/A 
M. smegmatis ML2217 (M. 
smegmatis mc2155; L5 attB, 
Psmyc::tetR38) 
This paper N/A 
M. smegmatis ML2218 (M. 
smegmatis mc2155; L5 attB, 
Psmyc::tetR38; tetO-4C5G::aftD, 
hygr) 
This paper N/A 
M. smegmatis ML2730 
(Derivative ML2253, Ms6 
attB::pML4214 (aph, pBR322 
origin, Ms6 integrase, Ms6 attP)) 
This paper N/A 
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M. smegmatis ML2731 
(Derivative ML2218, Ms6 
attB::pML4225 (aph, PaftD-
Msm::aftDMab)) 
This paper N/A 
M. smegmatis ML2732 
(Derivative ML2218, Ms6 
attB::pML4226 (aph, PaftD-
Mab::aftDMab)) 
This paper N/A 
M. smegmatis ML2733 
(Derivative ML2218, Ms6 
attB::pML4214) 
This paper N/A 
M. smegmatis ML2734 
(Derivative ML2218, Ms6 
attB::pML4227 (aph, PaftD-
Mab::aftD K39A)) 
This paper N/A 
M. smegmatis ML2735 
(Derivative ML2218, Ms6 
attB::pML4228 (aph, PaftD-
Mab::aftD D41A)) 
This paper N/A 
M. smegmatis ML2736 
(Derivative ML2218, Ms6 
attB::pML4229 (aph, PaftD-
Mab::aftD E251A)) 
This paper N/A 
M. smegmatis ML2737 
(Derivative ML2218, Ms6 
attB::pML4231 (aph, PaftD-
Mab::aftD K361A)) 
This paper N/A 
M. smegmatis ML2738 This paper N/A 
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(Derivative ML2218, Ms6 
attB::pML4232 (aph, PaftD-
Mab::aftD D474A)) 
M. smegmatis ML2739 
(Derivative ML2218, Ms6 
attB::pML4233 (aph, PaftD-
Mab::aftD G1339W)) 
This paper N/A 
M. smegmatis ML2740 
(Derivative ML2218, Ms6 
attB::pML4235 (aph, PaftD-
Mab::aftD T1285Stop)) 
This paper N/A 
M. smegmatis ML2741 
(Derivative ML2218, Ms6 
attB::pML4236 (aph, PaftD-
Mab::aftD R310A)) 
This paper N/A 
M. smegmatis ML2742 
(Derivative ML2218, Ms6 
attB::pML4237 (aph, PaftD-
Mab::aftD R1389S)) 
This paper N/A 
M. smegmatis ML2743 
(Derivative ML2218, Ms6 
attB::pML4238 (aph, PaftD-
Mab::aftD R315A)) 
This paper N/A 
Recombinant DNA 
M. abscessus AftD-WT in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
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M. abscessus AftD-K39A in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-D41A in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-E251A in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-R357A in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-K381A in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-D474A in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-G1339W in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-V1335W in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-T1385Stop 
in pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-R310A in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-R1389S in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
M. abscessus AftD-R315A in 
pNYCOMPS-N23 
This study (Bruni and Kloss, 2013) 
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M. abscessus AftD-WT in 
pVVAP 
This study N/A 
pML3621 (pUC origin; L5 
integrase; L5 attP; hygr; loxP-
Psmyc::tetR38-loxP; 6392 bp) 
This study N/A 
pML4205 (pUC origin; hygr; 
tetO-4C5G::aftD(Msm)1-1089; 
5952 bp) 
This study N/A 
pML2714 (pUC origin; 
pAL5000ts; pgroEL-cre; pimc-
pamcherry1m; aph; 7613 bp) 
This study (Ofer et al., 2012) 
pML4214 (pBR322 origin; Ms6 
integrase; Ms6 attP; aph; 6165 
bp) 
This study N/A 
pML4225 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Msm::aftDMab; 11143 bp) 
This study N/A 
pML4226 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDMab; 11143 bp) 
This study N/A 
pML4227 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDK39A; 11143 bp) 
This study N/A 
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pML4228 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDD41A; 11143 bp) 
This study N/A 
pML4229 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDE251A; 11143 bp) 
This study N/A 
pML4230 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDR357A; 11143 bp) 
This study N/A 
pML4231 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDK361A; 11143 bp) 
This study N/A 
pML4232 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDD474A; 11143 bp) 
This study N/A 
pML4233 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDG133W; 11143 bp) 
This study N/A 
pML4234 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDV1335W; 11143 bp) 
This study N/A 
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pML4235 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDT1285Stop; 11143 bp) 
This study N/A 
pML4236 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDR310A; 11143 bp) 
This study N/A 
pML4237 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDR1389S; 11143 bp) 
This study N/A 
pML4238 (Derivative pML4214; 
pBR322 origin; Ms6 integrase; 
Ms6 attP; aph; PaftD-
Mab::aftDR315A; 11143 bp) 
This study N/A 
Software and Algorithms 
AutoIt AutoIt https://www.autoitscript.com 





GraphPad Prism 5 GraphPad https://www.graphpad.com 
Leginon (Suloway et al., 
2005) 
http://leginon.org 













GCTF (Zhang, 2016) https://www.mrc-
lmb.cam.ac.uk/kzhang/Gctf 





CryoSPARC (Punjani et al., 
2017b) 
https://cryosparc.com 





cisTEM (Grant et al., 
2018b) 
https://cistem.org 












Phenix (Adams et al., 






Buccaneer (Cowtan, 2006) http://www.ysbl.york.ac.uk/~
cowtan/buccaneer/buccaneer.
html 
CCP-EM (Burnley et al., 
2017) 
http://www.ccpem.ac.uk 





EMRinger  (Barad et al., 2015) http://emringer.com 
ResMap (Kucukelbir et al., 
2013) 
http://resmap.sourceforge.net 
3DFSC (Tan et al., 2017) https://3dfsc.salk.edu 
Voss Volume Voxelator server (Voss and Gerstein, 
2010) 
http://3vee.molmovdb.org 




PyMOL Schrodinger https://pymol.org 














Homemade carbon patterned 
nanowire grids 
(Wei et al., 2018) N/A 




CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for reagents may be directed to, and will be fulfilled by Dr. 





For calculations of Fourier shell correlations (FSC), the FSC cut-off criterion of 0.143 
(Rosenthal and Henderson, 2003a) was used. No statistical methods were used to predetermine 
sample size. The experiments were not randomized. The investigators were not blinded to 
allocation during experiments and outcome assessment. For calculation of M. smegmatis cell 
length and width, both D'Agostino & Pearson omnibus normality test and Shapiro-Wilk 
normality test showed that the distribution was not normal. Hence, one-way ANOVA Kruskal-
Wallis parametric test was done. Dunns post-test was then done between all pairs of samples. 
 
Phylogenetic and Conservation Analysis 
PSI-BLAST (Altschul and Koonin, 1998) was performed using the amino acid sequence of M. 
abscessus AftD until no more additional sequences were found, producing 2385 sequences. 
Duplicate sequences from the same species and truncated variants of the same protein were 
removed, resulting in 665 unique sequences. Lengths of these sequences were plotted in Figure 
S1. Membrane topology for these sequences were predicted using the TMHMM server (Krogh et 
al., 2001). 
 
In order to compare sequences that are more closely related to Mycobacterium AftD, sequences 
shorter than 95% the length of M. abscessus AftD (~1400 residues) were excluded. CD-HIT (Li 
and Godzik, 2006) was then used to provide representative sequences and remove biases in the 
distribution of the data – notably Mycobacterium sequences dominate the original sequence list 
likely because of the medical relevance of this genus. The 289 final sequences were then aligned 
with MUSCLE (Edgar, 2004) and used for conservation analysis. 
 
Generation of a M. smegmatis aftD Conditional Knockout Strain 
To construct a parent strain for aftD conditional knockout (cKO), a L5 integration vector 
pML3621 (L5 integrase, HygR, loxP-Psmyc::tetR38-loxP) was firstly transformed into wild-type 
M. smegmatis mc2155 cell to create ML2253 strain which can constitutively express a reverse 
TetR (TetR38). The ML2253 colony was selected on 7H10 plates supplemented with 50 μg/mL 
hygromycin (Fisher) after 4 days at 37°C. Subsequently, a temperature-sensitive replication 
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vector pML2714 (pAL5000ts, KanR, cre recombinase expression) was transformed into ML2253 
for unmarking. The unmarked colony (named ML2217) was selected on 7H10 plates 
supplemented with 30 μg/mL kanamycin (Fisher) after 7 days at 32°C. Next, the unmarking 
plasmid ML2714 was removed by temperature selection on 7H10 (no antibiotic) plates at 40°C 
for 4 days.  
 
To conditionally knockout aftD in M. smegmatis mc2155, a suicide vector pML4205 containing a  
TetR38-binding region (tetO-4C5G) and an N-terminus of aftD gene (1st to 1089th bp) was 
transformed into the parent strain ML2217 for single cross-over selection on 7H10 plates 
supplemented with 50 μg/mL hygromycin at 37°C for 4 days. PCR validation was then 
performed for the single cross-over colonies. The correct colonies were named ML2218, the aftD 
conditional KO strain. In the presence of 20 ng/mL tetracycline, TetR38-tetracycline complex 
binds the upstream region (tetO-4C5G) of aftD and represses the transcription of aftD gene. 
 
M. abscessus aftD Complementation 
For the complementation experiment, the M. abscessus aftD gene, as well as the aftD variations, 
were cloned into an Ms6 integration vector pML4214 (Ms6 integrase, Ms6 attP attachment site, 
KanR) individually with a 200-bp upstream DNA fragment of M. abscessus aftD gene. The 
pML4214 and the pML4214-derivative plasmids were transformed into ML2218 strain 
individually. All the colonies were selected on 7H10 plates supplemented with 30 μg/mL 
kanamycin (Fisher) after 4 days at 37°C.  
 
Phenotypic Assays for M. smegmatis aftD Conditional Knockout Strain 
To observe a clear phenotype of aftD conditional knockout mutant, the remaining cellular AftD 
protein levels were depleted as much as possible. First, the ML2218 seed culture was grown to 
an OD600 of 1.0 at 37°C with a shaking speed of 200 rpm. For the AftD depletion, ML2218 cells 
were grown in 10 mL of 7H9/glycerol/tyloxapol liquid media supplemented with 20 ng/mL 
tetracycline with an initial OD600 of 0.002 at 37°C, 200 rpm for 2-3 days. Subsequently, the 




For the growth curve assay, all the AftD-depleted strains were inoculated into the fresh 10 mL of 
7H9/glycerol/tyloxapol liquid media supplemented with or without 20 ng/mL tetracycline with 
an initial OD600 of 0.005. The cultures were then grown at 37°C, 200 rpm and time points taken 
approximately every 4-8 hours till stationary phase. All experiments were done in triplicate. 
 
For the microplate appearance assay, all the AftD-depleted strains were inoculated into 12-well 
plates (Costar). Each well contains 3 mL of 7H9/glycerol/tyloxapol liquid media supplemented 
with or without 20 ng/mL tetracycline with an initial OD600 of 0.05. The 12-well plates were 
shaking at 120 rpm at 37°C for 2-3 days. 
 
For the colony forming assay, all the AftD-depleted cells were streaked on 7H10 plates with or 
without 20 ng/mL of tetracycline. The plates were kept at 37°C for 6 days. 
 
Scanning Electron Microscopy 
10mL of M. smegmatis cells are harvested by spinning cells at 8000g for 1 min with a Sorvall ST 
16 R centrifuge (Thermo Scientific) to give around 0.4-0.5g of cell pellet mass. Supernatant was 
discarded. Cell pellet was then resuspended with 2.5% glutaraldehyde (Tousimis) in a 15mL 
Falcon tube and incubated at 4°C for 2 hours. The suspension was then spun down again at 
8000g for 1 min and resuspended with PBS for 2 times, then with an ethanol (Fisher) gradient 
(30%, 50%, 70%, 100%) 15 min for dehydration. Each step takes 15 minutes, and will be 
followed with a spin down and resuspension. After the final dehydration, fixed cells are left to air 
dry overnight. 
 
The cells were then smeared onto a scanning electron microscope sample holder using a pipette 
tip for imaging. The entire surface of the specimen was then sputter coated with a thin layer of 
gold/palladium. The cells were imaged using secondary electron mode in a FEI Helios Nanolab 
650 (FEI). Images were recorded using the scanning electron microscope beam at 2 keV and 100 
pA with a working distance of 4.0 ± 0.5 mm. Data acquisition occurred manually using an in-
house AutoIt script (https://www.autoitscript.com/) written by Bill Rice. The raw images were 
3072 pixels by 2048 pixels, with 6.08 nm pixel width, a horizontal field width (HFW) of 18.67 




To measure the dimensions of cells, Adobe Photoshop was used to select out each cell. The cell 
length and width were calculated using ImageJ’s plugin, Pombe Measurer (Zhou Zhou, 
www.columbia.edu/~zz2181/Pombe_Measurer.html). Both D'Agostino & Pearson omnibus 
normality test and Shapiro-Wilk normality test showed that the distribution of lengths and widths 
were not normal. Hence, one-way ANOVA Kruskal-Wallis parametric test was done. Dunns 
post-test was then done between all pairs of samples. Statistical tests were done using GraphPad 
Prism 5. 
 
Genomic Expansion and Small-Scale Screening 
AftD genes were identified from a collection of fourteen Mycobacterium genomes using a 
bioinformatics approach (Love et al., 2010). Ligation independent cloning (LIC) was used to 
clone these targets from the genomes into five LIC-adapted expression vectors (pNYCOMPS-
Nterm, pNYCOMPS-Cterm, pNYCOMPS-N23, pNYCOMPS-C23 and pMCSG7-10x) that 
contained a Tobacco Etch Virus (TEV) protease cleave site (ENLYFQSYV) and decahistidine 
affinity tag. Small and medium scale expression was done in a high throughput manner as 
described in detail in a previous protocol by Bruni & Kloss (Bruni and Kloss, 2013). Only one 
construct, M. abscessus AftD in the pNYCOMPS-N23 plasmid, was successfully cloned and 
expressed in small and medium scale. This construct was thus brought forward for further 
structural studies. 
 
M. abscessus AftD Mutagenesis 
Site-directed mutagenesis on the M. abscessus aftD gene was done with overlapping primers 
designed per mutant using the Quick Change Lightning Kit (Agilent). The same pairs of primers 
were used on aftD in pNYCOMPS-N23 plasmid (for E. coli expression) and pML4214-Mab 
Promoter::aftD M. abscessus (for M. smegmatis expression). 
 
Small scale expression tests were carried out for the AftD mutants in the pNYCOMPS-N23 
plasmid as described in detail in a previous protocol by Bruni & Kloss (Bruni and Kloss, 2013) 




M. abscessus AftD expression, purification and nanodisc reconstitution  
M. abscessus AftD WT in the pNYCOMPS-N23 plasmid was transformed into BL21 (DE3) 
pLysS E. coli competent cells and plated onto Luria broth (LB) agar (Fisher) plates 
supplemented with 100 μg/mL ampicillin (Sigma) and 35 μg/mL chloramphenicol (Sigma) and 
grown overnight at 37°C. In the next day, a colony was picked and used to inoculate a starter 
culture containing 150 mL of Terrific broth (TB) medium (Fisher) supplemented with 100 
μg/mL ampicillin and 35 μg/mL chloramphenicol. The starter culture was grown overnight at 
37°C with shaking (240 r.p.m.) in an incubator shaker (New Brunswick Scientific). In next day, 
12 2L baffled flasks each with 800 mL of Terrific broth (TB) medium (Fisher) supplemented 
with 100 μg/mL ampicillin and 35 μg/mL chloramphenicol were inoculated with 10 mL of 
starter culture. The cultures were then grown at 37°C with shaking (240 r.p.m.) until optical 
density (OD) at 600nm reached 1.0 (approximately 3 hours). Temperature was then reduced to 
22°C and AftD expression was induced with 0.2 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (Fisher). The culture was then incubated overnight with shaking (240 r.p.m.). In the next 
day, the cells were harvested by centrifugation at 4,000 g in H6000A/HBB6 rotor (Sorvall) for 
30 min at 4°C. The supernatant was discarded and the pellet was resuspended in chilled 1x 
phosphate buffered saline (PBS) and centrifuged again at 4,000 g for 30 min at 4°C. The 
supernatant was again discarded and the pellet was resuspended in lysis buffer containing 20 mM 
HEPES pH 7.5, 200 mM NaCl, 20 mM MgSO4, 10 μg/mL DNase I (Roche), 8 μg/mL RNase A 
(Roche), 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 1 mM PMSF, 1 tablet/1.5 
L buffer EDTA-free cOmplete protease inhibitor cocktail (Roche). For 9.6 L of culture, there 
was ~15-20g of wet cell pellet mass, which was resuspended with ~250 mL of lysis buffer. Cells 
were lysed by putting the suspension through a chilled Emulsiflex C3 homogenizer (Avestin) 
three times. To isolate the membrane fractions, the lysate was put through ultracentrifugation at 
37,000g in Type 45 Ti Rotor (Beckman Coulter) at 4°C for 30 min. The supernatant was 
discarded and the pellet was resuspended in the lysis buffer up to a volume of 240 mL and 
homogenized using a hand-held glass homogenizer (Konte). The membrane fraction was then 
stored at -80°C until the use. 
 
The thawed membrane fraction was solubilized by adding n-dodecyl-β-D-maltopyranoside 
(DDM) to a final concentration of 1% (w/v) detergent for 2 hours at 4°C with gentle rotation. 
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Insoluble material was removed by ultracentrifugation at 40,000g in Type 45 Ti Rotor at 4°C for 
30 min. The supernatant was added to six Falcon tubes containing pre-equilibrated Ni2+-NTA 
resin (Qiagen) in the presence of 40 mM imidazole and incubated with gentle rotation at 4°C for 
2 hours. The resin was washed with 10 column volumes of wash buffer containing 20mM 
HEPES pH 7.5, 200 mM NaCl, 60mM Imidazole, 0.1% DDM and eluted with elution buffer 
containing 20 mM HEPES pH 7.5, 200mM NaCl, 200mM Imidazole, 0.05% DDM. The eluted 
protein was exchanged into a buffer containing 20 mM HEPES pH 7.5, 200mM Imidazole, 0.05% 
DDM using a PD-10 desalting column (GE), and concentrated down using a 100-kDa 
concentrator (Pierce) to ~ 1 mg/mL. 
 
The protein was then incorporated into lipid nanodisc (Bayburt and Sligar, 2010) with the molar 
ratio 1:360:6 of E. coli polar lipid extract (Avanti): membrane scaffold protein 1E3D1 
(MSP1E3D1) and incubated for 2 hours with gentle agitation at 4°C. Reconstitution was initiated 
by removing detergent with the addition of 150 mg Bio-beads (Bio-Rad) per mL of protein 
solution for overnight with constant rotation at 4°C.  Bio-beads were removed by passing the 
protein solution through an Ultrafree centrifugal filter unit (Fisher) and the nanodisc 
reconstitution mixture was re-bound to Ni2+-NTA resin with 15 mM imidazole for 2 hours at 4°C 
in order to remove free nanodisc. The resin was washed with 10 column volumes of wash buffer 
consisting of 20 mM HEPES pH 7.5, 200 mM NaCl and 20 mM Imidazole, followed by 3 
column volumes of elution buffer consisting of 20 mM HEPES pH 7.5, 200 mM NaCl and 200 
mM Imidazole.  
 
TEV protease (Kapust et al., 2002) (~0.5 mg TEV protease added per pellet equivalent from 800 
mL of initial bacterial culture) was added to the eluted protein, which was then injected into a 
Slide-A-Lyzer™ dialysis cassette (Thermo Fisher) and dialyzed against 200 mL of 20 mM 
HEPES pH 7.5 and 200 mM NaCl overnight at 4°C. The mixture was then re-bound to Ni2+-
NTA resin with 15 mM imidazole for 1 hour at 4°C in order to remove uncleaved AftD, cleaved 
tag, TEV protease and contaminant proteins. The resin was washed with 3 column volumes of 
wash buffer consisting of 20 mM HEPES pH 7.5, 200 mM NaCl. The flowthrough and wash 
were concentrated using a 100-kDa concentrator to under 500 μL and loaded onto a Superdex 
200 Increase 10/300 GL size-exclusion column (GE Healthcare Life Sciences) in gel filtration 
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buffer (20 mM HEPES pH 7.5 and 200 mM NaCl). Throughout the entire process of purification, 
15 μL of samples were taken and added to 5 μL of 6X reducing Laemmli SDS sample buffer 
(Bioland Scientific). The samples were then loaded on a 4–20% Mini-PROTEAN TGX precast 
protein gel (Bio-rad) for protein gel electrophoresis in a Tris/Glycine/SDS buffer. The gel was 
developed using InstantBlue (Sigma) protein stain. 
 
For M. abscessus AftD-R1389S, the expression and purification protocol is largely the same 
except for the following. Firstly, AftD-R1389S was not able to be cleaved by TEV protease, 
hence the protein was not put through overnight TEV cleavage. Secondly, during the second 
nickel affinity purification after reconstitution into nanodiscs, additional washes of 5 column 
volumes of 20 mM HEPES pH 7.5, 500 mM NaCl and 20 mM Imidazole and 5 column volumes 
of 20 mM HEPES pH 7.5, 500 mM NaCl, 5 mM ATP and 20 mM Imidazole were done in order 
to increase purity of the protein, given TEV cleavage was no longer done. 
 
Single-Particle Cryo-EM Sample Vitrification 
Purified AftD WT was concentrated using a 100-kDa concentrator (Pierce) to between 5-20 μL 
of sample at ~1 mg/mL. Due to the low yields obtained, the samples were vitrified using a semi-
automated Spotiton V1.0 robot (Razinkov et al., 2016, Jain et al., 2012, Dandey et al., 2018). 
This is a device for vitrifying cryo-EM samples that uses piezo-electric dispensing to apply small 
(50 pl) drops of sample across a ‘self-blotting’ nanowire grid as it flies past en-route to plunging 
into liquid ethane. Owing to the small amounts of sample required per vitrified grid, only ~3 μL 
of sample was required to be aspirated for multiple grids. Homemade carbon support nanowire 
grids with a regular array of holes were used (Wei et al., 2018), and were plasma-cleaned (Gatan 
Solarus) for 15s using an H2/O2 mixture. The Spotiton V1.0 robot was operating at room 
temperature and moderate humidity.  
  
For purified AftD-R1389S, the protein was concentrated using a 100-kDa concentrator (Pierce) 
to between ~10 μL of sample at ~2 mg/mL. 2.5 μL of sample was added to a plasma-cleaned 
(Gatan Solarus) 1.2/1.3 µm holey gold grid (Quantifoil UltrAuFoil) and blotted using filter paper 
on one side for 2s using the Leica GP plunger system before plunging immediately into liquid 
ethane for vitrification. The plunger was operating at 6°C with >80% humidity to minimize 
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evaporation and sample degradation. Due to conditions previously optimized using Spotiton, 
Leica GP plunging could be used to obtain good grids for the mutant without expending too 
much of the protein sample. 
 
Data Acquisition 
Images were recorded on a Titan Krios electron microscope (FEI) equipped with a K2 summit 
direct detector with a Quantum energy filter (Gatan) operating at 1.0605 Å per pixel in counting 
mode using the Leginon software package (Suloway et al., 2005). Pixel size was calibrated in-
house using a proteasome test sample. Energy filter slit width of 15 eV was used during the 
collection and aligned automatically every hour using Leginon. Data collection was performed 
using a dose of ~95.72 e-/Å2 across 90 frames (150 msec per frame) at a dose rate of ~8.2 e–
/pix/sec, using a set defocus range of -1.0 μm to -2.0 μm. 100 µm objective aperture was used. 
For AftD WT, a total of 7,274 micrographs were recorded over a four sessions using an image 
beam shift data collection strategy (Cheng et al., 2018a). For AftD-R1389S, the same strategy 
over a single session of three days yielded 4,886 micrographs. The dose was marginally different 
at 96.78 e–/Å2. 
 
Data Processing 
For M. abscessus WT AftD, data from the four sessions were processed separately and combined 
towards the end of the processing pipeline. Movie frames were aligned using MotionCor2 
(Zheng et al., 2017b) with 5 by 5 patches and B-factor of 100 through the Appion software 
package (Lander et al., 2009b). Micrograph CTF estimation was performed using both 
CTFFind4 (Rohou and Grigorieff, 2015) and GCTF (Zhang, 2016), and best estimate based on 
confidence was selected within the Appion software package. Template free particle picking 
with Gautomatch (Kai Zhang, unpublished, https://www.mrc-
lmb.cam.ac.uk/kzhang/Gautomatch/) using an extremely lenient threshold (to avoid missing any 
particles) was used to pick 2,800,102 particles (extracted 256 box size binned by 2) that were 
transferred into Relion 2.1 (Scheres, 2012b, Kimanius et al., 2016) for 2D classification. 2D class 
averages that were ice or showed no features were discarded. An initial model was then 
generated in CryoSPARC ab initio (Punjani et al., 2017b) and used for Relion 3D refinement. 
The Euler angles and shifts were then used to re-extract the particles and re-center them. Relion 
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3D classification was then performed using 7 classes and only classes with clear structural 
features were selected. 
 
At this stage, a total of 498,060 selected particles from all four session were combined and re-
extracted unbinned. Per-particle CTF using GCTF was then performed before the particles were 
put through a Relion 3D refinement using the previously obtained initial model. A mask 
generated around the transmembrane region was then used to performed 3D classification with 8 
classes, and particles belonging to classes with high resolution features were selected and re-
extracted with a bigger box size of 288. A total of 490,616 particles were left in the final stack. 
 
CryoSPARC non-uniform refinement produced a 3.2 Å map, which was then put through 
cisTEM (Grant et al., 2018b) CTF refinement to obtain better defocus values. The particles with 
the refined defocus values were then put through another round of CryoSPARC non-uniform 
refinement to produce a 3.0 Å map. Signal subtraction was then done in Relion to remove the 
nanodisc and flexible ACP density, and the signal subtracted particles were then put through 
CryoSPARC non-uniform refinement. The resulting Euler angles and shifts were then used to 
reconstruct the non-signal subtracted particles to produce a 2.9 Å map, called the AftD global 
refined map. This final map was sharpened using phenix.auto_sharpen (Adams et al., 2010, 
Afonine et al., 2018), which automatically determined that b_iso sharpening to high_resolution 
cutoff should be the algorithm to use. Overall b_sharpen applied was 56.04 Å2 and final b_iso 
obtained was 44.30 Å2. 
 
When examining the map by eye, it was noticed the domain corresponding to CBM3 had a lower 
resolution (poor density) compared to the rest of the map. In order to better improve the 
resolution at this flexible portion, signal subtraction was performed to isolate just the CBM3 
region, and focused classification using ten classes without alignment was done. A total of 
50,410 particles were present in the highest resolution class. The resulting Euler angles and shifts 
were then used to reconstruct the non-signal subtracted particles to produce a 3.0 Å map, called 
the AftD-CBM3 focused classified map. This final map was sharpened using 
phenix.auto_sharpen, which automatically determined that b_iso sharpening to high_resolution 
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cutoff should be the algorithm to use. Overall b_sharpen applied was 29.62 Å2 and final b_iso 
obtained was 45.97 Å2. 
 
For M. abscessus AftD-R1389S, the same data processing strategy was used except for the 
following differences. Firstly, 226,478 particles were picked initially and a consensus map of 
150,978 particles was obtained. Secondly, from these 150,978 particles, signal subtraction was 
done using a spherical mask around the putative active site of AftD where additional density 
could be seen. Focused 3D classification without alignments was then performed using Relion 
with five classes. Different T values (10, 20, 30, 40, 50, 60, 70, 80 and 90) were titrated and 
T=60 was determined by visual inspection and comparison of classes to give the best 
classification. Classes 3, 4 and 5 looked noisy and not significantly different. Classes 1 and 2 had 
high resolution details and had significant differences between them. A CryoSPARC non-
uniform refinement was then performed using particles from each of these classes to give final 
maps at 3.5 Å and 3.4 Å each respectively. Both final maps were sharpened using 
phenix.auto_sharpen, using b-factors of -125.09 Å2 and -129.19 Å2 respectively. 
 
All conversions between Relion, CryoSPARC, and cisTEM were performed using Daniel 
Asarnow’s pyem script (unpublished, https://github.com/asarnow/pyem). 
 
Model Building and Refinement 
In order to aid in model building against a single structure, phenix.combine_focused_maps 
(Adams et al., 2010, Afonine et al., 2018) was used to combine the WT AftD global refined map 
and WT AftD-CBM3 focused classified map into the WT AftD composite map. 
 
For model building of WT AftD, the Chimera (Pettersen et al., 2004) program was first used to 
segment out the protein components and exclude the nanodisc. De novo model building for the 
cryo-EM map its primary sequence was initiated using Buccaneer (Cowtan, 2006) within the 
CCP-EM software suite (Burnley et al., 2017). After 2 rounds of Buccaneer model building, the 
partial model was brought into Coot (Emsley and Cowtan, 2004) program for manual model 
building. After the model was built, it was refined against the cryo-EM map utilizing real space 
refinement in the Phenix program. Restraints for the lipids were generated using phenix.eLBOW 
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and for the metal ions using phenix.ready_set. Thereafter, model adjustment and refinement were 
performed iteratively in Coot and Phenix, with the statistics being examined using Molprobity 
(Chen et al., 2010) until no further improvements were observed. The final map and model were 
then validated using 1) EMRinger (Barad et al., 2015) to compare map to model, 2) ResMap 
(Kucukelbir et al., 2013) to calculate map local resolution and 3) 3DFSC program suite (Tan et 
al., 2017)  to calculate degree of directional resolution anisotropy through the 3DFSC. Map-to-
model FSCs were also calculated by first converting the model to a map using Chimera molmap 
function at Nyquist resolution (2.121 Å). A mask was made from this map using Relion (after 
low-pass filtering to 8 Å, extending by 1 pixel and applying a cosine-edge of 3 pixels), and was 
then applied to the density map. Map-to-model FSC was calculated using EMAN (Ludtke et al., 
1999) proc3d between these maps. 
 
For model building of AftD-R1389S, the WT structure was overlaid and Coot was used to 
manually remove or build residues. Other than that, the model building and refinement strategy 
mirrored the WT AftD mentioned above. 
 
Model Analysis 
A cavity search using the Solvent Extractor from Voss Volume Voxelator server (Voss and 
Gerstein, 2010) was performed using an outer probe radius of 5 Å and inner probe radius of 2 Å. 
In order to search for other PDB structures with similar fold, a Dali server (Holm and Laakso, 
2016) search was performed – first globally and then against the different domains of the model. 
 
Screening, Imaging and Data Analysis of the Glycan Array 
Glycan array analysis was done with M. abscessus AftD WT protein solubilized in DDM. Slides 
were prewetted in buffer A (25 mM Tris-HCl pH 7.8, 0.15 mM NaCl, 2 mM CaCl2 and 0.05% 
Tween 20) for 5 min, rinsed with buffer B (25 mM Tris-HCl pH 7.8, 0.15 mM NaCl, and 2 mM 
CaCl2) three times, and blocked overnight with buffer C (1% BSA in 25 mM Tris-HCl pH 7.8, 
0.15mM NaCl, and 2 mM CaCl2) at 4 °C. Aliquots (500 μL) of serial dilutions of protein 
samples in buffer C were transferred to wells of the slide module immediately after aspiration of 
the blocking buffer. Wells were sealed with an adhesive seal and incubated for 60 min at 37 °C. 
Protein was removed by aspiration, and slides were washed 10 times with buffer A and three 
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times with buffer B. Fluorescence was measured directly or after addition of a secondary 
antibody in buffer C (1:1000 dilution). Slides were incubated with a secondary antibody at room 
temperature for 40 min before being washed repeatedly with buffer A and deionized water.  
 
Before being scanned, slides were dried by centrifugation. Microarrays were scanned at 5 μm 
resolution with a GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA). The fluorescent 
signal was detected at 532 nm for Cy3 or Alexa Fluor 555 and 488 nm for Alexa Fluor 488. The 
laser power was 100%, and the photomultiplier tube gain was 400. The fluorescent signals were 
analyzed by quantifying the pixel density (intensity) of each spot using GenePix ProMicroarray 
Image Analysis Software version 6.1. Fluorescence intensity values for each spot and its 
background were calculated. The local background signal was automatically subtracted from the 
signal of each separate spot, and the mean signal intensity of each spot was used for data analysis. 
Averages of triplicate experiments and standard deviations were calculated using Microsoft 
Excel. 
 
M. smegmatis Overexpression of M. abscessus AftD 
M. abscessus AftD, containing N-terminal FLAG and His10 and tags, was cloned into pVVAP 
(Catalão et al., 2010) plasmid for over-expression. This plasmid contains a pAL5000 replication 
origin, a kanamycin resistance cassette, and allows expression of N‐terminally FLAG+His10‐
tagged AftD. The plasmid was transformed by electroporation into M. smegmatis MC2155 and 
plated onto Middlebrook 7H10 (Sigma-Aldrich), plates, supplemented with 0.5% glucose and 15 
µg mL-1 kanamycin, and left at 37°C until single colonies were visible (2 to 3 days). A single 
colony was picked to inoculate 30 mL of Middlebrook 7H9 medium (USBiological) 
supplemented with 0.5% glucose, 0.05% Tween 80 and 15 µg mL-1 kanamycin, to grow 
overnight at 37°C with constant orbital shaking at 220 rpm. The starter culture was then used the 
next day to inoculate 5 L of Middlebrook 7H9 medium (USBiological) supplemented with 0.2% 
succinate, 0.05% Tween 80 and 15 µg mL-1 kanamycin, at an initial OD600nm of 0.05, and left to 
grow overnight at 37°C with constant orbital shaking at 220 rpm. The next morning, AftD 
expression was induced by adding acetamide to a final concentration of 0.2%, once the culture 
reached an OD600nm of 0.8 to 1.0, roughly 16 hr after inoculation. The culture was grown for 24 
hr after induction at 37°C with constant orbital shaking at 220 rpm, then harvested at 4°C by 
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centrifugation for 20 min at 4000 rpm (JA-10 rotor, Beckman Coulter). Supernatant was then 
discarded, and the cell pellet was washed once with PBS, centrifuged again at 4°C for 20 min at 
4000 rpm, then frozen at -20°C. 
 
The cells were thawed and resuspended in lysis buffer containing 20 mM HEPES pH 7.5, 200 
mM NaCl, 20 mM MgSO4, 10 μg/mL DNase I, 1 mM TCEP, 1 tablet/1.5 L buffer EDTA-free 
cOmplete protease inhibitor cocktail (Roche). For 5 L of culture, there was ~10 g of wet cell 
pellet mass, which was resuspended in ~60mL of lysis buffer. Cells were then lysed in a French 
Press, at 1500 bar, after 4 passages. To isolate the membrane fractions, the lysate was put 
through ultracentrifugation at 42,000g in Type 45 Ti Rotor (Beckman Coulter) at 4°C for 45 min. 
The supernatant was discarded, the pellet was resuspended in the lysis buffer up to a volume of 
15 mL and homogenized using a hand-held glass homogenizer (Wheaton) and then stored at -
20°C. The thawed membrane fraction was solubilized by adding DDM to a final concentration of 
1% (w/v) detergent for 3 hours at 4°C with gentle rotation. Insoluble material was removed by 
ultracentrifugation at 42,000g in Type 45 Ti Rotor at 4°C for 45 min. The supernatant was added 
to a Falcon50 tube containing pre-equilibrated ANTI-FLAG® M2 Affinity Gel (Sigma) and 
incubated with gentle rotation overnight at 4°C. The gel was washed with 10 column volumes of 
wash buffer containing 20 mM HEPES pH 7.5, 200 mM NaCl, 0.05% DDM and incubated at 
4°C with gentle rotation for 1h with elution buffer containing 20 mM HEPES pH 7.5, 200mM 
NaCl, 0.05% DDM, 100 μg mL-1 FLAG peptide (Sigma), then finally eluted. The eluted fraction 
was then run on both SDS-PAGE and Native-PAGE gels and sent for subsequent mass 
spectrometry analysis. 
 
Mass spectrometry analysis and protein identification 
Samples were subjected to trypsin digestion. Briefly, protein sample was reduced with 10 mM 
DTT (Sigma) for 40 min at 56 °C followed by alkylation with iodoacetamide (Sigma) 55 mM for 
30 min in the dark. Excessive iodoacetamide was quenched by further incubation with DTT (10 
mM for 10 min in the dark). The resulting sample was digested overnight with trypsin 
(Proteomics grade from Promega) at 37 °C (1:50 protein/trypsin ratio), dried and resuspended in 




Nano-liquid chromatography-tandem mass spectrometry (nanoLC-MS/MS) analysis was 
performed on an ekspert™ NanoLC 425 cHiPLC® system coupled with a TripleTOF® 6600 
with a NanoSpray® III source (Sciex). Peptides were separated through reversed-phase 
chromatography (RP-LC) in a trap-and-elute mode. Trapping was performed at 2 µl/min with 
100% A (0.1% formic acid in water, Fisher Chemicals, Geel, Belgium), for 10 min, on a Nano 
cHiPLC Trap column (Sciex 200 µm x 0.5 mm, ChromXP C18-CL, 3 µm, 120 Å). Separation 
was performed at 300 nl/min, on a Nano cHiPLC column (Sciex 75 µm x 15 cm, ChromXP C18-
CL, 3 µm, 120 Å). The gradient was as follows: 0-1 min, 5% B (0.1% formic acid in acetonitrile, 
Fisher Chemicals); 1-61 min, 5-30% B; 61-63 min, 30-80% B; 63-71 min, 80% B; 71-73 min, 
80-5% B; 73-90 min, 5% B. 
 
Peptides were sprayed into the MS through an uncoated fused-silica PicoTip™ emitter (360 µm 
O.D., 20 µm I.D., 10 ± 1.0 µm tip I.D., New Objective). The source parameters were set as 
follows: 15 GS1, 0 GS2, 30 CUR, 2.5 keV ISVF and 100 ⁰C IHT. An information dependent 
acquisition (IDA) method was set with a TOF-MS survey scan of 400-2000 m/z for 250 msec. 
The 50 most intense precursors were selected for subsequent fragmentation and the MS/MS were 
acquired in high sensitivity mode (150-1800 m/z for 40 msec each). The selection criteria for 
parent ions included a charge state between +2 and +5 and counts above a minimum threshold of 
125 counts per second. Ions were excluded from further MSMS analysis for 12 s. Fragmentation 
was performed using rolling collision energy with a collision energy spread of 5. 
 
The obtained spectra were processed and analyzed using ProteinPilot™ software, with the 
Paragon search engine (version 5.0, Sciex). The following search parameters were set: search 
against M. smegmatis and E. coli from Uniprot/SwissProt database, and protein sequence of 
AftD from M. abscessus; Iodoacetamide, as Cys alkylation; Tryspsin, as digestion; TripleTOF 
6600, as the Instrument; ID focus as biological modifications and Amino acid substitutions; 
search effort as thorough; and a FDR analysis. Only the proteins with Unused Protein Score 
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The use of single-particle cryo-EM has been invaluable in elucidating the structures of these 
small membrane bound enzymes. With the apo-structure of AftD, the next logical step will be 
the addition of substrates to trap the enzyme in various stages of its catalytic cycle. This was 
actually attempted a few times using substrate mimics like decaprenyl phosphate, undecaprenyl 
phosphate, undecaprenyl phosphate with fluorinated arabinose, fluorinated arabinose by itself 
and the sugar donors, to no avail. Chemical engineering is likely required to modify the 
substrates to be more like an inhibitor that binds more tightly to the enzyme. Verification of 
inhibitory nature of any substrate derivatives will need to come from in vitro activity assays, 
which currently has not been established either. This is similar to what has been done for locking 
down the intermediate reaction states of PglB (Napiórkowska et al., 2017). 
 
The presence of a bound ACP to AftD as a regulator throws up a very interesting route of 
investigation – why is the ACP there and what upstream pathways are responsible for putting 
this ACP on and off in the cell in order to regulate AftD activity? In vivo pulldown with 
crosslinking might help identify protein partners that bind directly. Potential binding partners can 
then be verified by expressing both in M. smegmatis with a split GFP (Cabantous and Waldo, 
2006) or FRET-compatible GFP (Gadella et al., 1999) to observe their in vivo interaction. If ACP 
acts instead as a secondary messenger, the upstream regulatory proteins might not directly 
interact with AftD. To investigate these components, knocking down or impeding AftD function 
and looking at changes in other cellular pathways via RNAseq analysis, microarray analaysis or 
proteomics might be necessary. 
 
Finally, the end goal of having these structures is hopefully to aid in the antitubercular efforts. 
For AftD, no drugs are known to target it. Using the conditional knock-out in M. smegmatis, the 
M. tuberculosis AftD gene can be complemented in and use to screen against compound libraries. 
Those that target the M. tuberculosis AftD specifically will result in a growth defect in the 
aforementioned cells but not in control M. smegmatis cells, and will hopefully serve as useful 
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I have been very fortunate to have entered the field of single-particle cryo-EM during the time of 
its revolution renaissance. The convergence of software and hardware technologies that have 
brought single-particle cryo-EM to the near-atomic resolution ranges have in turn attracted a 
wealth of expertise that will continue to push the boundaries of the technique for years to come. 
 
The application of cutting edge single-particle cryo-EM was indeed instrumental in my thesis, 
allowing for elucidating structures of ribosome biogenesis intermediates, preferentially 
orientated hemagglutinin trimer, AAV2 viral capsid, malarial drug transporter and mycobacterial 
glycosyltransferase. The atomic structural models of these macromolecules however are just the 
first steps in understanding their biology. To relate structure to function, mutants and complexes 
of these macromolecules have to be solved and elucidated biochemically. To put these findings 
in a biological context, examining these macromolecules in the cellular context using cryogenic 
electron tomography would be logical. At the end of the day, technology has indeed driven the 
biology, but the need to understand the biology has also directed the advancement of the 
technology – and how to harness this synergistic relationship has been one of the greatest 




Appendix 1: Other Collaborative Projects 
 
I have had the honor as well of being involved in a number of other collaborative projects. These 
have been immensely rewarding for me, because they allow me to dabble and play around in 
other fun scientific endeavors and acquaint myself with many giants in other fields. Below, I 
have put the titles, authors and abstract of these projects. 
 
List of Project Titles 
1. Big data in cryoEM: automated collection, processing and accessibility of EM data 
2. Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by 
human insulin degrading enzyme 
3. Spotiton: New features and applications 
4. Routine single particle CryoEM sample and grid characterization by tomography 
5. Reducing effects of particle adsorption to the air–water interface in cryo-EM 
6. The structure of a 15-stranded actin-like filament from Clostridium botulinum 
7. The MmpL3 interactome reveals a complex crosstalk between cell envelope biosynthesis 








Big data in cryoEM: automated collection, processing and accessibility of EM data 
 
Philip R Baldwin1, Yong Zi Tan1,2, Edward T Eng1, William J Rice1, Alex J Noble1, Carl J 
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2Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 
10032, USA 
3Life Sciences Institute and Department of Biological Chemistry, University of Michigan, Ann 
Arbor, MI 48109, USA 
 
The scope and complexity of cryogenic electron microscopy (cryoEM) data has greatly increased, 
and will continue to do so, due to recent and ongoing technical breakthroughs that have led to 
much improved resolutions for macromolecular structures solved using this method. This big 
data explosion includes single particle data as well as tomographic tilt series, both generally 
acquired as direct detector movies of ∼10–100 frames per image or per tilt-series. We provide a 
brief survey of the developments leading to the current status, and describe existing cryoEM 
pipelines, with an emphasis on the scope of data acquisition, methods for automation, and use of 








Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human 
insulin degrading enzyme 
 
Zhening Zhang1,†, Wenguang G Liang2,†, Lucas J Bailey3, Yong Zi Tan1,4, Hui Wei1, Andrew 
Wang2, Mara Farcasanu2, Virgil A Woods5, Lauren A McCord2, David Lee5, Weifeng Shang6, 
Rebecca Deprez-Poulain7, Benoit Deprez7, David R Liu8, Akiko Koide9,10,11, Shohei Koide9,10,11, 
Anthony A Kossiakoff3, Sheng Li5*, Bridget Carragher1,4*, Clinton S Potter1,4*, Wei-Jen Tang2* 
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5Department of Medicine, University of California, San Diego, La Jolla, United States 
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Insulin degrading enzyme (IDE) plays key roles in degrading peptides vital in type two diabetes, 
Alzheimer's, inflammation, and other human diseases. However, the process through which IDE 
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recognizes peptides that tend to form amyloid fibrils remained unsolved. We used cryoEM to 
understand both the apo- and insulin-bound dimeric IDE states, revealing that IDE displays a 
large opening between the homologous ~55 kDa N- and C-terminal halves to allow selective 
substrate capture based on size and charge complementarity. We also used cryoEM, X-ray 
crystallography, SAXS, and HDX-MS to elucidate the molecular basis of how amyloidogenic 
peptides stabilize the disordered IDE catalytic cleft, thereby inducing selective degradation by 
substrate-assisted catalysis. Furthermore, our insulin-bound IDE structures explain how IDE 
processively degrades insulin by stochastically cutting either chain without breaking disulfide 
bonds. Together, our studies provide a mechanism for how IDE selectively degrades 








Spotiton: New features and applications 
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We present an update describing new features and applications of Spotiton, a novel instrument 
for vitrifying samples for cryoEM. We have used Spotiton to prepare several test specimens that 
can be reconstructed using routine single particle analysis to ∼3 Å resolution, indicating that the 
process has no apparent deleterious effect on the sample integrity. The system is now in routine 
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Single particle cryo-electron microscopy (cryoEM) is often performed under the assumption that 
particles are not adsorbed to the air-water interfaces and in thin, vitreous ice. In this study, we 
performed fiducial-less tomography on over 50 different cryoEM grid/sample preparations to 
determine the particle distribution within the ice and the overall geometry of the ice in grid holes. 
Surprisingly, by studying particles in holes in 3D from over 1000 tomograms, we have 
determined that the vast majority of particles (approximately 90%) are adsorbed to an air-water 
interface. The implications of this observation are wide-ranging, with potential ramifications 
regarding protein denaturation, conformational change, and preferred orientation. We also show 
that fiducial-less cryo-electron tomography on single particle grids may be used to determine ice 
thickness, optimal single particle collection areas and strategies, particle heterogeneity, and de 
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Reducing effects of particle adsorption to the air–water interface in cryo-EM 
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Most protein particles prepared in vitreous ice for single-particle cryo-electron microscopy 
(cryo-EM) are adsorbed to air–water or substrate–water interfaces, which can cause the particles 
to adopt preferred orientations. By using a rapid plunge-freezing robot and nanowire grids, we 
were able to reduce some of the deleterious effects of the air–water interface by decreasing the 
dwell time of particles in thin liquid films. We demonstrated this by using single-particle cryo-
EM and cryo-electron tomography (cryo-ET) to examine hemagglutinin, insulin receptor 
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The structure of a 15-stranded actin-like filament from Clostridium botulinum 
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Actin microfilaments and tubulin microtubules, which provide force and organization for 
processes such as cell division and DNA segregation, are extremes in eukaryotic cytoskeleton 
cross-sectional dimensions. Microtubules typically form 13-stranded filaments of diameter ~25 
nm, while actin adopts a ~7 nm wide polymer structure formed from the close association of two 
filament strands. This brings into question whether the filament architectures are limited by the 
actin or tubulin protomer folds. Here, we report the cryoelectron microscopy structure of a more 
complex actin-like filament formed from the association of 15 protofilaments. This actin-like 
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ParM is encoded on the large 257 kb pCBH Clostridium botulinum plasmid that produces a 
neurotoxin. In cross-section, the filament architecture comprises a central helical protofilament 
that is surrounded by intermediate and outer layers of increasing radii composed of six and eight 
twisted protofilaments, respectively, to produce a filament diameter of ~26 nm. Alternating 
polarity of the layers allows for similar lateral contacts between each layer, and is consistent with 
the bidirectional segregation of the plasmid. This filament design is stiffer than the actin filament, 
and has likely been selected for during evolution to move large cargos. The comparable size and 
number of strands in microtubules and the pCBH actin-like filament, indicate that the larger 
architectures of these filaments are not limited by the protomer fold. Instead, function appears to 
have been the evolutionary driving force to produce broad, complex filaments.  
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Integral membrane transporters of the Mycobacterial Membrane Protein Large (MmpL) family 
and their interactome play important roles in the synthesis and export of mycobacterial outer 
membrane lipids. Despite the current interest in the mycolic acid transporter, MmpL3, from the 
perspective of drug discovery, the nature and biological significance of its interactome remain 
largely unknown. We here report on a genome-wide screening by two-hybrid system for MmpL3 
binding partners. While a surprisingly low number of proteins involved in mycolic acid 
biosynthesis was found to interact with MmpL3, numerous enzymes and transporters 
participating in the biogenesis of peptidoglycan, arabinogalactan and lipoglycans, and the cell 
division regulatory protein, CrgA, were identified among the hits. Surface plasmon resonance 
and co-immunoprecipitation independently confirmed physical interactions for three proteins in 
vitro and/or in vivo. Results are in line with the focal localization of MmpL3 at the poles and 
septum of actively-growing bacilli where the synthesis of all major constituents of the cell wall 
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core are known to occur, and are further suggestive of a role for MmpL3 in the coordination of 
new cell wall deposition during cell septation and elongation. This novel aspect of the 
physiology of MmpL3 may contribute to the extreme vulnerability and high therapeutic potential 
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